SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark one)

x	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934	~~QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~
For the quarterly period ended March 31, 2009
	For the quarterly period ended June 30, 2009
OR	OR
¨		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from to .

For the transition period from to .

Commission File No. 0-19312

MEDAREX, INC.

(Exact Name of Registrant as Specified in Its Charter)

New Jersey		22-2822175
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

707 State Road, Princeton, New Jersey		08540
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (609) 430-2880

Indicate by check x whether registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the ~~Securities~~ Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has ~~been~~ been subject to such filing requirements for the past 90 days. Yes x No ¨o

Indicate by check x whether registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨o No ¨o

Indicate by check x whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer x Accelerated filer ¨o Non-accelerated filer ¨o Smaller Reporting Company ¨o (Do not check if a smaller reporting Company)

Indicate by check x whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ o No x

Indicate the number of shares of each of the issuer’s classes of common stock, as of the latest practicable date:

Class		Outstanding at ~~April~~July 3031, 2009
Common Stock, $.01 par value		~~128~~129,~~544~~052,~~398~~783

Table of Contents

TABLE OF CONTENTS

		Page	~~Page~~
PART I — FINANCIAL INFORMATION
Item 1.	Consolidated Interim Financial Statements (Unaudited)
	Consolidated Balance Sheets as of March 31, 2009 (Unaudited) and December 31, 2008 (Unaudited)		3
	Consolidated Balance Sheets as of June 30, 2009 (Unaudited) and December 31, 2008 (Unaudited)	3
	Consolidated Statements of Operations for the Three Months Ended March 31, 2009 and 2008 (Unaudited)		4
	Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2009 and 2008 (Unaudited)	4
	Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2009 and 2008 (Unaudited)		5
	Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2009 and 2008 (Unaudited)	5
	Notes to Consolidated Interim Financial Statements (Unaudited)	6	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	27	23
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	49	40
Item 4.	Controls and Procedures	50	41
PART II — OTHER INFORMATION
Item 1.	Legal Proceedings	50	42
Item 1A.	Risk Factors	51	42
Item 6.	Exhibits		67
Item 4.	Submission of Matters to a Vote of Security Holders	75
	Signatures		68
Item 6.	Exhibits	77
	Signatures	78

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except share data)

	March 31,			December 31,
	June 30,			December 31,
	2009			2008
ASSETS
Current assets:
Cash and cash equivalents	$	4478,~~897~~976		$	72,482
Marketable securities	~~277~~261,~~939~~672			281,186
Prepaid expenses and other current assets	1418,~~281~~661			21,793
Total current assets	~~337~~359,~~117~~309			375,461
Property, buildings and equipment:
Land	6,780			6,780
Buildings and leasehold improvements	86,~~920~~963			86,901
Machinery and equipment	6869,~~035~~011			70,314
Furniture and fixtures	4,~~932~~947			4,932
	166,667			168,927
	167,701			168,927
Less accumulated depreciation and amortization	(~~102~~105,~~177~~421		)	(101,773		)
	64,490			67,154
	62,280			67,154
Marketable securities — Genmab	8578,~~274~~596			87,428
Investment in Celldex Therapeutics	631			3,047
Marketable securities — Celldex Therapeutics	23,154			—
Investment in Celldex Therapeutics	—			3,047
Investments in, and advances to, other partners	790			790
Segregated securities	1,300			1,300
Other assets	1,~~498~~321			1,675
Total assets	$	~~491~~526,~~100~~750		$	536,855
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Trade accounts payable	$	64,~~129~~991		$	5,721
Accrued liabilities	3043,~~971~~287			30,516
Deferred contract revenue - current	2726,~~134~~919			28,062
Total current liabilities	6475,~~234~~197			64,299
Deferred contract revenue - long-term	7097,~~788~~997			73,577
Other long-term liabilities	4,~~744~~415			4,670
2.25% Convertible senior notes due May 15, 2011	~~145~~146,~~911~~392			145,430
Commitments and contingencies	—			—
Shareholders’ equity:
Preferred stock, $1.00 par value, 2,000,000 shares authorized; none issued and outstanding	—			—
Common stock, $.01 par value; 200,000,000 shares authorized; 128,563,038 shares issued and 128,529,198 shares outstanding at March 31, 2009 and 128,539,618 shares issued and 128,505,778 shares outstanding at December 31, 2008	1,286			1,285
Common stock, $.01 par value; 200,000,000 shares authorized; 128,773,193 shares issued and 128,739,353 shares outstanding at June 30, 2009 and 128,539,618 shares issued and 128,505,778 shares outstanding at December 31, 2008	1,288			1,285
Capital in excess of par value	1,~~199~~206,~~194~~100			1,192,709
Treasury stock, at cost 33,840 shares in 2009 and 2008	(85		)	(85		)
Accumulated other comprehensive income	82102,~~817~~482			84,156
Accumulated deficit	(1,~~077~~107,~~789~~036		)	(1,029,186		)
Total shareholders’ equity	~~205~~202,~~423~~749			248,879
Total liabilities and shareholders’ equity	$	~~491~~526,~~100~~750		$	536,855

See notes to these unaudited consolidated financial statements.

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share data)

	Three Months Ended March 31,
	Three Months Ended June 30,						Six Months Ended June 30,
	2009			2008			2009			2008
Contract and license revenues	$	615,~~976~~493		$	75,~~110~~516		$	22,469		$	12,626
Contract and license revenues from Genmab	~~545~~179			~~874~~375			724			1,249
Reimbursement of development costs	3,~~316~~829			4,~~019~~069			7,145			8,088
Total revenues	1019,~~837~~501			129,~~003~~960			30,338			21,963
Costs and expenses:
Research and development	4750,~~069~~759			4952,~~292~~574			97,828			101,866
General and administrative	10,~~513~~527			12,~~409~~435			21,040			24,844
Total costs and expenses	5761,~~582~~286			6165,~~701~~009			118,868			126,710
Operating loss	(4641,~~745~~785		)	(4955,~~698~~049		)	(88,530		)	(104,747		)
Equity in net loss of affiliate	(2,~~416~~500		)	(13,~~785~~546		)	(4,916		)	(5,331		)
Interest and dividend income and realized gains	2,~~041~~157			43,~~528~~710			4,198			8,238
Gain on sale of Genmab stock	—			~~151,834~~—			—			151,834
Interest expense	(1,499		)	(1,544		)
Gain on sale of Celldex Therapeutics stock	14,300			3,331			14,300			3,331
Income (loss) before provision (benefit) for income taxes	(48,619		)	103,335
Interest expense	(1,499		)	(1,545		)	(2,998		)	(3,089		)
Provision (benefit) for income taxes	(16		)	23
Income (loss) before provision (benefit) for income taxes	(29,327		)	(53,099		)	(77,946		)	50,236
Net income (loss)	$	(48,603	)	$	103,312
Provision (benefit) for income taxes	(80		)	—			(96		)	23
Net income (loss) per share:
Net income (loss)	$	(29,247	)	$	(53,099	)	$	(77,850	)	$	50,213
basic	$	(0.38	)	$	0.81
Net income (loss) per share:
diluted	$	(0.38	)	$	0.76
basic	$	(0.23	)	$	(0.42	)	$	(0.60	)	$	0.39
Weighted average number of common shares outstanding:
diluted	$	(0.23	)	$	(0.42	)	$	(0.60	)	$	0.38
basic	128,629			127,643
Weighted average number of common shares outstanding:
diluted	128,629			138,580
basic	128,931			127,724			128,803			127,927
diluted	128,931			127,724			128,803			138,864

See notes to these unaudited consolidated financial statements.

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

	Three Months Ended March 31,
	Six Months Ended June 30,
	2009			2008
Operating activities:
Net income (loss)	$	(4877,~~603~~850	)	$	~~103~~50,~~312~~213
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation	26,~~948~~192			36,~~434~~932
Amortization	~~659~~1,321			~~726~~1,435
Amortization of net bond premium/discount	~~276~~554			(~~740~~1,206		)
Stock based compensation and vesting of restricted stock units	511,~~310~~655			512,~~113~~506
Equity in net loss of Celldex Therapeutics	24,~~416~~916			15,~~785~~331
Gain on sale of Genmab stock	—			(151,834		)
Gain on sale of Celldex Therapeutics/AVANT stock	(14,300		)	(3,331		)
Gain on sale of IDM Pharma stock	(157		)	—
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	71,~~512~~263			96,~~292~~557
Trade accounts payable	~~408~~(730		)	~~684~~(1,685		)
Accrued liabilities	113,~~710~~160			(155,~~430~~789		)
Deferred contract revenue	(323,~~717~~277		)	(14,~~711~~532		)
Net cash used in operating activities	(3130,~~081~~699		)	(4585,~~369~~403		)
Investing activities:
Purchase of property and equipment	(~~284~~1,318		)	(12,~~278~~988		)
Proceeds from sale of Genmab stock	—			151,834
Proceeds from sale of Celldex Therapeutics/AVANT stock	14,300			4,343
Decrease in segregated cash	—			49
Purchase of marketable securities	—			(3560,~~872~~160		)
Sales and maturities of marketable securities	323,~~786~~121			4277,~~000~~264
Net cash provided by investing activities	336,~~502~~103			~~156~~170,~~733~~342
Financing activities:
Cash received from sales of securities and exercise of stock options, net	101,121			13,~~046~~204
Principal payments under capital lease obligations	(1631		)	(1233		)
Net cash provided by (used in) financing activities	(6		)	1,034
Net cash provided by financing activities	1,090			3,171
Effect of exchange rate differences on cash and cash equivalents	—			(20		)
Effect of change in accounting from consolidation to equity method	—			3,584
Net increase (decrease) in cash and cash equivalents	(27,585		)	115,962
Net increase in cash and cash equivalents	6,494			91,674
Cash and cash equivalents at beginning of period	72,482			37,335
Cash and cash equivalents at end of period	$	4478,~~897~~976		$	~~153~~129,~~297~~009
Non-cash investing and financing activities:
Unrealized loss on investment in Genmab	$	(28,~~154~~832	)	$	(2352,~~744~~277	)
Unrealized gain on investment in Celldex Therapeutics	$	23,154		$	—
Supplemental disclosures of cash flow information
Cash paid during period for:
Income taxes	$	—		$	22—
Interest	$	—1,688		$	—1,688

See notes to these unaudited consolidated financial statements.

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Dollars in thousands, unless otherwise indicated, except per share data)

1. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements are unaudited and have been prepared from the books and records of Medarex, Inc. and its subsidiaries (collectively, the “Company”) in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. The consolidated interim financial statements, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results for the interim periods ended ~~March~~June 3130, ~~2009~~ 2009 and 2008.

The Company’s financial statements consolidate all of its subsidiaries, including those that it controls and those in which it holds a majority voting interest. Medarex currently owns approximately 3118.47% of the outstanding common stock of Celldex Therapeutics, Inc. (“Celldex Therapeutics”) (see Note 2). All significant intercompany balances and transactions have been eliminated in consolidation.

The unaudited consolidated results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. The unaudited consolidated balance sheet at December 31, 2008 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required for complete financial statements. These consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto, which are contained in the Company’s annual report on Form 10-K for the year ended December 31, 2008 filed with the Securities and Exchange Commission, or SEC.

Use of Estimates

The preparation of the financial statements and related disclosures in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s consolidated balance sheets and the amounts of revenues and expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue recognition, stock-based compensation, income taxes, loss contingencies and accounting for research and development costs. Actual results could differ from those estimates.

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Dollars in thousands, unless otherwise indicated, except per share data)

Net Income (Loss) per Share

Basic and diluted net income (loss) per share are calculated in accordance with SFAS No. 128, Earnings per Share. Basic net income (loss) per share is based upon the number of weighted average shares of common stock outstanding. Diluted net income (loss) per share is based upon the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding. Potentially ~~dilutive~~ dilutive securities have been excluded from the computation of diluted net loss ~~per~~ per share for the three and six month ~~period~~periods ended ~~March~~June 3130, 2009 and the three month period ended June 30, 2008, as their effect is antidilutive. Potential shares of common stock result from the assumed ~~exercise~~ conversion of convertible ~~outstanding~~senior ~~stock~~notes ~~options,~~and ~~with~~are ~~exercise~~included ~~prices~~in ~~less than~~ the ~~average~~ ~~market~~calculation ~~price~~ of ~~the~~diluted ~~Company’s~~net income ~~common~~per ~~stock~~share ~~during~~for the ~~three~~six month period ended ~~March~~June 3130, 2008~~, which are included under the treasury stock method, as well as the assumed conversion of convertible senior notes~~. Stock options have been excluded from the computation of diluted net income per share for the ~~three~~six month period ended ~~March~~June 3130, 2008 as their effect is antidilutive. A summary of such potentially dilutive securities is as follows:

The following table sets forth the computation of basic and diluted income per share for the ~~three~~six month period ended ~~March~~June 3130, 2008:

Income (Numerator):
Net income for basic and diluted income per share	$	~~103~~50,~~312~~213
Adjustment for interest expense on convertible notes	12,~~491~~982
Income for diluted income per share	$	~~104~~53,~~803~~195
Shares (Denominator):
Weighted average shares for basic income per share	127,~~642~~926,~~821~~596
Effect of dilutive securities (stock options)	—
Effect of convertible notes, after assumed conversion	10,936,935
Weighted average shares for diluted income per share	138,~~579~~863,~~756~~531
Basic net income per share	$	0.8139
Diluted net income per share	$	0.7638

Potential shares of common stock that would be issued if all outstanding stock options were exercised (1918,~~389~~992,~~418~~313 shares), without regard to whether the outstanding stock options were “in the money”, are not included in the computation of diluted net income per share for the ~~three~~ six months ended ~~March~~June 3130, 2008 because to do so would be antidilutive.

The following table sets forth potential shares of common stock that would be issued if all of the convertible notes were converted to common stock and all of the outstanding stock options were exercised, without regard to whether the convertible notes or outstanding stock options were “in the money”. These potential shares of common stock are not included in the computation of diluted loss per share for the three ~~month~~and six ~~period~~month periods ended ~~March~~June 3130, 2009 and the three month period ended June 30, 2008 because to do so would be antidilutive.

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Dollars in thousands, unless otherwise indicated, except per share data)

	Three Months Ended March 31, 2009
	Three Months Ended June 30, 2009	Six Months Ended June 30, 2009	Three Months Ended June 30, 2008
Convertible notes	10,936,935	10,936,935	10,936,935
Outstanding stock options	20,~~637~~424,~~483~~235	20,424,235	18,992,313
	31,574,418
Total shares	31,361,170	31,361,170	29,929,248

Marketable Securities and Long-Term Non-Marketable Investments

Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. Under SFAS No. 115, Accounting for Certain Investments in Debt and Equity Securities (“SFAS No. 115”), these investments are classified as available-for-sale and are reported at fair value on the Company’s consolidated balance sheet. Unrealized holding gains and losses are reported within accumulated other comprehensive income as a separate component of shareholders’ equity. Under the Company’s accounting policy, a decline in the fair value of equity securities is deemed to be “other than temporary” and such equity securities are generally considered to be impaired if their fair value is less than the Company’s cost basis for more than six months, or some other period in light of the particular facts and circumstances surrounding the equity securities. If a decline in the fair value of a marketable security below the Company’s cost basis is determined to be other than temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge.

In addition, the Company has investments in several of its partners whose securities are not publicly traded. These investments are accounted for under the cost basis. Because these securities are not publicly traded, the Company values these investments by using information acquired from industry trends, management of these companies, such companies’ financial statements and other external sources. Specifically, the Company’s determination of any potential impairment of the value of the privately held securities includes an analysis of the following for each company on a periodic basis: review of interim and year-end financial statements, cash position and overall rate of cash used to support operations, the progress and development of technology and product platform, the per share value of subsequent financings and potential strategic alternatives. Based on the information acquired through these sources, the Company records an impairment charge when it believes an investment has experienced a decline in value that is considered to be other than temporary.

The Company recorded no impairment charges related to investments in partners whose securities are publicly traded for the three and six month periods ended ~~March~~June 3130, 2009 and 2008. The Company recorded no impairment ~~charges~~ charges related to investments in partners whose securities are privately held for the three and six month periods ended ~~March~~June 3130, 2009 and 2008. If the Company deems any of its investments to be impaired at the end of any future period, it may incur impairment charges on these investments.

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Dollars in thousands, unless otherwise indicated, except per share data)

~~Estimated Fair Value of~~ Financial Instruments

~~On January 1,~~The ~~2008,~~fair ~~the~~values ~~Company~~of ~~adopted~~cash ~~SFAS~~and ~~No. 157~~cash equivalents, marketable ~~Fair~~securities, ~~Value~~accounts ~~Measurements~~payable ~~(“Statement~~and ~~No. 157”). Statement~~accrued ~~No. 157~~liabilities ~~defines~~are ~~and~~not ~~establishes~~materially adifferent ~~framework~~from ~~for~~their ~~measuring~~carrying ~~fair~~amounts ~~value~~as ~~and~~of ~~expands~~June 30, ~~disclosures~~2009 ~~about fair~~and ~~value instruments~~December 31, 2008. InAs ~~accordance with~~of ~~Statement No.~~June ~~157~~30, 2009, the estimated ~~Company~~fair ~~has~~value ~~categorized~~of ~~its~~the ~~financial~~Company’s ~~assets, based~~convertible onsenior ~~the~~notes ~~priority~~payable ofwas approximately ~~the~~$142.2 ~~inputs~~million as compared to ~~the~~a ~~valuation~~carrying ~~technique,~~value ~~into~~of aapproximately ~~three-level~~$146.4 ~~fair~~million. As ~~value~~of ~~hierarchy~~December 31, 2008, asthe ~~set~~estimated ~~forth~~fair ~~below. The~~value ~~Company~~of ~~does~~the ~~not~~Company’s ~~have~~convertible ~~any~~senior ~~financial~~notes ~~liabilities~~payable ~~that~~was ~~are~~approximately ~~required~~$104.2 tomillion beas ~~measured~~compared atto ~~fair~~a carrying value onof approximately a$145.4 ~~recurring basis~~million. IfThe estimated ~~the~~fair ~~inputs~~value ~~used~~of ~~to measure~~ the ~~financial~~ ~~instruments~~Company’s ~~fall~~convertible ~~within~~senior ~~different~~notes ~~levels~~payable as of ~~the~~June 30, 2009 ~~hierarchy~~and December 31, ~~the categorization~~2008 isare based on ~~the~~quoted ~~lowest~~market ~~level~~prices. ~~input~~Receivables from ~~that~~partners isare ~~significant~~concentrated toprimarily in the pharmaceutical and ~~fair~~biotechnology ~~value~~industries. ~~measurement~~Although ofthe Company’s partners are concentrated primarily within these two industries, management considers the ~~instrument~~likelihood of material credit risk as remote.

Financial assets recorded on the consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows:

· Level 1 — Financial assets whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which the company has the ability to access at the measurement date (examples include active exchange-traded equity securities and most U.S. Government and agency securities).

· Level 2 — Financial assets whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.

· Level 3 — Financial assets whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset. The Company does not currently have any Level 3 financial assets.

A summary of the fair value of the Company’s financial assets (allocated by Level) as of March 31, 2009 is as follows:

	Level 1		Level 2		Total
Money Market Funds/Cash	$	44,897	$	—	$	44,897
U.S. Treasury Obligations	179,492		—		179,492
U.S. Corporate Debt Securities	—		65,929		65,929
Mortgage-Backed Securities	—		27,635		27,635
Equity Securities	4,883		—		4,883
Equity Securities - Genmab	85,274		—		85,274
Total	$	314,546	$	93,564	$	408,110

Revenue Recognition

The Company receives payments from customers and partners from the sale of antibodies, for licenses to its proprietary technology for product development, for services and from the achievement of product development milestones. These payments are generally non-refundable and are reported as deferred revenue until they are recognizable as revenue. The Company follows the following principles in recognizing revenue:

· Fees received from the licensing of the Company’s proprietary technologies for research and development performed by its customers and partners are recognized generally on a straight line basis over the term of the respective license period beginning after both the license period has begun and the technology has been delivered.

· Fees received for product development services are recognized ratably over the period during which the services are performed.

· Milestone payments are recognized as revenue upon the achievement of mutually agreed milestones, provided that (i) the milestone event is substantive and its achievement is not reasonably assured at the inception of the agreement and (ii) there are no continuing performance obligations associated with the milestone payment. Milestone payments are triggered either by the results of research efforts or by the efforts of the Company’s partners and include such events as submission of an Investigational New Drug Application, or IND, commencement of Phase 1, 2 or 3 clinical trials, submission of a Biologic License Application, or BLA, and regulatory approval of a product. Milestone payments are substantially at risk at the inception of an agreement.

· Revenue arrangements that include multiple deliverables are divided into separate units of accounting if the deliverables meet certain criteria, including whether the fair value of the delivered items can be determined and whether there is evidence of fair value of the undelivered items. In addition, the consideration is allocated among the separate units of accounting based on their fair values, and the applicable revenue recognition criteria are considered separately for each of the separate units of accounting.

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Dollars in thousands, unless otherwise indicated, except per share data)

· Fees received for product development services are recognized ratably over the period during which the services are performed.

· Revenues derived from reimbursements of costs associated with the development of product candidates are recorded in compliance with EITF Issue 99-19, Reporting Revenue Gross as a Principal Versus Net as an Agent (“EITF 99-19”). According to the criteria established by EITF 99-19, in transactions where the Company acts as a principal, with discretion to choose suppliers, bears credit risk and performs part of the services required in the transaction, the Company believes it has met the criteria to record revenue for the gross amount of the reimbursements.

· The Company sells antibodies primarily to partners in the United States and overseas. Revenue from these sales is recognized when the antibodies are shipped and the Company has no further obligations related to the development of the antibodies.

· Grant revenues are recognized as the Company provides the services stipulated in the underlying grant based on the time and materials incurred. Amounts received in advance of services provided are recorded as deferred revenue and amortized as revenue when the services are provided.

Income Taxes

The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statement amounts and their respective tax bases. The Company reviews its deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s tax provision in the period of change.

Recently Adopted Accounting Pronouncements

In December 2007, the EITF reached a consensus on Issue No. 07-1, Accounting for Collaborative Arrangements (“EITF 07-1”). The EITF concluded on the definition of a collaborative arrangement and that revenues and costs incurred with third parties in connection with collaborative arrangements would be presented gross or net based on the criteria in EITF 99-19 and other accounting literature. Based on the nature of the arrangement, payments to or from collaborators would be evaluated and the terms, the nature of the entity’s business, and whether those payments are within the scope of other accounting literature would be presented. Companies are also required to disclose the nature and purpose of collaborative arrangements along with the accounting policies and the classification and amounts of significant financial statement amounts related to the arrangements. Activities in the arrangement conducted in a separate legal entity should be accounted for under other accounting literature; however required disclosure under EITF 07-1 applies to the entire collaborative agreement. EITF 07-1 is effective for financial statements issued for fiscal years beginning after December 15, 2008, and interim periods within those fiscal years, and is to be applied retrospectively to all periods presented for all collaborative arrangements existing as of the effective date. The Company adopted EITF 07-1 effective January 1, 2009 and its adoption did not have a significant impact on its consolidated financial statements.

In December 2007, the FASB issued SFAS No. 141 (R), Business Combinations (“Statement No. 141 (R)”), which replaces SFAS No. 141, Business Combinations, and requires an acquirer to recognize the assets acquired, the liabilities assumed and any non-controlling interest in the acquiree at the acquisition date, measured at their fair values as of that date, with limited exceptions. Statement No. 141 (R) also requires the

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Dollars in thousands, unless otherwise indicated, except per share data)

~~likely than~~acquirer ~~not~~in ~~that~~a ~~its~~business ~~deferred~~combination ~~tax~~achieved in stages to recognize the identifiable assets ~~will~~and ~~not~~liabilities, beas ~~realized.~~well ~~Changes~~as the non-controlling interest in ~~valuation~~the ~~allowances~~acquiree, ~~from~~at ~~period~~the full amounts of their fair values. Statement No. 141 (R) makes various other amendments to ~~period~~authoritative ~~are~~literature ~~included~~intended to provide additional guidance or conform the guidance in that literature to that provided in Statement No. 141 (R). Statement No. 141 (R) applies prospectively to business combinations for which the ~~Company’s~~acquisition ~~tax~~date is on or ~~provision~~after inthe beginning of the first annual reporting period beginning on or after December 15, 2008. The adoption of ~~change~~Statement No. 141 (R) did not have a significant impact on the Company’s consolidated financial statements.

~~Recently~~In ~~Adopted~~December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements (“Statement No. 160”), which amends Accounting ~~Pronouncements~~Research Bulletin No. 51, Consolidated Financial Statements, to improve the relevance, comparability and transparency of the financial information that a reporting entity provides in its consolidated financial statements. Statement No. 160 establishes accounting and reporting standards that require the ownership interests in subsidiaries not held by the parent to be clearly identified, labeled and presented in the consolidated statement of financial position within equity, but separate from the parent’s equity. Statement No. 160 also requires the amount of consolidated net income attributable to the parent and to the non-controlling interest to be clearly identified and presented on the face of the consolidated statement of operations. Changes in a parent’s ownership interest while the parent retains its controlling financial interest must be accounted for consistently, and when a subsidiary is deconsolidated, any retained non-controlling equity investment in the former subsidiary must be initially measured at fair value. The gain or loss on the deconsolidation of the subsidiary is measured using the fair value of any non-controlling equity investment. Statement No. 160 also requires entities to provide sufficient disclosures that clearly identify and distinguish between the interests of the parent and the interests of the non-controlling owners. Statement No. 160 applies prospectively to all entities that prepare consolidated financial statements and applies prospectively for all fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008. The Company adopted Statement No. 160 effective January 1, 2009 and its adoption did not have a significant impact on its consolidated financial statements.

In ~~December~~ November ~~2007~~2008, the ~~EITF~~ ~~reached~~FASB aratified the consensus onreached in EITF Issue No. 0708-16, Equity ~~Accounting~~Method ~~for~~Investment ~~Collaborative~~Accounting ~~Arrangements~~Considerations (“EITF 07 08-1”6). The ~~EITF~~ ~~concluded~~equity onmethod ~~the definition~~ of aaccounting is ~~collaborative~~required ~~arrangement~~for ~~and~~investments ~~that revenues~~when ~~and~~the ~~costs~~investor ~~incurred~~does ~~with~~not ~~third~~control ~~parties~~an ininvestee ~~connection with collaborative~~but ~~arrangements~~has ~~would~~the beability ~~presented~~to ~~gross~~exercise orsignificant ~~net~~influence ~~based~~over onits ~~the~~operating ~~criteria~~and financial policies in ~~EITF 99-19~~accordance ~~and~~with ~~other~~APB ~~accounting~~Opinion ~~literature~~No. 18, ~~Based~~The onEquity ~~the~~Method ~~nature~~ of ~~the~~Accounting ~~arrangement, payments~~for toInvestments orin ~~from~~Common ~~collaborators~~Stock. The ~~would~~EITF beconcluded ~~evaluated~~that ~~and~~an ~~the~~equity ~~terms, the nature~~method ofinvestor ~~the~~shall ~~entity’s~~recognize ~~business,~~gains and ~~whether~~losses ~~those~~in ~~payments~~earnings ~~are~~for ~~within~~ the ~~scope~~issuance of ~~other~~shares ~~accounting~~by ~~literature would be presented. Companies are also required to disclose~~ the ~~nature~~equity ~~and~~method ~~purpose~~investee, ofprovided ~~collaborative~~that ~~arrangements along with~~ the ~~accounting~~ ~~policies~~issuance ~~and the classification and amounts~~ of ~~significant financial~~shares ~~statement~~qualifies ~~amounts~~as ~~related to the arrangements. Activities in the arrangement conducted in~~ a ~~separate~~sale ~~legal~~of ~~entity~~shares should be accounted for under other accounting literature; however required disclosure under EITF 07-1 applies to the entire collaborative agreement. EITF 07-1 is effective for financial statements issued for fiscal years beginning after December 15, 2008, (and ~~interim~~ ~~periods~~not ~~within~~a ~~those fiscal years~~financing, ~~and~~as iswould to be ~~applied~~the ~~retrospectively to~~case ~~all~~if ~~periods presented for all collaborative arrangements existing as of~~ the ~~effective~~shares ~~date.~~were ~~The~~sold ~~Company~~subject ~~adopted~~to ~~EITF 07-1 effective January 1, 2009 and its adoption did not have~~ a ~~significant~~forward ~~impact~~contract onto ~~its~~repurchase ~~consolidated financial~~the ~~statements~~shares).

~~In December 2007, the~~Prior ~~FASB issued SFAS No. 141 (R), Business Combinations (“Statement No. 141 (R)”), which replaces SFAS No. 141, Business Combinations, and requires an acquirer~~ to ~~recognize~~ the ~~assets~~adoption ~~acquired,~~of ~~the~~EITF ~~liabilities assumed and any non~~08-~~controlling~~6, ~~interest~~equity inmethod ~~the~~investors ~~acquiree~~followed at the ~~acquisition~~guidance ~~date,~~of ~~measured~~Staff atAccounting ~~their~~Bulletin ~~fair~~No. 51, ~~values~~Accounting asfor Sales of Stock ~~that~~by ~~date,~~a ~~with~~Subsidiary ~~limited~~(SAB ~~exceptions. Statement~~ No. ~~141 (R~~51) ~~also~~, ~~requires the acquirer~~ in aaccounting ~~business combination~~for ~~achieved in stages to recognize~~ the ~~identifiable assets and~~ ~~liabilities,~~issuance asof ~~well~~shares asby the ~~non-controlling~~equity ~~interest~~method ininvestee. ~~the~~SAB ~~acquiree,~~No. 51 ~~at the~~precludes ~~full~~gain ~~amounts~~recognition ofin ~~their~~certain ~~fair~~situations ~~values~~(e. ~~Statement No~~g. ~~141~~ ~~(R) makes various~~share ~~other~~issuance ~~amendments~~as topart ~~authoritative~~of ~~literature intended to provide~~a ~~additional~~broader ~~guidance~~corporate orreorganization, ~~conform~~situations ~~the~~where ~~guidance~~an inentity’s ~~that~~ability ~~literature~~ to ~~that provided~~exist is in ~~Statement~~question, Noetc. ~~141 (R~~). ~~Statement~~and ~~No. 141~~otherwise ~~(R) applies prospectively~~permits toa ~~business~~registrant ~~combinations~~to ~~for~~elect ~~which~~an ~~the~~accounting policy ~~acquisition~~of ~~date~~recognizing isgains onin ~~or after~~ the ~~beginning~~statement of ~~the~~operations ~~first annual reporting period beginning on~~ or ~~after~~in ~~December 15, 2008~~equity. EITF ~~The~~08-6 ~~adoption~~eliminated ofthe ~~Statement~~SAB No. ~~141~~51 exceptions ~~(R) did~~to ~~not~~gain ~~have~~recognition ~~a significant~~and ~~impact on~~ the ~~Company’s~~accounting ~~consolidated~~policy ~~financial statements~~choice.

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements (“Statement No. 160”), which amends Accounting Research Bulletin No. 51, Consolidated Financial Statements, to improve the relevance, comparability and transparency of the financial information that a reporting entity provides in its consolidated financial statements. Statement No. 160 establishes accounting and reporting standards that require the ownership interests in subsidiaries not held by the parent to be clearly identified, labeled and presented in the consolidated statement of financial position within equity, but separate from the parent’s equity. Statement No. 160 also requires the amount of consolidated net income attributable to the parent and to the non-controlling interest to be clearly identified and presented on the face of the consolidated statement of operations. Changes in a parent’s ownership interest while the parent retains its controlling financial interest must be accounted for consistently, and when a subsidiary is deconsolidated, any retained non-controlling equity investment in the former subsidiary must be initially measured at fair value. The gain or loss on the deconsolidation of the subsidiary is measured using the fair value of any non-controlling equity investment. Statement No. 160 also requires entities to provide sufficient disclosures that clearly identify

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Dollars in thousands, unless otherwise indicated, except per share data)

and distinguish between the interests of the parent and the interests of the non-controlling owners. Statement No. 160 applies prospectively to all entities that prepare consolidated financial statements and applies prospectively for all fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008. The Company adopted Statement No. 160 effective January 1, 2009 and its adoption did not have a significant impact on its consolidated financial statements.

In November 2008, the FASB ratified the consensus reached in EITF Issue No. 08-6, Equity Method Investment Accounting Considerations (EITF 08-6). The equity method of accounting is required for investments when the investor does not control an investee but has the ability to exercise significant influence over its operating and financial policies in accordance with APB Opinion No. 18, The Equity Method of Accounting for Investments in common Stock. The EITF concluded that an equity method investor shall recognize gains and losses in earnings for the issuance of shares by the equity method investee, provided that the issuance of shares qualifies as a sale of shares (and not a financing, as would be the case if the shares were sold subject to a forward contract to repurchase the shares).

Prior to the adoption of EITF 08-6, equity method investors followed the guidance of Staff Accounting Bulletin No. 51, Accounting for Sales of Stock by a Subsidiary (SAB No. 51), in accounting for the issuance of shares by the equity method investee. SAB No. 51 precludes gain recognition in certain situations (e.g. share issuance as part of a broader corporate reorganization, situations where an entity’s ability to exist is in question, etc.) and otherwise permits a registrant to elect an accounting policy of recognizing gains in the statement of operations or in equity. EITF 08-6 eliminated the SAB No. 51 exceptions to gain recognition and the accounting policy choice.

The Company previously accounted for sales of stock by a subsidiary in accordance with SAB No. 51 and accordingly, accounted for any gains as a component of equity as opposed to including such gains in the statement of operations. With the adoption of EITF 08-6, any gains arising out of sales of stock by a subsidiary will be included in the Company’s statement of operations.

In May 2008, the FASB issued FASB Staff Position APB 14-1, Accounting for Convertible Debt Instruments That May Be Settled in Cash Upon Conversion (“FSP APB 14-1”). FSP APB 14-1 requires the issuer of certain debt instruments that may be settled in cash (or other assets) on conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer’s nonconvertible debt borrowing rate. FSP APB 14-1 is effective for financial statements issued for fiscal years beginning after December 15, 2008 and requires retroactive application to all periods presented and does not grandfather existing instruments. The Company adopted FSP APB 14-1 effective January 1, 2009 and its adoption did not have any impact on its consolidated financial statements.

Recently Issued and Adopted Accounting Pronouncements

At its April 2009 Board meeting, the FASB issued the following:

· Staff Position No. 115-2, FAS 124-2 and EITF 99-20-2, Recognition and Presentation of Other-Than-Temporary Impairments (FSP 115-2). FSP 115-2 provides new guidance on the recognition of an Other Than Temporary Impairment and provides new disclosure requirements. The recognition and presentation provisions apply only to debt securities classified as available for sale and held to maturity.

· Proposed Staff Position No. FAS 107-1 and APB 28-1, Interim Disclosures about Fair Value of Financial Instruments; An amendment of FASB Statement No 107 (FSP 107-1). FSP 107-1 extends the disclosure requirements of FASB Statement No. 107, Disclosures about Fair Value of Financial Instruments (Statement No. 107), to interim financial statements of publicly traded companies. Statement No. 107 requires disclosures of the fair value of all financial instruments (recognized or unrecognized), when practicable to do so. These fair value disclosures must be presented together with the carrying amount of the financial instruments in a manner that clearly distinguishes between assets and liabilities and indicates how the carrying amounts relate to amounts reported on the balance sheet. An entity must also disclose the methods and significant assumptions used to estimate the fair value of the financial instruments.

· FASB Staff Position No. FAS 157-4, Determining Fair Value When the Volume and Level of Activity for the Asset or Liability has Significantly Decreased and Identifying Transactions that are Not Orderly (FSP 157-4). FSP 157-4 amends FASB Statement No. 157, Fair Value Measurement, to provide additional guidance on estimating fair value when the volume and level of activity for an asset or liability has significantly decreased in relation to normal market activity for the asset or liability.

· SFAS No. 165, Subsequent Events (“Statement No. 165”) provides authoritative literature for a topic that was previously addressed only in the accounting literature, AICPA AU Section 560, Subsequent Events. Statement No. 165 resulted in three modifications to the guidance under AU

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Dollars in thousands, unless otherwise indicated, except per share data)

~~recognition~~Section 560: (i) the ~~and~~names ~~presentation~~of ~~provisions~~the ~~apply~~two ~~only~~types of subsequent events have been changed to ~~debt~~recognized ~~securities~~subsequent events ~~classified~~(currently referred to as ~~available~~Type ~~for~~I) ~~sale~~and nonrecognized subsequent events (currently referred to as Type II), (ii) the definition of subsequent events has been modified to refer to events or transactions that occur after the balance sheet date, but before the issuance of the financial statements; and ~~held~~(iii) establishing a requirement for all entities to ~~maturity~~disclose the date through which the entity has evaluated subsequent events.

~~· Proposed Staff Position No. FAS 107-1~~The ~~and~~Company ~~APB~~adopted ~~28-1,~~the ~~Interim~~above ~~Disclosures~~standards ~~about~~during ~~Fair Value of Financial Instruments; An amendment of FASB Statement No 107 (FSP 107-1). FSP 107-1 extends~~ the ~~disclosure requirements~~quarter ofended ~~FASB Statement No.~~June ~~107~~30, ~~Disclosures~~ ~~about Fair Value of Financial Instruments (Statement No~~2009. ~~107), to~~ The ~~interim~~adoption ~~financial statements~~ of ~~publicly~~these ~~traded~~accounting ~~companies. Statement~~pronouncements ~~No. 107~~did ~~requires~~not ~~disclosures of~~have the fair value of all financial instruments (recognized or unrecognized), when practicable to do so. These fair value disclosures must be presented together with the carrying amount of the financial instruments in a ~~manner that clearly distinguishes between assets and~~ ~~liabilities~~material ~~and~~impact ~~indicates how the carrying amounts relate to amounts reported~~ on the ~~balance~~consolidated ~~sheet. An entity must also disclose the methods and significant assumptions used to estimate the fair value of the~~ financial ~~instruments~~statements.

~~· FASB~~In ~~Staff~~June 2009, ~~Position~~the FASB issued SFAS No. ~~FAS 157-4~~168, ~~Determining~~The ~~Fair~~FASB ~~Value~~Accounting Standards ~~When~~Codification and the ~~Volume~~Hierarchy ~~and~~of ~~Level~~Generally ofAccepted ~~Activity~~Accounting Principles ~~for~~(Statement ~~the~~No. 168). ~~Asset~~Statement orNo. 168 ~~Liability~~will ~~has~~become ~~Significantly~~the ~~Decreased~~source ~~and~~of ~~Identifying~~authoritative ~~Transactions~~U.S. ~~that~~generally ~~are~~accepted ~~Not~~accounting ~~Orderly~~principles (~~FSP 157-4~~GAAP) recognized by the FASB to be applied by nongovernmental entities. Rules and ~~FSP~~interpretive ~~157-4~~releases ~~amends~~of ~~FASB~~the SEC under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants. On the effective date of Statement No. ~~157~~168, ~~Fair~~the ~~Value~~Codification will supersede all then-existing ~~Measurement,~~non-SEC toaccounting ~~provide~~and ~~additional~~reporting ~~guidance~~standards. onAll ~~estimating~~other ~~fair~~non-grandfathered ~~value~~non-SEC ~~when~~accounting literature not included in the ~~volume~~Codification ~~and~~will ~~level~~become non-authoritative. ofStatement ~~activity~~No. 168 is effective for anfinancial ~~asset~~statements issued orfor ~~liability~~interim ~~has~~and annual periods ending after September 15, ~~significantly~~2009. The ~~decreased~~Company indoes ~~relation~~not expect the adoption of Statement No. 168 to ~~normal~~have ~~market~~an ~~activity~~impact ~~for~~on the ~~asset~~Company’s orresults ~~liability~~of operations, financial condition or cash flows.

~~Each of the accounting~~2. Cash ~~pronouncements~~and ~~listed~~Available ~~above is effective~~ for ~~interim~~Sale and annual periods ending after June 15, 2009. The Company is in the process of reviewing the impact of each of the accounting pronouncements listed above but does not expect the adoption of these accounting pronouncements to have a material impact on its consolidated financial statements.Investments

~~2. Investment~~Cash and inavailable ~~Celldex~~for ~~Therapeutics, Inc./AVANT~~sale ~~Immunotherapeutics~~investments consisted of the following as of June 30, 2009 and December ~~Inc.~~31, 2008:

As a result of a series of transactions, the Company owned an approximate 60% interest in Celldex as of December 31, 2007.

	As of June 30, 2009									As of December 31, 2008
	Cost		Unrealized Gain		Unrealized Loss			Fair Value		Cost		Unrealized Gain		Unrealized Loss			Fair Value
Cash Balances	$	22,397	$	—	$	—		$	22,397	$	1,981	$	—	$	—		$	1,981
Money market funds	56,581		—		(2		)	56,579		70,496		11		(6		)	70,501
U.S. Treasury Obligations	164,840		2,710		(4		)	167,546		130,714		3,373		—			134,087
U.S. Corporate Debt Securities	66,646		666		(47		)	67,265		113,355		302		(1,562		)	112,095
Mortgage-Backed Securities	29,448		530		(3,295		)	26,683		33,619		339		(3,180		)	30,778
Equity Securities	9		169		—			178		6,779		—		(2,553		)	4,226
Equity Securities — Genmab	—		78,596		—			78,596		—		87,428		—			87,428
Equity Securities – Celldex Ther.	—		23,154		—			23,154		—		—		—			—
	$	339,921	$	105,825	$	(3,348	)	$	442,398	$	356,944	$	91,453	$	(7,301	)	$	441,096

Included in cash and cash equivalents	$	78,978	$	—	$	(2	)	$	78,976	$	72,477	$	11	$	(6	)	$	72,482
Included in marketable securities	260,943		105,825		(3,346		)	363,422		284,467		91,442		(7,295		)	368,614
Total available for sale securities	$	339,921	$	105,825	$	(3,348	)	$	442,398	$	356,944	$	91,453	$	(7,301	)	$	441,096

On March 7, 2008, AVANT Immunotherapeutics, Inc. and Celldex merged with the combined company named AVANT Immunotherapeutics, Inc. (“AVANT”) which traded under the NASDAQ ticker symbol AVAN through September 30, 2008.

Under the terms of the merger agreement, Celldex shareholders received approximately 4.96 shares of AVANT common stock in exchange for each share of Celldex stock they owned. In connection with the merger, AVANT’s board of directors approved a 1-for-12 reverse stock split of AVANT’s common stock which became effective on March 7, 2008. The Company received a total of 5,312,539 shares of AVANT representing approximately 35.6% of the total post-split outstanding shares of AVANT.

For the period from January 1, 2008 through March 6, 2008, the Company (as the majority shareholder) continued to record 100% of Celldex’s losses which amounted to approximately $2.3 million.

As a result of the merger with AVANT and the corresponding reduction in the Company’s ownership from

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Dollars in thousands, unless otherwise indicated, except per share data)

~~approximately~~Approximately ~~60%~~$0.2 tomillion ~~approximately~~and 35$151.~~6%, the~~9 ~~Company~~million ~~ceased~~was ~~consolidating~~reclassified ~~the~~from ~~operations~~other ofcomprehensive ~~Celldex~~income asand ofrecorded ~~March 6,~~as ~~2008~~a realized ~~and~~gain ~~began~~for tothe ~~account~~six ~~for~~month ~~its~~period ~~investment~~ended inJune 30, ~~AVANT~~2009 ~~under~~and the ~~equity~~year ~~method~~ended ~~of accounting in accordance with APB No.~~December 1831, ~~The Equity~~ ~~Method~~2008, ~~of Accounting for Investments in Common Stock (APB No~~respectively. ~~18).~~

The Company’s ~~recorded~~available ~~a non-cash~~for ~~change~~sale ~~in interest gain of approximately $14~~U.~~3 million during the~~S. ~~three~~Treasury ~~month~~Obligations ~~period~~and ~~ended March 31, 2008 associated with the change from the consolidation basis to the equity method of accounting~~U. ~~Because~~S. ofCorporate ~~the~~Debt ~~uncertainty~~Securities ~~surrounding~~had the ~~ultimate~~ ~~realizability of the gain, the gain was recorded as an increase to~~following ~~capital~~maturities inat ~~excess of par value~~June 30, ~~a component of shareholders’ equity.~~2009:

In May 2008, AVANT sold 781,250 shares of its common stock to a corporate partner in connection with a license and commercialization agreement. As a result of this sale of common stock, the Company’s ownership percentage in AVANT was reduced to approximately 33.8%. The difference between the Company’s proportionate share of the equity and the carrying value after completion of AVANT’s sale of stock to the corporate partner was approximately $2.9 million and was accounted for in accordance with APB Opinion No. 18 and Staff Accounting Bulletin No. 51, Accounting for Sales of Stock by a Subsidiary. This transaction is reflected as an increase to capital in excess of par value in the Company’s consolidated financial statements as of December 31, 2008.

Due in one year or less	$	110,218
Due after one year, less than five years	124,594
Due after five years	—

InFor the three month periods ended June ~~2008~~30, ~~the~~ ~~Company~~2009 ~~sold~~and ~~351~~2008,~~691~~ ~~shares~~realized ofgains ~~AVANT~~totaled ~~for~~ $1214.355 ~~per~~million ~~share~~and ~~resulting in net proceeds of approximately~~ $43.3 million. , ~~The~~respectively, ~~Company~~and realized alosses ~~gain~~totaled of$0 ~~approximately~~and $30.32 million, respectively. For ~~from~~the ~~this~~six month periods ~~transaction. As~~ended aJune 30, ~~result~~2009 ofand ~~this~~2008, ~~sale~~realized ofgains totaled $14.5 million and ~~common~~$155.2 ~~stock~~million, ~~the~~respectively, ~~Company’s~~and ~~ownership~~realized ~~percentage~~losses intotaled ~~AVANT~~$0.1 ~~was~~million ~~further~~and ~~reduced~~$0.2 tomillion, ~~approximately 31~~respectively.~~6%.~~

~~Pursuant~~Unrealized toloss ~~the~~positions ~~Amended~~related to ~~Certificate~~various ofdebt ~~Incorporation~~securities ~~approved~~for bywhich ~~its~~other-than-temporary ~~stockholders~~impairments inhave ~~September 2008,~~not ~~AVANT~~been ~~changed~~recognized ~~its~~at ~~name to Celldex Therapeutics,~~June ~~Inc. (“Celldex Therapeutics”) and began trading under the symbol CLDX effective October 1~~30, ~~2008. In~~ ~~October 2008~~2009, ~~Celldex Therapeutics~~is ~~issued~~summarized ~~81,512~~as ~~shares of its common stock in settlement of a payable further reducing the Company’s ownership percentage to approximately 31.4%.~~follows:

As of March 31, 2009, the Company had a receivable from Celldex Therapeutics of approximately $3.0 million which is included within prepaid expenses and other current assets in the Company’s March 31, 2009 consolidated balance sheet.

	Fair Value		Unrealized Loss
Purchased and held less than one year	$	12,822	$	(48	)
Purchased and held greater than one year	$	17,975	$	(3,298	)

AUnrealized losses ~~member~~in of the ~~Company’s~~portfolio relate to various debt securities including U.S. ~~board~~treasury ofobligations, ~~directors~~asset isbacked ~~also~~securities ~~the~~and ~~chairman~~corporate ofbonds. The ~~the~~unrealized ~~board~~losses ofrelating ~~directors~~to ofdebt securities ~~Celldex~~(primarily asset backed securities) were due to changes in interest ~~Therapeutics~~rates and perceived possible uncertainties regarding scheduled payments. As ofThe Company ~~March 31,~~has ~~2009,~~concluded that unrealized losses in its debt securities are not other-than-temporary as the ~~market~~respective ~~value~~issuers ofhave ~~the~~not defaulted on any payments and Company’s ~~investment~~has inthe ~~Celldex~~ability ~~Therapeutics~~to ~~was~~hold securities to maturity date or the ~~approximately~~recovery ~~$32~~period.3 There ~~million~~were no unrealized losses related to equity securities as of June 30, 2009.

~~Summary financial~~Estimated ~~information~~Fair ~~for~~Value ~~Celldex Therapeutics is as follows as~~ of ~~and~~Financial ~~for the three months ended March 31, 2009:~~Instruments

On January 1, 2008, the Company adopted SFAS No. 157, Fair Value Measurements (“Statement No. 157”). Statement No. 157 defines and establishes a framework for measuring fair value and expands disclosures about fair value instruments. In accordance with Statement No. 157, the Company has categorized its financial assets, based on the priority of the inputs to the valuation technique, into a three-level fair value

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Dollars in thousands, unless otherwise indicated, except per share data)

Current Assets	$	41,839
Non-Current Assets	21,644
Current Liabilities	14,052
Non-Current Liabilities	37,641
Revenue	3,732
Net Loss	(7,704		)

hierarchy as set forth below. The Company does not have any financial liabilities that are required to be measured at fair value on a recurring basis. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

~~3. Equity-Based~~Financial assets ~~Compensation~~recorded on the consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows:

~~The Company’s~~· Level ~~equity~~1 ~~awards~~— ~~are~~Financial ~~governed~~assets ~~by its 2005 Equity Incentive Plan, as~~whose ~~amended~~values ~~(the~~are ~~“Plan”). The~~based ~~purchase price~~on ofunadjusted ~~stock~~quoted ~~options~~prices ~~under~~for ~~the~~identical ~~Plan~~assets isor liabilities ~~determined~~ in ~~accordance~~an ~~with~~active ~~the Company’s~~market ~~Equity~~which ~~Grant Policy as approved by~~ the ~~Board~~company ofhas ~~Directors of~~ the ~~Company. The~~ ~~term~~ability isto ~~fixed~~access ~~by the~~at ~~Compensation and Organization Committee of~~ the ~~Board~~measurement ofdate ~~Directors,~~(examples ~~but~~include ~~no incentive~~active ~~stock~~exchange-traded ~~option~~equity ~~is exercisable after 10 years from the date of~~securities ~~grant. Stock~~and ~~options~~most ~~generally vest over a four year period~~U.S. AsGovernment ofand ~~March 31,~~agency ~~2009, a total of 8,739,152 shares were available for future grants under the Plan~~securities).

~~Total~~· Level ~~stock~~2 ~~based compensation~~— ~~expense~~Financial ofassets ~~approximately $4.9 million for the three month period~~whose ~~ended~~values ~~March 31,~~are ~~2009~~based ~~has~~on ~~been~~quoted ~~included~~market prices in ~~the~~markets ~~consolidated~~where ~~statement~~trading ofoccurs ~~operations~~infrequently ~~within~~or ~~research~~whose ~~and~~values ~~development~~are ~~expenses~~based ~~($2.6~~on ~~million)~~quoted ~~and~~prices ~~general~~of instruments with ~~and~~similar ~~administrative~~attributes ~~expenses~~in ~~($2.3~~active ~~million)~~markets.

~~Total~~· Level ~~stock~~3 ~~based~~— Financial assets whose ~~compensation~~values ~~expense~~are ofbased ~~approximately~~on ~~$5.3~~prices ~~million~~or ~~for~~valuation ~~the~~techniques ~~three~~that ~~month~~require ~~period ended~~inputs ~~March 31,~~that ~~2008~~are both ~~has~~unobservable ~~been~~and ~~included~~significant into the ~~consolidated~~overall ~~statement~~fair ofvalue measurement. These inputs reflect management’s own ~~operations~~assumptions ~~within~~about ~~research~~the ~~and~~assumptions ~~development~~a ~~expenses~~market ~~($2~~participant would use in pricing the asset.0 The ~~million)~~Company ~~and~~does ~~general~~not currently ~~and~~have ~~administrative~~any ~~expenses~~Level ($3.3 ~~million)~~financial assets.

~~The~~A ~~following~~summary ~~summarizes~~of ~~all~~the ~~stock~~fair ~~option~~value ~~transactions~~of ~~for~~ the Company’s ~~under~~financial ~~the Plan~~assets ~~for~~(allocated ~~the~~by Level) ~~period~~as ~~from~~of ~~January~~June 130, 2009 ~~through~~is ~~March 31,~~as ~~2009.~~follows:

	Common Stock Options		Weighted Average Exercise Price			Weighted Average Remaining Contractual Life (years)		Aggregate Intrinsic Value
	Level 1			Level 2			Total
Outstanding at January 1, 2009	17,730,125		$	10.08
Money Market Funds/Cash	$	78,976		$	—		$	78,976
Granted	3,074,180		$	3.73
U.S. Treasury Obligations	167,546			—			167,546
Exercised	(2,300	)	$	4.19
U.S. Corporate Debt Securities	—			67,265			67,265
Canceled	(45,623	)	$	6.57
Mortgage-Backed Securities	—			26,683			26,683
Forfeited	(118,899	)	$	9.66
Equity Securities	178			—			178
Outstanding at March 31, 2009	20,637,483		$	9.14		6.4 years		$	4,846
Equity Securities - Genmab	78,596			—			78,596
Exercisable at end of period	13,091,998		$	9.57		4.9 years		$	563
Equity Securities – Celldex Therapeutics	23,154			—			23,154
Vested and unvested expected to vest at March 31, 2009	20,029,305		$	9.18		6.3 years		$	4,473
Total	$	348,450		$	93,948		$	442,398

3. Investment in Celldex Therapeutics, Inc./AVANT Immunotherapeutics, Inc.

As a result of a series of transactions, the Company owned an approximate 60% interest in Celldex as of December 31, 2007.

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Dollars in thousands, unless otherwise indicated, except per share data)

~~The~~became ~~weighted-average~~effective ~~grant-date~~on ~~fair value of options granted during the three month periods ended~~ March 317, ~~2009 and~~ 2008 ~~were $2~~.~~66 and $6.54, respectively.~~ The Company ~~aggregate~~received ~~intrinsic~~a ~~value~~total of ~~options exercised during these same periods was $13 thousand and $0.3 million~~5,312,539 ~~respectively. The~~shares ~~grant-date fair value~~ of ~~shares~~AVANT ~~which vested during the three month~~representing ~~periods~~approximately ~~ended March 31, 2009 and 2008 was $6~~35.6% ~~million~~of ~~and $3.2 million, respectively. Cash proceeds from stock options exercised during~~ the ~~three~~total ~~month~~post-split ~~periods~~outstanding ~~ended~~shares ~~March 31,~~of ~~2009 and 2008 totaled $10 thousand and $0~~AVANT.~~5 million, respectively.~~

~~The~~For ~~fair value of each option grant is estimated using~~ the ~~Black-Scholes option pricing method. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting~~ period ~~(generally~~from ~~4 years). Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. To estimate the grant date fair value~~January 1, ~~option~~2008 ~~pricing~~through ~~models require the use of estimates and assumptions as to (i)~~March ~~the~~6, ~~expected term of the option~~2008, ~~(ii)~~ the ~~expected~~Company ~~volatility of the price of the underlying stock,~~ (~~iii) the~~as ~~risk free interest rate for~~ the ~~expected~~majority ~~term of the option and (iv~~shareholder) ~~pre-vesting forfeiture~~ ~~rates.~~continued ~~The~~to ~~expected~~record ~~term~~100% of the option is based upon the contractual term, taking into account expected employee exercise and expected post-vesting termination behavior. The expected volatility of the price of the underlying stock is based on the historical volatility of the CompanyCelldex’s ~~common stock. The~~losses ~~risk~~which ~~free~~amounted ~~interest rate is based on U.S. Treasury zero-coupon issues with a remaining term equal~~ to ~~the~~approximately ~~expected life assumed on the date of grant~~$2. ~~Pre-vesting~~3 ~~forfeiture rates are estimated based on past voluntary termination behavior, as well as an analysis of actual option forfeitures~~million. ~~The following table sets forth the assumptions used to calculate the fair value of options granted for the three month periods ended March 31, 2009 and 2008:~~

	Three Months Ended March 31,
	2009		2008
Expected stock price volatility	81.7	%	81.5	%
Risk-free interest rate	1.66	%	2.57	%
Expected life of options (years)	6.4		6.4
Expected dividend yield	0	%	0	%

As a result of the merger with AVANT and the corresponding reduction in the Company’s ownership from approximately 60% to approximately 35.6%, the Company ceased consolidating the operations of Celldex as of March 6, 2008 and began to account for its investment in AVANT under the equity method of accounting in accordance with APB No. 18, The Equity Method of Accounting for Investments in Common Stock (APB No. 18).

AsThe Company recorded a non-cash change in interest gain of ~~March~~approximately $14.3 million during the six month period ended June 3130, ~~2009,~~2008 ~~the~~associated ~~total~~with ~~unrecognized~~the ~~compensation~~change ~~cost~~from ~~related~~the consolidation basis to ~~non-vested~~ ~~stock~~the ~~options~~equity ~~was~~method ~~approximately~~of ~~$33~~accounting.~~2 million.~~ ~~This~~Because ~~cost~~of isthe ~~expected~~uncertainty surrounding the ultimate realizability of the gain, the gain was recorded as an increase to becapital ~~recognized~~in ~~over~~excess aof ~~weighted~~par ~~average~~value, ~~period~~a component of ~~2.5~~shareholders’ ~~years~~equity.

AIn ~~summary~~May 2008, AVANT sold 781,250 shares of its common stock to a corporate partner in connection with a license and commercialization agreement. As a result of this sale of common stock, the Company’s ownership percentage in AVANT was reduced to approximately 33.8%. The difference between the Company’s ~~non-vested~~proportionate ~~restricted~~share ~~stock~~of asthe equity and the carrying value after completion of ~~March 31,~~AVANT’s ~~2009~~sale of stock to the corporate partner was approximately $2.9 million and ~~changes~~was ~~during~~accounted ~~the~~for ~~three~~in ~~month~~accordance ~~period~~with ~~ended~~APB ~~March~~Opinion No. 3118 and Staff Accounting Bulletin No. 51, ~~2009~~Accounting for Sales of Stock by a Subsidiary. This transaction is reflected as an increase to capital in excess of par value in ~~follows:~~the Company’s consolidated financial statements as of June 30, 2008.

Non-Vested Restricted Stock	Number of Awards
Non-vested as of January 1, 2009	376,333
Granted	—
Vested	(1,667	)
Cancelled	(5,000	)
Non-vested as of March 31, 2009	369,666

In June 2008, the Company sold 351,691 shares of AVANT for $12.35 per share resulting in net proceeds of approximately $4.3 million. The Company realized a gain of approximately $3.3 million from this transaction. As a result of this sale of common stock, the Company’s ownership percentage in AVANT was further reduced to approximately 31.6%.

Pursuant to the Amended Certificate of Incorporation approved by its stockholders in September 2008, AVANT changed its name to Celldex Therapeutics, Inc. (“Celldex Therapeutics”) and began trading under the symbol CLDX effective October 1, 2008. In October 2008, Celldex Therapeutics issued 81,512 shares of its common stock in settlement of a payable further reducing the Company’s ownership percentage to approximately 31.4%.

On June 24, 2009, the Company sold 2,000,000 shares of Celldex Therapeutics for $7.15 per share resulting in net proceeds of approximately $14.3 million. The Company realized a gain of approximately $14.3 million from this transaction. As a result of this sale of common stock, the Company’s ownership percentage in Celldex Therapeutics was reduced to approximately 18.7%. As a result of the decrease in the Company’s ownership below 20%, on June 25, 2009 the Company began accounting for its investment in Celldex Therapeutics as a marketable security in accordance with SFAS No. 115. Accounting for the Company’s investment in Celldex Therapeutics as a marketable security in accordance with SFAS No. 115 resulted in an unrealized gain of approximately $23.2 million as of June 30, 2009. Such unrealized gain is also included

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Dollars in thousands, unless otherwise indicated, except per share data)

within accumulated other comprehensive income classified within shareholders’ equity in the June 30, 2009 consolidated balance sheet.

As of June 30, 2009, the Company had a receivable from Celldex Therapeutics of approximately $3.0 million which is included within prepaid expenses and other current assets in the Company’s June 30, 2009 consolidated balance sheet.

A member of the Company’s board of directors is also the chairman of the board of directors of Celldex Therapeutics. As of June 30, 2009, the market value of the Company’s investment in Celldex Therapeutics was approximately $23.2 million.

4. Equity-Based Compensation

The Company’s equity awards are governed by its 2005 Equity Incentive Plan, as amended (the “Plan”). The purchase price of stock options under the Plan is determined in accordance with the Company’s Equity Grant Policy as approved by the Board of Directors of the Company. The term is fixed by the Compensation and Organization Committee of the Board of Directors, but no incentive stock option is exercisable after 10 years from the date of grant. Stock options generally vest over a four year period. As of June 30, 2009, a total of 8,928,979 shares were available for future grants under the Plan.

Total stock based compensation expense of approximately $4.7 million for the three month period ended June 30, 2009 has been included in the consolidated statement of operations within research and development expenses ($2.4 million) and general and administrative expenses ($2.3 million). Total stock based compensation expense of approximately $6.2 million for the three month period ended June 30, 2008 has been included in the consolidated statement of operations within research and development expenses ($2.6 million) and general and administrative expenses ($3.6 million).

Total stock based compensation expense of approximately $9.6 million for the six month period ended June 30, 2009 has been included in the consolidated statement of operations within research and development expenses ($5.1 million) and general and administrative expenses ($4.5 million). Total stock based compensation expense of approximately $11.5 million for the six month period ended June 30, 2008 has been included in the consolidated statement of operations within research and development expenses ($4.6 million) and general and administrative expenses ($6.9 million).

The following summarizes all stock option transactions for the Company under the Plan for the period from January 1, 2009 through June 30, 2009.

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Dollars in thousands, unless otherwise indicated, except per share data)

	Common Stock Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (years)	Aggregate Intrinsic Value
Outstanding at January 1, 2009	17,730,125		$	10.08
Granted	3,102,830		$	3.76
Exercised	(27,215	)	$	5.32
Canceled	(157,809	)	$	9.68
Forfeited	(223,696	)	$	8.03
Outstanding at June 30, 2009	20,424,235		$	9.15	6.1 years	$	27,122

Exercisable at end of period	13,699,723		$	9.71	4.8 years	$	13,005

Vested and unvested expected to vest at June 30, 2009	19,860,262		$	9.19	6.0 years	$	25,873

The weighted-average grant-date fair value of options granted during the six month periods ended June 30, 2009 and 2008 were $2.68 and $6.48, respectively. The aggregate intrinsic value of options exercised during these same periods was $0.2 million and $1.3 million, respectively. The grant-date fair value of shares which vested during the six month periods ended June 30, 2009 and 2008 was $13.5 million and $9.9 million, respectively. Cash proceeds from stock options exercised during the six month periods ended June 30, 2009 and 2008 totaled $0.1 million and $2.2 million, respectively.

The fair value of each option grant is estimated using the Black-Scholes option pricing method. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period (generally 4 years). Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. To estimate the grant date fair value, option pricing models require the use of estimates and assumptions as to (i) the expected term of the option, (ii) the expected volatility of the price of the underlying stock, (iii) the risk free interest rate for the expected term of the option and (iv) pre-vesting forfeiture rates. The expected term of the option is based upon the contractual term, taking into account expected employee exercise and expected post-vesting termination behavior. The expected volatility of the price of the underlying stock is based on the historical volatility of the Company’s common stock. The risk free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term equal to the expected life assumed on the date of grant. Pre-vesting forfeiture rates are estimated based on past voluntary termination behavior, as well as an analysis of actual option forfeitures. The following table sets forth the assumptions used to calculate the fair value of options granted for the three and six month periods ended June 30, 2009 and 2008:

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Dollars in thousands, unless otherwise indicated, except per share data)

	Three Months Ended June 30,		Six Months Ended June 30,
	2009	2008	2009	2008
Expected stock price volatility	81.5%-81.8%	81.8%	80.1%-81.8%	81.5%-81.9%
Weighted average expected volatility	81.6%	81.9%	81.7%	81.5%
Risk-free interest rate	2.03%-2.57%	3.32%	1.66%-2.57%	2.57%-3.50%
Expected life of options (years)	6.3	6.4	6.4	6.4
Expected dividend yield	0%	0%	0%	0%

As of June 30, 2009, the total unrecognized compensation cost related to non-vested stock options was approximately $28.2 million. This cost is expected to be recognized over a weighted average period of 2.2 years.

A summary of the Company’s non-vested restricted stock as of June 30, 2009 and changes during the six month period ended June 30, 2009 is as follows:

Non-Vested Restricted Stock	Number of Awards
Non-vested as of January 1, 2009	376,333
Granted	—
Vested	(124,167	)
Cancelled	(5,000	)
Non-vested as of June 30, 2009	247,166

Deferred Compensation

The Company maintains deferred compensation programs, under which each of the Company’s executive officers may elect to have a portion of their bonuses, which were otherwise payable in cash, converted to restricted stock units representing shares of the Company’s common stock. Participants in the deferred compensation programs can elect to defer up to 100% of their respective bonuses. The number of restricted stock units awarded upon such conversion is determined by dividing (i) the amount of the bonus to be converted by (ii) the fair market value of the Company’s common stock on the grant date. Participants in the deferred compensation programs elect to defer receipt of these restricted stock units until at least the earlier of three years from the grant date or the participant’s termination from the Company. The bonus portion deferred by each participant was matched by the Company at 25%, for deferrals related to 2008 bonuses, and 100% for deferrals related to bonuses prior to 2008. The Company match related to the 2008 bonus deferrals vests ratably on the first, second and third anniversaries of the grant date. For deferrals prior to 2008, 25% of the match vested on the grant date, with an additional 25% vesting on each anniversary of the grant date for the next three years. All benefits under each of the deferred compensation programs are distributed in a single payment and will be paid exclusively in the form of shares of the Company’s common stock. The Company’s matching contribution was approximately $0.2 million and $0.12 million for the three month periods ended ~~March~~June 3130, 2009 and 2008, respectively, and $0.4 million and $0.3 million for the six month periods ended June 30, 2009 and 2008, respectively.

~~A summary of the Company’s non-vested restricted stock units as of March 31, 2009 and changes during the three month period ended March 31, 2009 is as follows:~~19

Non-Vested Restricted Stock Units	Number of Units
Non-vested as of January 1, 2009	258,013
Granted	557,643
Vested	(231,296	)
Forfeited	—
Non-vested as of March 31, 2009	584,360

Table of Contents

4MEDAREX, INC. ~~Investments~~ inAND ~~Genmab~~SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Dollars in thousands, unless otherwise indicated, except per share data)

A summary of the Company’s non-vested restricted stock units as of June 30, 2009 and changes during the six month period ended June 30, 2009 is as follows:

Non-Vested Restricted Stock Units	Number of Units
Non-vested as of January 1, 2009	258,013
Granted	557,643
Vested	(292,846	)
Forfeited	(11,667	)
Non-vested as of June 30, 2009	511,143

5. Investments in Genmab

The Company accounts for its investment in Genmab A/S (“Genmab”) in accordance with Statement of Financial Accounting Standards (“SFAS”) No. 115, Accounting for Certain Investments in Debt and Equity Securities.

As a result of a series of transactions, including an initial public offering by Genmab of its ordinary shares in October 2000, the Company owned an approximate 10.8% interest in Genmab as of December 31, 2007.

On February 1, 2008, the Company completed the sale of 2,500,000 shares of Genmab through a block trade. The Company received net proceeds of approximately $151.8 million from such block trade. As a result of this transaction, the Company’s ownership percentage in Genmab was reduced to approximately 5.1%.

As of ~~March~~June 3130, 2009, the market value of the Company’s investment in Genmab was approximately $8578.36 million.

176. Collaboration Agreements

Bristol-Myers Squibb Collaboration

In January 2005, the Company entered into a collaboration and co-promotion agreement and a related securities purchase agreement with Bristol-Myers Squibb Company (“BMS”), pursuant to which the Company and BMS each granted the other certain intellectual property licenses and product rights on a worldwide basis to enable the parties to collaborate in research and development of certain antibody-based product candidates for the treatment of cancer and other diseases, and, in the event that further development work is successful, to commercialize any resulting products. In particular, the collaboration includes a grant by the Company to BMS of a license to commercialize ipilimumab, a fully human antibody product developed using the Company’s UltiMAb® technology, that is antagonistic to cytotoxic T-lymphocyte antigen 4 (CTLA-4). Ipilimumab is currently under investigation for the treatment of a broad range of cancers and other diseases.

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Dollars in thousands, unless otherwise indicated, except per share data)

5development efforts that relate solely to regulatory approval in the European Union and other parts of the world. ~~Bristol~~ Approximately $2.6 million and $3.2 million of the Company’s revenue for the three month periods ended June 30, 2009 and 2008, respectively, and approximately $4.7 million and $6.6 million of the Company’s revenue for the six month periods ended June 30, 2009 and 2008, respectively, represented the reimbursement of 65% of the Company’s costs associated with the development of ipilimumab recorded in accordance with EITF 99-~~Myers~~19. The Company’s share of the BMS development ~~Squibb~~costs ~~Collaboration~~for the three month periods ended June 30, 2009 and 2008 was approximately $11.1 million and $6.7 million, respectively, and the Company’s share of BMS development costs for the six month periods ended June 30, 2009 and 2008 was approximately $20.3 million and $13.1 million, respectively.

As part of the collaboration, BMS is responsible for 65% of all development costs related to clinical trials intended to support regulatory approval in both the United States and Europe, with the remaining 35% to be paid by the Company. The parties will share equally the costs of any clinical trials of products intended solely for regulatory approval in the United States, and BMS will be fully responsible for all development efforts that relate solely to regulatory approval in Europe and other parts of the world. Approximately $2.1 million and $3.5 million of the Company’s revenue for the three month periods ended March 31, 2009 and 2008, respectively, represented the reimbursement of 65% of the Company’s costs associated with the development of ipilimumab recorded in accordance with EITF 99-19. The Company’s share of the BMS development costs for the three month periods ended March 31, 2009 and 2008 was approximately $9.2 million and $5.3 million, respectively.

Under the terms of the collaboration, the Company has the option to co-promote any product in the U.S. If the Company exercises a co-promotion option with respect to a product for use in the first cancer indication for which an initial regulatory approval filing is accepted by the U.S. Food and Drug Administration (“FDA”), the Company will have the right and obligation to co-promote such product for use in all cancer indications, even if such indications are the subject of additional filings or approvals, and even if the Company opted-out of the development of any such indication. Even if the Company elects to co-promote a product for cancer indications, however, the Company would need to exercise a separate option to co-promote that product with respect to any indication other than cancer. If the Company does not exercise its co-promotion option with respect to a product for use in the first cancer indication for which an initial regulatory approval filing is accepted by the FDA, then the Company will not have the right or obligation to co-promote such product for any cancer indications, unless the filing for that first cancer indication is not approved by the FDA.

Under the terms of the collaboration, the Company could receive up to $205.0 million from BMS if all regulatory milestones are met, plus up to an additional $275.0 million in sales-related milestones. In addition, if the Company exercises its co-promotion option with respect to ipilimumab for the metastatic melanoma indication, and regulatory approval is obtained, the Company would receive 45% of any profits ~~from~~and bear 45% of all losses from commercial sales of such product in the U.S. In the event the Company chooses not to exercise its co-promotion rights with respect to a product, BMS will have exclusive commercial rights in the U.S. and will pay the Company royalties on commercial sales. Regardless of whether or not the Company exercises its co-promotion option outside the U.S., BMS will have exclusive commercial rights for products and will pay the Company royalties on commercial sales.

18As part of the collaboration, BMS made a cash payment to the Company on January 21, 2005 of $25.0 million and also purchased 2,879,223 shares of the Company’s common stock at a purchase price equal to $8.6829 per share for an aggregate purchase price of $25.0 million.

The Company determined that all elements under the collaboration and co-promotion agreement should be accounted for as a single unit of accounting under EITF 00-21, Accounting for Revenue Arrangements with Multiple Deliverables (“EITF 00-21”). In accordance with SAB No. 104 (Topic 13, Revenue Recognition), deferral of revenue is appropriate regarding nonrefundable, upfront fees received in single unit of accounting arrangements. As the Company has continuing obligations under the collaboration and co-promotion agreement, and as significant development risk remains, the Company recorded the $25.0 million upfront fee as deferred revenue and the Company is recognizing this amount over the enforceable term of the technology sublicensed to BMS under the collaboration and co-promotion agreement of approximately 11 years, as well as the technology and know-how to be delivered in connection therewith.

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Dollars in thousands, unless otherwise indicated, except per share data)

AsThe ~~part~~BMS collaboration became effective in January 2005, and unless terminated earlier, will continue with respect to each product until the expiration of the ~~collaboration,~~last ~~BMS~~profit ~~made~~sharing aor ~~cash~~royalty ~~payment~~obligation with respect to such product. BMS, however, may terminate the ~~Company~~collaboration under certain conditions, in its entirety, on ~~January 21~~a country-by-country basis or on a product-by-product basis, ~~2005~~resulting in the return of ~~$25.0~~all ~~million~~rights ~~and~~to ~~also~~Medarex with respect to such ~~purchased~~country 2and/or product. In addition,~~879,223~~ either ~~shares~~party ofmay terminate the ~~Company~~other party’s ~~common~~co-promotion ~~stock~~rights atin athe ~~purchase~~U.S. ~~price~~in ~~equal~~the event that such other party fails to $8satisfy certain performance criteria.~~6829~~ Either ~~per~~party ~~share~~may ~~for~~terminate anthe collaboration ~~aggregate~~in ~~purchase~~the ~~price~~event of ~~$25.0~~certain ~~million~~specified material breaches by the other party.

~~The~~Merck ~~Company~~License determined that all elements under the collaboration and co-promotion agreement should be accounted for as a single unit of accounting under EITF 00-21, Accounting for Revenue Arrangements with Multiple Deliverables (“EITF 00-21”). In accordance with SAB No. 104 (Topic 13, Revenue Recognition), deferral of revenue is appropriate regarding nonrefundable, upfront fees received in single unit of accounting arrangements. As the Company has continuing obligations under the collaboration and co-promotion agreement, and as significant development risk remains, the Company recorded the $25.0 million upfront fee as deferred revenue and the Company is recognizing this amount over the enforceable term of the technology sublicensed to BMS under the collaboration and co-promotion agreement of approximately 11 years, as well as the technology and know-how to be delivered in connection therewith.Agreement

~~The BMS collaboration became effective in~~On ~~January~~April ~~2005~~20, ~~and~~2009 ~~unless~~Merck & ~~terminated earlier, will continue for as long as development and/or commercialization of any collaboration product continues~~Co. ~~BMS~~, Inc. ~~however~~(“Merck”), ~~may~~Medarex ~~terminate~~and ~~the~~Massachusetts ~~collaboration~~Biologic onLaboratories a(“MBL”) ~~country-by-country~~announced ~~basis~~that atthey ~~any~~had ~~time~~signed ~~and,~~an exclusive ~~under~~worldwide ~~certain conditions,~~license onagreement afor ~~product~~MDX-by066/MDX-~~product basis~~1388, ~~resulting~~an ininvestigational fully ~~the~~human ~~return~~monoclonal ofantibody ~~all rights~~combination developed to ~~the~~target ~~Company~~and ~~with~~neutralize ~~respect~~Clostridium todifficile ~~such~~toxins ~~country~~A and~~/or~~ ~~product. In addition~~B, ~~BMS~~for ~~may~~use ~~terminate~~with ~~the Company’s~~respect ~~co-promotion~~to ~~rights in the U~~C.S. indifficile ~~the event that the Company fails to satisfy certain performance criteria~~infection. ~~The Company~~MDX-066 ~~may~~and ~~terminate~~MDX-1388 ~~the~~were ~~BMS~~co-developed ~~collaboration in the event of certain specified material breaches~~ by ~~BMS (in which case product rights would revert to~~ the Company), and ~~the Company may terminate BMS’s co-promotion rights in the event that BMS fails to satisfy certain performance criteria~~MBL.

6Under the terms of the agreement, Merck gains worldwide rights to develop and commercialize MDX-066 and MDX-1388. ~~Contingencies~~ The Company and MBL each received an upfront payment of $30.0 million and are potentially eligible to each receive additional cash payments up to $82.5 million upon the achievement of certain events associated with the development and approval of a drug candidate covered by the license agreement. These payments are dependent upon completion of certain clinical and regulatory milestones as defined in the Merck License Agreement. There can be no assurance that these clinical and regulatory achievements will be met and therefore there can be no assurance that the Company will receive such future payments. Upon commercialization, the Company and MBL will also be eligible to receive double digit royalties on product sales and milestone payments if certain sales targets are met. In accordance with the pre-existing collaboration agreement between the Company and MBL, all payments will be divided equally.

The Company determined that all elements under the Merck License Agreement should be accounted for as a single unit of accounting under EITF 00-21. Accordingly deferral of revenue is appropriate regarding nonrefundable upfront fees received in single unit of accounting arrangements. Due to the Company’s continuing obligations under the Merck License Agreement, the Company has recorded the $30.0 million nonrefundable payment as deferred revenue. The Company is not currently able to determine the obligation period under the Merck License Agreement. The Company will continue to defer the revenue from the upfront fee until the Company can determine the obligation period.

7. Contingencies

Kirin Collaboration

In 2002, the Company entered into a collaboration and license agreement with Kirin Brewery Co., Ltd. (“Kirin”) which cross-licenses certain of the Company’s and Kirin’s technologies for the development and commercialization of human antibody products. Under the collaboration and license agreement, the Company and Kirin developed the KM-Mouse®, a unique crossbred mouse which combines the traits of the Company’s HuMAb-Mouse® with Kirin’s TC Mouse™ and exchanged cross-licenses with respect to the KM-Mouse and other antibody-generating mice. In addition, each of the cross-licenses granted under the collaboration and license agreement are subject to certain license, milestone and royalty payments by each party to the other.

1922

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Dollars in thousands, unless otherwise indicated, except per share data)

~~Through March~~HuMAb-Mouse® ~~31,~~with ~~2009, the Company has not made any milestone payments to~~ Kirin~~. However, approximately $3.0 million has been paid to Kirin through March 31, 2009 primarily representing a payment due Kirin as a result of the Company~~’s ~~collaboration with~~TC ~~Pfizer,~~Mouse™ ~~Inc.~~and ~~Based~~exchanged oncross-licenses ~~products~~with ~~the~~respect ~~Company is developing, which use~~to or the ~~Company~~KM-Mouse ~~believes may use Kirin technology~~ and ~~that~~other ~~(i) are currently~~antibody-generating inmice. ~~clinical~~In ~~trials~~addition, oreach ~~(ii) the Company anticipates may enter clinical trials by the end~~ of ~~2010,~~ the ~~Company may be required to make~~ ~~milestone~~cross-licenses ~~payments~~granted tounder ~~Kirin~~the ~~aggregating~~collaboration upand tolicense ~~approximately~~agreement ~~$4.25 million per~~are ~~product~~subject ~~with respect~~ to ~~such~~certain ~~products.~~license, ~~The Company’s future~~ milestone ~~payment obligations to Kirin may or may not be triggered,~~ and ~~may~~royalty ~~vary~~payments inby ~~size, depending~~each onparty ato ~~number of variables, almost all of which are currently unknown, including~~ the ~~following:~~ other.

Through June 30, 2009, the Company has not made any milestone payments to Kirin. However, approximately $3.0 million has been paid to Kirin through June 30, 2009 primarily representing a payment due Kirin as a result of the Company’s collaboration with Pfizer, Inc. Based on products the Company is developing, which use or the Company believes may use Kirin technology and that (i) are currently in clinical trials, or (ii) the Company anticipates may enter clinical trials by the end of 2010, the Company may be required to make milestone payments to Kirin aggregating up to approximately $4.25 million per product with respect to such products. The Company’s future milestone payment obligations to Kirin may or may not be triggered, and may vary in size, depending on a number of variables, almost all of which are currently unknown, including the following:

· whether or not a decision is made to request a license from Kirin;

· the type of license requested (research or commercial);

· the success and timing of development efforts and clinical trials of product candidates covered by any such licenses;

· the type of product developed (payment obligations differ depending on whether a product is an ex vivo therapeutic, in vivo therapeutic, research reagent or diagnostic); and

· other financial provisions of the Kirin agreement that provide for variations in fee levels and netting of certain payments over specified periods of time that may impact the total amount potentially payable to Kirin for any particular license fee or milestone payment.

Whether the Company may be obligated to make milestone payments to Kirin in the future is subject to the success of its efforts with respect to products the Company or its partners are developing that utilize the Kirin technology and, accordingly, is inherently uncertain.

Unless terminated earlier, the collaboration and license agreement expires on December 31, 2014. The collaboration and license agreement can be terminated by either party in the event of a material breach by the other party if the breach is not cured during a specified cure period. In addition, either party may terminate any commercial license with respect to a specific biologic target granted to it by the other party under the agreement at any time.

Other Contingent Arrangements

The Company has entered into a number of other agreements that contain in-licenses of third-party technology (in addition to Kirin) which may be used together with the Company’s own platform technologies for the generation, development and/or manufacture of its antibody products. In addition, the Company has entered into other third-party agreements that contain in-licenses associated with antibody products that target specific antigens. Many of these agreements contain milestones payments that are due with respect to products using/targeting the licensed technology/antigen only if and when certain specified pre-commercialization events occur. Not all of the Company’s products currently under development trigger such milestone payments. Through ~~March~~June 3130, 2009, the Company has made milestone payments under these agreements of approximately $2.2 million. In addition, under the agreements the Company currently has in place (other than with Kirin), based on a total of ten products the Company is developing for which milestones are potentially due and that (i) are now in clinical trials or (ii) which the Company anticipates may enter clinical trials before the end of 2010, the Company may be obligated to make future milestone payments aggregating up to approximately

2023

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Dollars in thousands, unless otherwise indicated, except per share data)

based on a total of ten products the Company is developing for which milestones are potentially due and that (i) are now in clinical trials or (ii) which the Company anticipates may enter clinical trials before the end of 2010, the Company may be obligated to make future milestone payments aggregating up to approximately $57.5 million with respect to such products. In general, potential milestone payments for antibody ~~product~~ product candidates may or may not be triggered under these licenses, and may vary in size, depending on a number of variables, almost all of which are ~~currently~~ currently uncertain. Typically, the events that trigger these milestone payments per product include:

· submission of IND(s) or foreign equivalents;

· commencement of Phase 1, Phase 2 and/or Phase 3 clinical trials or foreign equivalents;

· submission of BLA(s) or foreign equivalents; and

· receipt of marketing approval(s) to sell products in a particular country or region.

In addition, the licenses above may trigger royalty payments in connection with the commercialization of certain of the Company’s products. Whether the Company will be obligated to make milestone or royalty payments in the future is subject to the success of its product development efforts and, accordingly, is inherently uncertain.

Stock Option Grant Practices

The SEC is conducting an informal inquiry into the Company’s historical stock option granting practices and related accounting and disclosures. In addition, the United States Attorney’s Office for the District of New Jersey is conducting a grand jury investigation relating to the same matters. At the conclusion of the SEC’s informal inquiry and the U.S. Attorney’s Office investigation, the Company could be subject to criminal or civil charges and fines or penalties or other contingent liabilities; however, no outcome is determinable at this time.

The Company is unable to reasonably estimate any possible range of loss or liability associated with the stock option inquiry due to its uncertain resolution.

In conjunction with the review of the Company’s stock option grant practices, the Company has also evaluated the related tax issues to determine if the Company may be subject to additional tax liability as a result of the matters under review. In addition, due to revision of measurement dates, certain stock options that were previously treated as incentive stock options may not actually qualify for such treatment and may be treated as non-statutory stock options. Accordingly, the Company may be subject to fines, penalties or both relating to the tax treatment of such stock options. While the Company believes that its accrual for additional tax liabilities associated with the matters under review is appropriate under the circumstances, it is possible that additional liabilities exist and the amount of such additional liabilities could be material.

Legal Proceedings

In the ordinary course of its business, the Company is at times subject to various legal proceedings. The Company does not believe that any of the currently pending ordinary course legal proceedings, individually or in the aggregate, will have a material adverse effect on its operations or financial condition.

~~7. Comprehensive Income (Loss)~~24

Comprehensive income (loss) is comprised of net income (loss) and other comprehensive income (loss).

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Dollars in thousands, unless otherwise indicated, except per share data)

~~Other comprehensive income (loss) includes changes in the fair value of the Company’s marketable securities and foreign exchange translation adjustments~~8. Comprehensive ~~The~~Income ~~following table sets forth the components of comprehensive income~~ (~~loss~~Loss):

	Three Months Ended March 31,
	2009			2008
Net income (loss)	$	(48,603	)	$	103,312
Unrealized loss on securities	(1,339		)	(18,612		)
Unrealized loss on foreign exchange	—			(2,572		)
Total comprehensive income (loss)	$	(49,942	)	$	82,128

Comprehensive income (loss) is comprised of net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) includes changes in the fair value of the Company’s marketable securities and foreign exchange translation adjustments. The following table sets forth the components of comprehensive income (loss):

8. Segment Information

	Three Months Ended June 30,						Six Months Ended June 30,
	2009			2008			2009			2008
Net income (loss)	$	(29,247	)	$	(53,099	)	$	(77,850	)	$	50,213
Unrealized gain (loss) on securities	19,665			(31,544		)	18,326			(50,156		)
Unrealized loss on foreign exchange	—			—			—			(2,572		)
Total comprehensive loss	$	(9,582	)	$	(84,643	)	$	(59,524	)	$	(2,515	)

9. Segment Information

The Company is an integrated monoclonal antibody-based company with antibody discovery, development and clinical manufacturing capabilities. The operations of the Company and its subsidiaries constitute one business segment.

Revenue from partners representing 10% or more of total revenues is as follows:

	Three Months Ended March 31,
	Three Months Ended June 30,				Six Months Ended June 30,
Partner	2009		2008		2009		2008
Bristol-Myers Squibb	2818	%	3640	%	21	%	38	%
Pfizer	28	%	24	%
Centocor	32	%	—	%	21	%	—	%
MedImmune	13	%	2	%
Novartis	16	%	2	%	11	%	2	%
Pfizer	15	%	28	%	20	%	26	%

910. Subsequent ~~Event~~ Events

~~On April 20,~~BMS ~~2009~~Merger Merck & Co., Inc. (“Merck”), Medarex and Massachusetts Biologic Laboratories (“MBL”) announced that they had signed an exclusive worldwide license agreement for MDX-066/MDX-1388, an investigational fully human monoclonal antibody combination developed to target and neutralize Clostridium difficile toxins A and B, for use with respect to C. difficile infection. MDX-066 and MDX-1388 were co-developed by Medarex and MBL.Agreement

~~Under~~On July 22, ~~the terms of the agreement~~2009, ~~Merck~~BMS ~~gains worldwide rights to develop~~ and ~~commercialize~~the ~~MDX-066~~Company ~~and~~announced ~~MDX-1388. Medarex~~that ~~and~~the ~~MBL~~companies ~~will each receive an upfront~~have ~~payment~~signed ofa ~~$30.0~~definitive ~~million~~merger ~~and~~agreement ~~are~~providing ~~potentially~~for ~~eligible to each receive additional cash payments up to $82.5 million upon~~ the ~~achievement~~acquisition of ~~certain events associated with~~ the ~~development and approval of a drug candidate covered~~ Company by ~~the~~BMS ~~license~~for ~~agreement~~$16. ~~Upon commercialization,~~00 ~~Medarex~~per ~~and~~share ~~MBL~~in ~~will also be eligible to receive double digit royalties on product sales and milestone payments if certain sales targets are met~~cash. ~~In accordance with the~~ ~~pre-existing collaboration agreement between Medarex and MBL, all payments will be divided equally.~~ The ~~closing of the~~ transaction ishas ~~subject~~been toapproved ~~clearance~~by ~~under~~ the ~~Hart-Scott-Rodino~~boards ~~Antitrust Improvement~~of ~~Act,~~directors asof ~~well as other customary closing conditions~~both companies.

22Under the terms of the definitive merger agreement, BMS commenced a cash tender offer on July 28, 2009 to purchase all of the outstanding shares of the Company for $16.00 per share in cash. The closing of the

Table of Contents

MEDAREX, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(Dollars in thousands, unless otherwise indicated, except per share data)

tender offer is subject to customary terms and conditions, including the tender of a number of shares that, together with the number of shares already owned by BMS, constitutes at least a majority of the Company’s outstanding shares of common stock (on a fully diluted basis) and expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The merger agreement also provides that, in connection with the termination of the merger agreement under specified circumstances involving competing transactions or a change in the Company’s Board of Directors’ recommendation, then the Company may be required to pay BMS a termination fee of $70.80 million, representing 2.95% of the aggregate offer price.

Litigation

On July 22, 2009, the Company and Bristol-Myers Squibb Company (“BMS”) announced the signing of a merger agreement providing for the acquisition of the Company by BMS, through a tender offer, for $16.00 per share in cash. Following that announcement, certain Company shareholders filed similar lawsuits relating to this transaction against the Company, the members of the Company’s board of directors, and BMS. Those lawsuits include: Blevins v. Medarex, Inc. et al., U.S. District Court, District of New Jersey, Case No. 3:09-cv-03778-AET-DEA (filed July 30, 2009); Blumberg v. Pien et al., U.S. District Court, District of New Jersey, Case No. 3:09-cv-03615-AET-DEA (filed July 23, 2009); Dessoye v. Pien et al., Superior Court of New Jersey, Law Division, Mercer County, (filed July 29, 2009); Gordon v. Medarex, Inc. et al., Superior Court of New Jersey, Chancery Division, Mercer County, Docket No. C-73-09 (filed July 24, 2009); Halegoua v. Medarex, Inc. et al., Superior Court of New Jersey, Chancery Division, Mercer County, Docket No. C-72-09 (filed July 23, 2009); Halegoua v. Medarex, Inc. et al., U.S. District Court of New Jersey, Case No. 3:09-cv-03824-FLW-DEA (filed July 31, 2009); Hersh v. Pien et al., Superior Court of New Jersey, Chancery Division, Mercer County, Docket No. C-71-09 (filed July 23, 2009); Jerjian v. Pien et al., Superior Court of New Jersey, Chancery Division, Mercer County (filed July 23, 2009); Roelofsz v. Pien et al., Superior Court of New Jersey, Chancery Division, Mercer County; Sargent v. Pien et al., Superior Court of New Jersey, Law Division, Middlesex County, Docket No. L-6438-09 (filed July 28, 2009); and Roth v. Rubin et al., Superior Court of New Jersey, Chancery Division, Mercer County, Docket No. C-75-09 (filed July 24, 2009).

The plaintiffs in these cases generally assert that the Company’s directors breached fiduciary duties owed to shareholders. The plaintiffs generally allege that the price offered by BMS in the tender offer is inadequate, and that the Company’s directors did not take sufficient steps to maximize shareholder value in connection with the decision to enter into an agreement with BMS. The plaintiffs allege that the Company and BMS aided and abetted the purported breaches of fiduciary duties by the directors. In addition, the plaintiff in the federal version of the Halegoua lawsuit asserts a similar claim based on Section 14(e) of the Securities Exchange Act of 1934. These complaints seek to enjoin the proposed tender offer, in addition to seeking other relief. The Company believes the plaintiffs’ claims lack merit, and intends to defend these cases vigorously.

The Company has evaluated all subsequent events and transactions through July 31, 2009.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Certain statements made in this Quarterly Report on Form 10-Q are “forward-looking statements” that are subject to risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include information concerning our future financial performance, business strategy, plans, goals and objectives. Statements preceded by, followed by or that otherwise include the words “believes”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, “forecasts”, “is likely to”, “projected” and similar expressions or future conditional verbs such as “should”, “would”, “may”, and “could” are generally forward-looking in nature and not historical facts. You should not place undue reliance on any such forward-looking statements as such statements speak only as of the date on which they are made, and we undertake no duty to update them to reflect changes that occur after the date they are made.

Overview

We are a biopharmaceutical company focused on the discovery, development and commercialization of fully human antibody-based therapeutic products to address major unmet healthcare needs in the areas of oncology, inflammation, autoimmune disorders and infectious diseases. We and our partners are developing fully human antibody therapeutics for a wide range of diseases through the use of our UltiMAb® technology platform for generating antibodies. In addition, we have enhanced our core UltiMAb® platform with a suite of technologies that optimize or augment the therapeutic activity of antibodies, including one important technology expansion for developing antibodies that can deliver a cytotoxic agent to disease sites, which is our proprietary Antibody-Drug Conjugate, or ADC, technology platform.

Our UltiMAb® and ADC technologies provide the foundation for our pipeline of innovative antibody-based therapeutics. Through the application of our technology platform assets, we are advancing a strong portfolio of strategic assets—those antibody-based product candidates with direct commercial opportunity for Medarex—through research, manufacturing and clinical development (the “Strategic Assets”). Our Strategic Assets provide us with the strategic options to either retain full economic rights to innovative antibody therapeutics or seek favorable economic terms through advantageous commercial partnerships. The most advanced of our Strategic Assets are in Phase 3 or Phase 2 clinical trials.

Beyond our Strategic Assets, a number of fully human antibody product candidates have been generated from Medarex technology and are being developed separately by licensing partners, including companies such as Amgen, Inc., Bristol-Myers Squibb Company, Centocor, Inc., Eli Lilly and Company, Genmab A/S, ImClone Systems Incorporated, MedImmune, Inc., Novartis Pharma AG and Pfizer Inc. (the “Financial Assets”). In general, the Financial Assets potentially generate development milestone payments and royalties upon commercialization. The most advanced of these products have received marketing approval or are the subject of regulatory applications for marketing authorization.

Our product development efforts, including those of our licensing partners, cover a wide range of medical conditions. The following table summarizes potential therapeutic indications and development stages for our most advanced Strategic Assets (the antibody products in which Medarex has direct commercial opportunity).

2327

Table of Contents

PRODUCT	INDICATION	CLINICAL STATUS	PARTNER/LICENSEE
ipilimumab (anti-CTLA-4)	Melanoma and other Cancers	Phase 3 and earlier	Co-developing with BMS
MDX-1100 (anti-IP10)	Ulcerative Colitis, Rheumatoid Arthritis	Phase 2	Wholly-owned
MDX-1342 (anti-CD19)	Chronic Lymphocytic Leukemia, Rheumatoid Arthritis	Phase 1	Wholly-owned
MDX-1106 (anti-PD-1)	Cancer, Hepatitis C	Phase 1	Co-developing with Ono Pharmaceutical Co. Ltd.
MDX-1203 (anti-CD70 ADC)	Cancer	Phase 1	Wholly-owned

In addition, we are currently engaging in preclinical and research activities with respect to a number of additional product candidates.

A portion of our revenue is derived from licensing our fully human antibody technology to pharmaceutical and biotechnology companies. The terms of these license agreements typically include potential license fees and a series of potential milestone payments commencing upon the initiation of clinical trials and continuing through commercialization. In general, we are also entitled to receive royalties on product sales. Additional revenue may be earned from the sales to, and in some cases, the manufacturing of antibodies for, our partners, as well as from government grants.

Our most significant costs on an annual basis are research and development expenses and general and administrative expenses. Research and development expenses represent those costs that support the advancement of our product pipeline and primarily consist of personnel costs, facilities (including depreciation), research and laboratory supplies, funding of outside research, license and technology access fees, expenses related to antibody manufacturing and clinical trial expenses. We believe that continued investment in research and development is critical to attaining our strategic objectives. General and administrative expenses consist primarily of personnel expenses for executive, finance, legal and administrative personnel, professional fees and other general corporate expenses. We may be required to add personnel in the future and incur additional costs as we expand our business activities.

We have a history of operating losses and may ~~not~~ not achieve profitability. As of ~~March~~June 3130, 2009, we had an accumulated ~~deficit~~ deficit of approximately $1.1 billion. Over the next several years, we expect to incur substantial expenses as we continue to identify, develop and manufacture our potential products, invest in research, move forward with our ~~product~~ product development and prepare to commercialize our product(s). Our commitment of of resources to research and the continued development and potential commercialization of our product candidates will require substantial additional funds. Our operating expenses may also increase as we invest in research or acquire additional technologies, as additional potential product candidates are selected for clinical development and as some of our earlier stage product candidates move into later stage clinical development. In addition, we may incur significant milestone payment obligations as our products progress towards commercialization. In the absence of substantial revenues from new corporate collaborations or other sources, we will incur substantial operating losses and may be required to raise additional funds through debt or equity financings or sales of

2428

Table of Contents

stock of partners in which we have an equity ownership or delay, reduce or eliminate certain of our research and development programs.

Recent Events

On July 22, 2009, BMS and us announced that the companies have signed a definitive merger agreement providing for the acquisition of us by BMS for $16.00 per share in cash. The transaction has been unanimously approved by the board of directors of both companies.

Under the terms of the definitive merger agreement, BMS commenced a cash tender offer on July 28, 2009 to purchase all of our outstanding shares for $16.00 per share in cash. The closing of the tender offer is subject to customary terms and conditions, including the tender of a number of shares that, together with the number of shares already owned by BMS, constitutes at least a majority of our outstanding shares of common stock (on a fully diluted basis) and expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Critical Accounting Policies

The methods, estimates and judgments we use in applying our most critical accounting policies have a significant impact on the results we report in our consolidated financial statements. We evaluate our estimates and judgments on an on-going basis. We base our estimates on historical experience and on assumptions that we believe to be reasonable under the circumstances. Our experience and assumptions form the basis for our judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may vary from what we anticipate and different assumptions or estimates about the future could materially change our reported results. We believe the following accounting policies are the most critical to us, in that they are important to the portrayal of our financial statements and they require our most difficult, subjective or complex judgments in the preparation of our consolidated financial statements.

Revenue Recognition

We receive payments from our customers and partners for the sale of antibodies, for licenses to our proprietary technology, for product development services and from the achievement of product development milestones. These payments are generally non-refundable and are reported as deferred revenue until they are recognizable as revenue. We follow the following principles in recognizing revenue:

· We receive research fees from the licensing of our proprietary technologies for research and development performed by our customers and partners. Revenue from these research fees is recognized generally on a straight-line basis over the term of the respective license period beginning only after both the license period has begun and the technology has been delivered.

· We receive fees for product development services (including manufacturing) we perform for our customers and partners. These fees are recognized ratably over the entire period during which the services are performed.

· Revenue from ~~milestone~~ milestone payments is recognized when each milestone is achieved, when collectibility of such milestone payment is assured and we have no future performance obligations relating to that event. Milestone payments are triggered either by the results of our research efforts or by the efforts of our partners and include such events as submission of an IND, commencement of Phase 1, 2 or 3 ~~clinical trials, submission of a BLA, and regulatory approval of a product. Milestone payments are substantially at risk at the inception of an agreement.~~

· Revenue arrangements that include multiple deliverables are divided into separate units of accounting if the deliverables meet certain criteria, including whether the fair value of the delivered items can be determined and whether there is evidence of fair value of the undelivered items. In addition, the consideration is allocated among the separate units of accounting based on their relative fair values, and the applicable revenue recognition criteria are considered separately for each of the separate units of accounting.29

· Revenues derived from reimbursements of costs associated with the development of product candidates are recorded in compliance with EITF Issue 99-19, Reporting Revenue Gross as a Principal Versus Net as an Agent (“EITF 99-19”). According to the criteria established by EITF 99-19, in transactions where we act as a principal, with discretion to choose suppliers, bear the credit risk

Table of Contents

~~and~~clinical trials, ~~perform~~submission ~~part~~ of ~~the services~~a ~~required~~BLA, inand ~~the~~regulatory ~~transaction,~~approval weof ~~believe~~a weproduct. ~~have~~Milestone payments ~~met~~are ~~the~~substantially ~~criteria~~at ~~to record~~risk ~~revenue~~at ~~for~~ the ~~gross~~inception ~~amount~~ of ~~the~~an ~~reimbursements~~agreement.

· Revenue arrangements that include multiple deliverables are divided into separate units of accounting if the deliverables meet certain criteria, including whether the fair value of the delivered items can be determined and whether there is evidence of fair value of the undelivered items. In addition, the consideration is allocated among the separate units of accounting based on their relative fair values, and the applicable revenue recognition criteria are considered separately for each of the separate units of accounting.

· Revenues derived from reimbursements of costs associated with the development of product candidates are recorded in compliance with EITF Issue 99-19, Reporting Revenue Gross as a Principal Versus Net as an Agent (“EITF 99-19”). According to the criteria established by EITF 99-19, in transactions where we act as a principal, with discretion to choose suppliers, bear the credit risk and perform part of the services required in the transaction, we believe we have met the criteria to record revenue for the gross amount of the reimbursements.

· We sell antibodies primarily to partners in the United States and overseas. Revenue from these sales is recognized when the antibodies are shipped and we have no further obligations related to the development of the antibodies.

· Grant revenues are recognized as we provide the services stipulated in the underlying grant based on the time and materials incurred. Amounts received in advance of services provided are recorded as deferred revenue and amortized as revenue when the services are provided.

Investments

Our investment policy calls for investments in fixed income high grade securities such as U.S. corporate debt securities, U.S. treasury obligations and money market funds for which we believe there is not a significant risk of loss. Our primary objectives for our investment ~~portfolio~~ portfolio are liquidity and safety of principal. Investments are made to achieve the highest rate of return consistent with these two objectives. However, in the course of our business, we have made and may continue to make investments in companies (both public and private) as part of our strategic collaborations. Investments in companies whose securities are publicly traded (other than Genmab) are classified as marketable securities on our consolidated ~~balance~~ balance sheets. The fair market value of investments in our partners whose ~~securities~~ securities are publicly traded (other than Genmab and Celldex Therapeutics) represented ~~approximately~~ 1approximately 0.51% and 1.2% of our total marketable securities as of ~~March~~June 3130, 2009 and December 31, 2008.

Under SFAS No. 115, Accounting for Certain Investments in Debt and Equity Securities, our marketable securities are classified as available-for-sale securities and are carried at fair value. Marketable securities will include those securities of debt and publicly traded equity securities accounted for under the fair value method. These securities trade on listed exchanges; therefore, fair value is readily available. These securities are also subject to an impairment charge when we believe an investment has experienced a decline in value that is other than temporary. Under our accounting policy, a decline in the value of our equity securities is deemed to be other than temporary and such equity securities are generally considered to be impaired if their value is less than our cost basis for more than six (6) months, or some other applicable period in light of the facts and circumstances surrounding the equity securities.

In addition, in connection with our collaborative partnering business, we sometimes make strategic investments in the securities of companies that are privately held. Investments in our partners whose equity is not publicly traded are classified in a separate line item in our consolidated balance sheet entitled “Investments in, and advances to, other partners” and were approximately $0.8 million as of March 31, 2009. These securities are carried at original investment cost and adjusted for other than temporary impairment charges, if any. Because these securities are not listed on a financial exchange, the value of these investments is inherently more difficult to estimate than investments in public companies. We value these investments by using information acquired from industry trends, management of these companies, financial statements, and other external sources. Specifically, our determination of any potential impairment of the value of privately-held securities includes an analysis of the following for each company on a periodic basis: review of interim and year-end financial statements, cash position and overall rate of cash used to support operations, the progress and development of technology and product platform, the per share value of subsequent financings and potential strategic alternatives. Based on the information acquired through these sources, we record an investment impairment charge when we believe an investment has experienced a decline in value that is other than temporary.30

Table of Contents

In addition, in connection with our collaborative partnering business, we sometimes make strategic investments in the securities of companies that are privately held. Investments in our partners whose equity is not publicly traded are classified in a separate line item in our consolidated balance sheet entitled “Investments in, and advances to, other partners” and were approximately $0.8 million as of June 30, 2009. These securities are carried at original investment cost and adjusted for other than temporary impairment charges, if any. Because these securities are not listed on a financial exchange, the value of these investments is inherently more difficult to estimate than investments in public companies. We value these investments by using information acquired from industry trends, management of these companies, financial statements, and other external sources. Specifically, our determination of any potential impairment of the value of privately-held securities includes an analysis of the following for each company on a periodic basis: review of interim and year-end financial statements, cash position and overall rate of cash used to support operations, the progress and development of technology and product platform, the per share value of subsequent financings and potential strategic alternatives. Based on the information acquired through these sources, we record an investment impairment charge when we believe an investment has experienced a decline in value that is other than temporary.

Future adverse changes in market conditions or adverse changes in financial condition and/or operating results of the companies in which we invest that may not be reflected in an investment’s current carrying value may also require an impairment charge in the future.

On January 1, 2008, we adopted SFAS No. 157, Fair Value Measurements (“Statement No. 157”). Statement No. 157 defines and establishes a framework for measuring fair value and expands disclosures about fair value instruments. In accordance with Statement No. 157, we have categorized our financial assets, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy. We do not have any financial liabilities that are required to be measured at fair value on a recurring basis. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

Financial assets recorded on the consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows:

· Level 1 — Financial assets whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which we have the ability to access at the measurement date (examples include active exchange-traded equity securities and most U.S. Government and agency securities).

· Level 2 — Financial assets whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.

· Level 3 — Financial assets whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset. We do not currently have any Level 3 financial assets.

Stock-Based Compensation Expense

Effective January 1, 2006, we adopted the fair value recognition provisions of FASB Statement No. 123(R), Share-Based Payment, or Statement No. 123(R), using the modified prospective transition method. Under the modified prospective transition method, compensation expense is recognized in the financial statements on a prospective basis for (i) all share based payments granted prior to, but not vested as of January 1, 2006, based upon the grant date fair value estimated in accordance with the original provisions of Statement No. 123, and (ii) share based payments granted on or subsequent to January 1, 2006, based upon the grant date fair value estimated in accordance with the provisions of Statement No. 123(R). The grant date fair value of awards expected to vest is expensed on a straight line basis over the vesting periods of the related awards. Under the modified prospective transition method, results for prior periods are not restated.

The fair value of each option grant is estimated using the Black-Scholes option pricing method. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period (generally 4 years). Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. In order to estimate the grant date fair value, option pricing models require the use of estimates and assumptions as to (i) the expected term of the option, (ii) the expected volatility of the price of the underlying stock, (iii) the risk free interest rate for the expected term of the option and (iv) pre-vesting forfeiture rates. The expected term of the option is based upon the contractual term, taking into account expected employee exercise and expected post-vesting termination behavior. The expected volatility of the price of the underlying stock is based on the historical volatility of our common stock. The risk free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term equal to the expected life 31

Table of Contents

~~assumed~~January 1, on2006, based upon the grant date fair value estimated in accordance with the original provisions of Statement ~~grant~~No. 123, ~~Pre-vesting~~and ~~forfeiture~~(ii) share ~~rates~~based ~~are~~payments ~~estimated~~granted ~~based~~ on ~~past~~or ~~voluntary termination~~subsequent ~~behavior~~to January 1, 2006, asbased ~~well~~upon asthe angrant ~~analysis~~date offair ~~actual~~value ~~option~~estimated ~~forfeitures~~in accordance with the provisions of Statement No. 123(R). The ~~following~~grant ~~table~~date ~~sets~~fair ~~forth~~value ~~the~~of ~~assumptions used~~awards expected to ~~calculate~~vest is expensed on a straight line basis over the ~~fair~~vesting ~~value~~periods of ~~options~~the ~~granted~~related ~~for~~awards. Under the ~~three~~modified ~~month~~prospective ~~periods~~transition ~~ended March 31~~method, ~~2009~~results ~~and~~for ~~2008:~~prior periods are not restated.

	Three Months Ended March 31,
	2009		2008
Expected dividend yield	0	%	0	%
Expected stock price volatility	81.7	%	81.5	%
Risk free interest rate	1.66	%	2.57	%
Expected life of options (years)	6.4		6.4

The fair value of each option grant is estimated using the Black-Scholes option pricing method. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period (generally 4 years). Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. In order to estimate the grant date fair value, option pricing models require the use of estimates and assumptions as to (i) the expected term of the option, (ii) the expected volatility of the price of the underlying stock, (iii) the risk free interest rate for the expected term of the option and (iv) pre-vesting forfeiture rates. The expected term of the option is based upon the contractual term, taking into account expected employee exercise and expected post-vesting termination behavior. The expected volatility of the price of the underlying stock is based on the historical volatility of our common stock. The risk free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term equal to the expected life assumed on the date of grant. Pre-vesting forfeiture rates are estimated based on past voluntary termination behavior, as well as an analysis of actual option forfeitures. The following table sets forth the assumptions used to calculate the fair value of options granted for the three and six month periods ended June 30, 2009 and 2008:

Our results of operations for the three month periods ended March 31, 2009 and 2008 include share based compensation expense of approximately $4.9 million and $5.3 million, respectively. As of March 31, 2009, the total unrecognized compensation cost related to non-vested stock options was approximately $33.2 million. This cost is expected to be recognized over a weighted average period of 2.5 years.

	Three Months Ended June 30,				Six Months Ended June 30,
	2009		2008		2009		2008
Expected dividend yield	0	%	0	%	0	%	0	%
Expected stock price volatility	81.5%-81.8	%	81.8	%	80.1%-81.8	%	81.5%-81.9	%
Weighted average expected volatility	81.6	%	81.9	%	81.7	%	81.5	%
Risk free interest rate	2.03%-2.57	%	3.32	%	1.66%-2.57	%	2.57%-3.50	%
Expected life of options (years)	6.3		6.4		6.4		6.4

Our results of operations for the three month periods ended June 30, 2009 and 2008 include share based compensation expense of approximately $4.7 million and $6.2 million, respectively. Our results of operations for the six month periods ended June 30, 2009 and 2008 include share based compensation expense of approximately $9.6 million and $11.5 million, respectively. As of June 30, 2009, the total unrecognized compensation cost related to non-vested stock options was approximately $28.2 million. This cost is expected to be recognized over a weighted average period of 2.2 years.

However, any significant awards granted during the remainder of the year, required changes in the estimated forfeiture rates, or significant changes in the market price of our stock could have an impact on this estimate.

Valuation of Long-Lived and Intangible Assets

We assess the impairment of long-lived assets and identifiable intangible assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors we consider important that could trigger an impairment review include the following:

· a significant underperformance relative to expected historical or projected future operating results;

Table of Contents

· a significant change in the manner of our use of the acquired asset or the strategy for our overall business; and/or

· a significant negative industry or economic trend.

When we determine that the carrying value of long-lived assets or of intangible assets are not recoverable based upon the existence of one or more of the above indicators of impairment, we may be required to record impairment charges for these assets that have not been previously recorded.

Loss Contingencies and Litigation Reserves

We assess potential losses in relation to legal proceedings and other pending or threatened legal or tax matters based upon the application of Statement of Financial Accounting Standards No. 5, Accounting ~~for~~ for Contingencies. If a loss is is considered probable and the amount can be reasonably estimated, we recognize an an expense for the estimated loss. If a loss is considered possible and the amount can be reasonably estimated, we disclose such loss if material. Litigation by its nature is uncertain and the determination of whether any particular case involves a probable loss or the amount thereof requires the exercise of considerable judgment, which is applied as of a certain date. Required reserves and estimates may change in the future due to new matters, developments in existing matters or if we determine to change our strategy with respect to any particular matter.

Table of Contents

matters, developments in existing matters or if we determine to change our strategy with respect to any particular matter.

Results of Operations

Three ~~months~~Months ~~ended~~Ended ~~March~~June 3130, 2009 and 2008

Contract and License Revenues

Contract and license revenues totaled $715.0 5 million and $75.15 million for the three month periods ended ~~March~~June 3130, 2009 and 2008, respectively, aan increase ~~decrease~~ of $010.10 million, or 2181%. The increase relates principally to $8.5 million in milestone payments received from our contracting and licensing business. Because contract and license revenues depend to a large extent on the product development efforts of our partners and licensees, our period-to-period contract and license revenues can fluctuate significantly and are inherently difficult to predict.

Contract and License Revenues from Genmab

Contract and license revenues from Genmab were $0.52 million and $0.94 million for the three month periods ended ~~March~~June 3130, 2009 and 2008, respectively, a decrease of $0.42 million, or 3852%. The decrease is primarily the result of a decrease in antibody exclusive licenses granted to Genmab in 2009 as compared to 2008.

Reimbursement of Development Costs

Revenues derived from the reimbursement of costs associated with the development of our product candidates are recorded in compliance with EITF Issue 99-19. Reimbursement of development costs totaled $3.38 million and $4.01 million for the three month periods ended ~~March~~June 3130, 2009 and 2008, respectively, a decrease of $0.73 million, or 176%. These costs related primarily to the development of ipilimumab with Bristol-Myers Squibb Company or BMS.

Table of Contents

Research and Development Expenses

Our research and development activities include research, pre-clinical development, manufacturing and clinical development, which generally includes clinical operations, safety, medical writing, regulatory and compliance. Research and development expenses consist primarily of costs of personnel to support these research and development activities, as well as technology licensing fees, costs of preclinical studies, costs of conducting our clinical trials, such as fees to Contract Research Organizations, or CROs, and clinical investigators, monitoring costs, data management and drug supply costs, research and development funding provided to third parties, stock-based compensation expense accounted for under Statement No. 123(R) and related facility, overhead and information technology costs.

Research and development expenses for our ~~products~~ products in development were $4750.18 million and $4952.36 million for the three month periods ended ~~March~~June 3130, 2009 and 2008, respectively, a decrease of $21.28 million, or 5 3%.

Our research costs consist of costs associated with the breeding, care and continued development of the HuMAb-Mouse® and KM-Mouse®, as well as costs associated with research and testing of our product candidates prior to reaching the clinical stage. Such research costs primarily include personnel costs, facilities (including depreciation), research supplies, funding of outside research and license and technology access fees.

Table of Contents

Our product development costs consist of costs of preclinical development (including manufacturing) and conducting and administering clinical trials (including manufacturing). Such product development costs also include personnel costs, facilities (including depreciation), supply expense related to antibody manufacturing and clinical trial expenses.

The following table sets forth a breakdown of our research and development expenses by those associated with research and those associated with product development for the periods indicated.

	Three Months Ended March 31,
	Three Months Ended June 30,
(Dollars in thousands)	2009		2008
Research	$	13,~~302~~346	$	1314,~~842~~909
Product Development	3337,~~767~~413		3537,~~450~~665
Total	$	4750,~~069~~759	$	4952,~~292~~574

Research Costs

Research costs for the three month period ended ~~March~~June 3130, 2009 decreased by $01.56 million, or 410%, as compared to the three month period ended ~~March~~June 3130, 2008. The decrease in research costs primarily relates to the following:

· Outside funding of research expenses includes funds paid to certain partners for research services. Third party research costs for the three month period ended ~~March~~June 3130, 2009 were zero, a decrease of $0.8 million as compared to the three month period ended ~~March~~June 3130, 2008. This decrease reflects the expiration and our non-renewal of one of our third party research agreements near the end of the second quarter of 2008.

· License and technology access fees for the three month period ended June 30, 2009 were $0.7 million, a decrease of $0.3 million or 31% as compared to the three month period ended June 30, 2008. Increases

Table of Contents

and decreases in license and technology access fees are related to the development of our pipeline and the related timing of payments due under license agreements. These costs represent fees paid to certain partners and research organizations in connection with certain of our collaboration and license agreements. Included in the costs for 2009 and 2008 are payments to certain companies and academic institutions and other entities for licenses of certain technologies.

· Personnel costs for the three month period ended June 30, 2009 were $6.0 million, a decrease of $0.3 million or 5% as compared to the three month period ended June 30, 2008. Personnel costs include primarily salary, benefits, payroll taxes, stock option compensation and recruiting costs.

Product Development Costs

Product development costs for the three month ~~period~~ period ended ~~March~~June 3130, 2009 decreased by $10.73 million, or 51%, as compared to the three month period ended ~~March~~June 3130, 2008. The decrease in product development costs primarily relates to the following:

· Our share of partners’ product development costs for the three month period ended ~~March~~June 3130, 2009 was $1011.34 million, an increase of $31.90 million, or 6110%, as compared to the three month period ended ~~March~~June 3130, 2008. These costs primarily represent our share (35%) of the BMS costs for the development of ipilimumab. We expect our 35% share of BMS’s costs ~~related~~ related to the development of ipilimumab may increase in the future as BMS continues to increase its development activities related to ipilimumab.

· Outside laboratory costs for the three month period ended ~~March~~June 3130, 2009 were $01.71 million, a decrease of $21.02 million, or 7551%, as compared to the three month period ended ~~March~~June 3130, 2008. This decrease primarily reflects the cost of various toxicology studies which occurred during the three month period ended ~~March~~June 3130, 2008 related to our antibody drug conjugate projects for which there were no comparable costs in the ~~first~~second quarter of 2009.

~~· Clinical~~The following table reflects research ~~fees~~and development costs recognized for our most advanced product candidates currently in development for the three and six month ~~period~~periods ended ~~March~~June 3130, 2009 ~~were~~and $42008.3 ~~million,~~Costs afor ~~decrease~~the product candidates identified in the following oftable ~~$1.7~~include, ~~million~~among other things, orlabor, ~~28%~~preclinical study support, ascontract manufacturing, ~~compared~~clinical totrial services and partner expense, where applicable. The project costs listed in the ~~three~~following ~~month~~table may fluctuate from period ~~ended~~to ~~March 31,~~period depending on the stage ~~2008.~~of ~~This~~development ~~decrease~~as well as other factors discussed below which can also impact the timing of costs incurred.

	Three Months Ended June 30,				Six Months Ended June 30,
(Dollars in thousands)	2009		2008		2009		2008
Ipilimumab (MDX-010)(1)	$	14,382	$	13,999	$	26,601	$	24,237
MDX-1100	2,674		2,978		6,093		5,800
MDX-1203/ADC	1,222		2,821		2,483		6,444
MDX-1106	2,779		1,887		4,627		3,830
MDX-1342	3,656		1,930		6,179		3,903
MDX-060	536		749		951		1,488
Other research and development projects(2)	9,096		12,102		19,834		22,307
Non-project related costs(3)	13,856		13,425		25,848		27,750
Stock-based compensation expense	2,558		2,683		5,212		4,861
Celldex research and development expenses(4)	—		—		—		1,246
Total research and development expenses	$	50,759	$	52,574	$	97,828	$	101,866

Table of Contents

~~resulted~~(1) Represents 100% ~~primarily~~of ~~from~~our ~~decreased~~development ~~Phase~~costs ~~3 clinical~~and ~~trial~~our ~~activity~~35% ~~(managed~~of byBMS ~~us)~~development ~~related~~costs to for ipilimumab. ~~Clinical research~~for ~~fees~~each ~~include~~of ~~clinical~~the ~~investigator~~years ~~site~~identified. ~~fees,~~We ~~external~~are ~~trial monitoring~~reimbursed ~~costs~~(by ~~and~~BMS) ~~data~~for ~~accumulation~~65% of our development costs. WeSuch ~~expect~~reimbursements ~~expenses~~are ~~related~~recognized ~~to clinical~~as ~~trials~~revenue. ~~may~~See Note ~~increase~~6 into the ~~future~~consolidated asfinancial westatements ~~continue~~for tofurther ~~develop~~explanation ~~our~~of the ~~therapeutic~~cost ~~product~~sharing ~~pipeline~~arrangement between us and BMS.

· Patent costs for the three month period ended March 31, 2009 were $0.7 million, a decrease of $1.1 million, or 61%, as compared to the three month period ended March 31, 2008. This decrease primarily reflects the timing of the costs associated with securing and maintaining our patent portfolio. Our period-to-period patent costs can fluctuate significantly and are difficult to predict.

The following table reflects research and development costs recognized for our most advanced product candidates currently in development for the three month periods ended March 31, 2009 and 2008. Costs for the product candidates identified in the following table include, among other things, labor, preclinical study support, contract manufacturing, clinical trial services and partner expense, where applicable. The project costs listed in the following table may fluctuate from period to period depending on the stage of development as well as other factors discussed below which can also impact the timing of costs incurred.

	Three Months Ended March 31,
(Dollars in thousands)	2009		2008
Ipilimumab (MDX-010)(1)	$	12,220	$	10,238
MDX-1100	3,419		2,822
MDX-1203/ADC	1,261		3,623
MDX-1106	1,849		1,943
MDX-1342	2,522		1,973
MDX-060	414		739
Other research and development projects(2)	10,739		10,205
Non-project related costs(3)	11,991		14,325
Stock-based compensation expense	2,654		2,178
Celldex research and development expenses(4)	—		1,246
Total research and development expenses	$	47,069	$	49,292

(1) Represents 100% of our development costs and our 35% of BMS development costs for ipilimumab for each of the years identified. We are reimbursed (by BMS) for 65% of our development costs. Such reimbursements are recognized as revenue. See Note 5 to the consolidated financial statements for further explanation of the cost sharing arrangement between us and BMS.

(2) Other research and development projects consist of the total research and development expenses for projects that do not individually constitute more than 3% of the total research and development expenses for the periods presented. Such projects are primarily in the early research, pre-clinical and Phase 1 stages of development.

(3) Non-project related costs consist of the total research and development expenses that are not associated with any particular project, but rather support our broader research and development efforts. Such expenses include costs associated with the breeding, care and continued development of the HuMAb-Mouse® and KM-Mouse®, and costs related to the discovery of new antibody candidates and facility, information technology and overhead charges.

(4) Represents 100% of Celldex research and development expenses for the period from January 1, 2008 through March 7, 2008 which were consolidated for accounting purposes prior to Celldex’s merger with AVANT Immunotherapeutics, Inc. on March 7, 2008 (see Note 23 to the consolidated financial statements for further explanation).

Our expenditures on current and future product candidates are subject to numerous uncertainties in timing and cost of completion. In addition, we may be obligated to make milestone payments on certain of our product candidates as they progress through the clinical trial process. We expect product development costs to increase in the future as more of our product candidates enter clinical trials and should our existing product candidates continue to progress to more advanced clinical trials. Completion of clinical trials may take several years or more. The length of time varies according to the type, complexity and intended use of the product candidate. We estimate that clinical trials of the type we generally conduct are typically completed over the following periods:

Table of Contents

We estimate that clinical trials of the type we generally conduct are typically completed over the following periods:

Clinical Phase		Estimated Completion Period
Phase 1		1-2 Years
Phase 2		1-2 Years
Phase 3		2-4 Years

The duration and cost of clinical trials may vary significantly over the life of a particular project as a result of, among other things, the following factors:

· the length of time required to recruit qualified patients for clinical trials;

· the duration of patient dosing and follow-up in light of trial results;

· the number of clinical sites required for trials; and

· the number of patients that ultimately participate.

We continue to explore new collaborative arrangements that may affect future spending for research and development. As part of our partnering strategy, a significant portion of the research and development expenses incurred in connection with products using our technology is expected to be borne by our partners. We believe this allows us to participate in the research and development of substantially more potential product candidates than we could develop on our own if we bore the entire cost of development. Products using our technology are currently in various stages of development from preclinical to Phase 3. The successful development of these product candidates is dependent on many factors, including among other things, the efforts of our partners, unforeseen delays in, or expenditures relating to, preclinical development, clinical testing, manufacturing or regulatory approval, failure to receive regulatory approval, failure to receive market acceptance, the emergence of competitive products and the inability to produce or market our products due to third-party proprietary rights.

Table of Contents

unforeseen delays in, or expenditures relating to, preclinical development, clinical testing, manufacturing or regulatory approval, failure to receive regulatory approval, failure to receive market acceptance, the emergence of competitive products and the inability to produce or market our products due to third-party proprietary rights.

We cannot forecast with any degree of certainty which of our product candidates will be subject to future collaborations or how such arrangements, if any, would affect our development plans or capital requirements. In addition, we anticipate that our research and development expenses may continue to grow in the foreseeable future as we continue our discovery and preclinical activities and advance new product candidates into clinical trials. These expenses may fluctuate based upon many factors including the degree of collaborative activities, timing of manufacturing runs, numbers of patients enrolled in our clinical trials and the outcome of each clinical trial.

General and Administrative Expenses

General and administrative expenses include compensation, professional services, consulting, travel and facilities (including depreciation) and other expenses related to legal, business development, finance, information systems and investor relations. General and administrative expenses totaled $10.5 million and $12.4 million for the three month periods ended ~~March~~June 3130, 2009 and 2008, respectively, a decrease of $1.9 million, or 15%. The decrease is primarily attributable to approximately $1.73 million of ~~Celldex~~lower ~~general and~~stock-based ~~administrative~~compensation ~~expenses for the period from January 1, 2008 through March 6, 2008 which were consolidated in our results of operations prior to Celldex’s merger with AVANT~~expense.

Table of Contents

Equity in Net Loss of Affiliate

Equity in net loss of affiliate represents our share of the net loss of Celldex Therapeutics. Equity in net loss of ~~affiliate~~ affiliate totaled $2.45 million and $13.85 million for the three month periods ended ~~March~~June 3130, 2009 and 2008, respectively, ana ~~increase~~decrease of $01.60 million, or 3530%. Beginning on March 7, 2008, we began to account for our investment in Celldex Therapeutics under the equity method of accounting in accordance with APB No. 18, The Equity Method of Accounting for Investments in Common Stock (see Note 2 to the consolidated financial statements for further information). ~~The~~On ~~recognition~~June 24, 2009, the Company sold 2,000,000 shares of ~~our~~Celldex Therapeutics for $7.15 per share ofresulting ~~the~~in net ~~losses~~proceeds of approximately $14.3 million. As a result of this sale of common stock, the Company’s ownership percentage in Celldex Therapeutics ~~reduces~~was reduced to approximately 18.7%. As a result of the ~~carrying~~decrease ~~value~~in the Company’s ownership below 20%, oron ~~basis~~June 25, of2009 ~~our~~the Company began accounting for its investment in Celldex Therapeutics as a marketable security in accordance with SFAS No. 115.

Interest and Dividend Income and Realized Gains

Interest and dividend income and realized ~~gains~~ gains consist primarily of interest earned from our cash, cash equivalents and marketable securities. Interest and dividend income and realized gains were $2.02 million and $43.57 million for the three month periods ended ~~March~~June 3130, 2009 and 2008, respectively, a decrease of $21.5 million, or 5542%. This decrease primarily reflects lower interest rates earned on our investment portfolio.

Gain on Sale of ~~Genmab~~Celldex Therapeutics Stock

In ~~February~~June ~~2008~~2009, we completed the sale of 2.5 0 million shares of ~~Genmab~~Celldex Therapeutics through a block trade for $7.15 Weper share ~~received~~resulting in net proceeds of approximately $~~151~~14.83 million. The ~~from~~Company ~~such~~realized ~~block trade resulting in~~ a ~~realized~~ gain of approximately $~~151~~14.83 million asfrom ~~our~~this ~~cost~~transaction ~~basis~~ for ~~these~~the ~~shares~~three ~~was~~month period ended June 30, ~~zero~~2009. As a result of this ~~transaction~~sale of common stock, our ownership percentage in ~~Genmab~~Celldex Therapeutics was reduced to approximately 518.17%. ~~There was no comparable sale of Genmab shares for the three month period ended March 31, 2009.~~

Table of Contents

In June 2008, we sold 351,691 shares of Celldex Therapeutics for $12.35 per share resulting in net proceeds of approximately $4.3 million. We realized a gain of approximately $3.3 million from this transaction for the three month period ended June 30, 2008. As a result of this sale of common stock, our ownership percentage in Celldex Therapeutics was reduced to approximately 31.6%.

Interest Expense

Interest expense for the three month periods ended ~~March~~June 3130, 2009 and 2008 relates primarily to interest and amortization of issuance costs on our 2.25% Convertible Senior Notes issued in May 2004, or the 2.25% notes. Interest expense was $1.5 million and $1.5 million for the three month periods ended ~~March~~June 3130, 2009 and 2008, respectively.

Provision (Benefit) for Income Taxes

Our provision (benefit) for income taxes was $(160.1) million ~~thousand~~ and ~~$23~~zero ~~thousand~~ for the three month periods ended ~~March~~June 3130, 2009 and 2008, respectively. The benefit for income taxes for the three month period ended ~~March~~June 3130, 2009 is the result of recently enacted legislation which provides certain companies the ~~opportunity~~ opportunity to receive tax refunds for certain research credit carryovers.

33Six Months Ended June 30, 2009 and 2008

Contract and License Revenues

Contract and license revenues totaled $22.5 million and $12.6 million for the six month periods ended June 30, 2009 and 2008, respectively, an increase of $9.9 million, or 78%. The increase relates principally to $8.5 million in milestone payments received from our contracting and licensing business. Because contract and license revenues depend to a large extent on the product development efforts of our partners and licensees, our period-to-period contract and license revenues can fluctuate significantly and are inherently difficult to predict.

Contract and License Revenues from Genmab

Contract and license revenues from Genmab were $0.7 million and $1.2 million for the six month periods ended June 30, 2009 and 2008, respectively, a decrease of $0.5 million, or 42%. This decrease is primarily the result of a decrease in antibody exclusive licenses granted to Genmab in the first half of 2009 as compared to the first half of 2008.

Reimbursement of Development Costs

Revenues derived from the reimbursement of costs associated with the development of our product candidates are recorded in compliance with EITF Issue 99-19. Reimbursement of development costs totaled $7.1 million and $8.1 million for the six month periods ended June 30, 2009 and 2008, respectively, a decrease of $1.0 million, or 12%. These costs related primarily to the development of ipilimumab with BMS.

Research and Development Expenses

Research and development expenses for our products in development were $97.8 million and $101.9 million for the six month periods ended June 30, 2009 and 2008, respectively, a decrease of $4.1 million, or 4%.

Table of Contents

The following table sets forth a breakdown of our research and development expenses by those associated with research and those associated with product development for the periods indicated.

	Six Months Ended June 30,
(Dollars in thousands)	2009		2008
Research	$	26,647	$	28,827
Product Development	71,181		73,039
Total	$	97,828	$	101,866

Research Costs

Research costs for the six month period ended June 30, 2009 decreased by $2.2 million, or 8%, as compared to the six month period ended June 30, 2008.

· Outside funding of research expenses includes funds paid to certain partners for research services. Third party research costs for the six month period ended June 30, 2009 were $25 thousand, a decrease of $1.6 million as compared to the six month period ended June 30, 2008. This decrease reflects the expiration and our non-renewal of one of our third party research agreements near the end of the second quarter of 2008.

Product Development Costs

Product development costs for the six month period ended June 30, 2009 decreased by $1.9 million, or 3%, as compared to the six month period ended June 30, 2008. The decrease in product development costs primarily relates to the following:

· Our share of partners’ product development costs for the six month period ended June 30, 2009 was $21.6 million, an increase of $4.9 million, or 29%, as compared to the six month period ended June 30, 2008. These costs primarily represent our share (35%) of the BMS costs for the development of ipilimumab. We expect our 35% share of BMS’s costs related to the development of ipilimumab to increase in the future as BMS continues to increase its development activities related to ipilimumab.

· Outside laboratory costs for the six month period ended June 30, 2009 were $1.8 million, a decrease of $3.2 million, or 64%, as compared to the six month period ended June 30, 2008. This decrease primarily reflects the cost of various toxicology studies which occurred during the first six months of 2008 related to our antibody drug conjugate projects for which there were no comparable costs during the first six months of 2009.

· Clinical research fees for the six month period ended June 30, 2009 were $9.3 million, a decrease of $2.0 million, or 18%, as compared to the six month period ended June 30, 2008. This decrease resulted primarily from decreased Phase 3 clinical trial activity (managed by us) related to ipilimumab. Clinical research fees include clinical investigator site fees, external trial monitoring costs and data accumulation costs. We expect expenses related to clinical trials to increase in the future as we continue to develop our therapeutic product pipeline.

Table of Contents

General and Administrative Expenses

General and administrative expenses include compensation, professional services, consulting, travel and facilities (including depreciation) and other expenses related to legal, business development, finance, information systems and investor relations. General and administrative expenses totaled $21.0 million and $24.8 million for the six month periods ended June 30, 2009 and 2008, respectively, a decrease of $3.8 million, or 15%. The decrease is primarily attributable to approximately $1.8 million in lower stock compensation expense and approximately $1.7 million of Celldex general and administrative expenses for the period from January 1, 2008 through March 6, 2008 which were consolidated in our results of operations prior to Celldex’s merger with AVANT.

Equity in Net Loss of Affiliate

Equity in net loss of affiliate represents our share of the net loss of Celldex Therapeutics. Equity in net loss of affiliate totaled $4.9 million and $5.3 million for the six month periods ended June 30, 2009 and 2008, respectively, a decrease of $0.4 million, or 8%. Beginning on March 7, 2008 we began to account for our investment in Celldex Therapeutics under the equity method of accounting in accordance with APB No. 18, The Equity Method of Accounting for Investments in Common Stock (see Note 3 to the consolidated financial statements for further information). The recognition of our share of the net losses of Celldex Therapeutics reduces the carrying value, or basis, of our investment in Celldex Therapeutics.

Interest and Dividend Income and Realized Gains

Interest and dividend income and realized gains consist primarily of interest earned from our cash, cash equivalents and marketable securities. Interest and dividend income and realized gains were $4.2 million and $8.2 million for the six month periods ended June 30, 2009 and 2008, respectively, a decrease of $4.0 million, or 49%. This decrease primarily reflects lower interest rates earned on our investment portfolio.

Gain on Sale of Genmab Stock

In February 2008, we completed the sale of 2.5 million shares of Genmab through a block trade. We received net proceeds of approximately $151.8 million from such block trade resulting in a realized gain of approximately $151.8 million as our cost basis for these shares was zero. As a result of this transaction, our ownership percentage in Genmab was reduced to approximately 5.1%. There was no comparable sale of Genmab shares for the six month period ended June 30, 2009.

Gain on Sale of Celldex Therapeutics Stock

In June 2009, we completed the sale of 2.0 million shares of Celldex Therapeutics through a block trade for $7.15 per share resulting in net proceeds of approximately $14.3 million. The Company realized a gain of approximately $14.3 million from this transaction for the six month period ended June 30, 2009. As a result of this sale of common stock, our ownership percentage in Celldex Therapeutics was reduced to approximately 18.7%.

In June 2008, we sold 351,691 shares of Celldex Therapeutics for $12.35 per share resulting in net proceeds of approximately $4.3 million. We realized a gain of approximately $3.3 million from this transaction for the six month period ended June 30, 2008. As a result of this sale of common stock, our ownership percentage in Celldex Therapeutics was reduced to approximately 31.6%.

Table of Contents

Interest Expense

Interest expense for the six month periods ended June 30, 2009 and 2008 relates primarily to interest and amortization of issuance costs on our 2.25% notes. Interest expense was $3.0 million and $3.1 million for the six month periods ended June 30, 2009 and 2008, respectively.

Liquidity and Capital Resources

We require cash to fund our operations, to make capital expenditures and strategic investments, and to pay debt service on our convertible notes. Since inception, we have financed our operations through the sale of our securities in public and private placements, sales of our products for research purposes, development and manufacturing services, technology transfer and license fees, milestone payments and sales of our marketable securities (such as Genmab and Celldex Therapeutics). We expect to continue to fund our cash requirements from these sources in the future.

	March 31,		December 31,
Liquidity and Capital Resources	June 30,		December 31,
Liquidity and Capital Resources	2009		2008
(Dollars in thousands)	2009		2008
(Dollars in thousands)
Cash, cash equivalents and marketable securities (other than Genmab and Celldex Therapeutics)	$	340,648	$	353,668
Cash, cash equivalents and marketable securities (other than Genmab)	$	322,836	$	353,668
Marketable securities — Genmab	$	78,596	$	87,428
Marketable securities — Genmab	$	85,274	$	87,428
Marketable securities — Celldex Therapeutics	$	23,154	—

We primarily invest our cash equivalents and marketable securities in highly liquid, interest-bearing, investment grade and government securities to preserve principal.

	Three Months Ended March 31,
Statement of Cash Flows	Six Months Ended June 30,
Statement of Cash Flows	2009			2008
(Dollars in thousands)	2009			2008
(Dollars in thousands)
Cash provided by (used in):
Operating activities	$	(3130,~~081~~699	)	$	(4585,~~369~~403	)
Investing activities	$	336,~~502~~103		$	~~156~~170,~~733~~342
Financing activities	$	(61,090	)	$	13,~~034~~171

Cash Used in Operating Activities

Cash used in operating activities was $3130.17 million and $4585.4 million for the ~~three~~ six month periods ended ~~March~~June 3130, 2009 and 2008, respectively. This reflects a decrease of $1454.37 million in 2009 as compared to the same period in 2008 and was primarily the result of ~~decreased~~an ~~research~~increase ~~and development~~in ~~expenses~~deferred ~~and~~contract ~~decreased~~revenue ~~general~~of $23.3 million and ~~administrative~~an ~~expenses~~increase ~~as described~~in accrued liabilities of $13.2 million. The increase in ~~“Results~~deferred revenue was primarily due to the receipt of ~~Operations”~~$30 asmillion ~~well~~from asthe aMerck ~~decrease~~license agreement (see further discussion below) and the increase in accrued liabilities was primarily the result of an increase in due to corporate partners.

We have incurred and will continue to incur significant costs in the area of research and development, including preclinical and clinical trials, as ~~our~~ our products are developed. We plan to spend significant amounts to progress ~~our~~ our current products through the clinical trial and the commercialization process as well as to develop additional product candidates on our own or with our partners. As our products progress through the clinical trial process, we may be obligated to make significant milestone payments on certain of our products. Furthermore, we expect our investment income to decrease as we fund our future operations and capital expenditures from our cash reserves. We anticipate that our operating expenditures may be partially offset by revenues from partners for license fees, milestone payments, and development and manufacturing services.

3441

Table of Contents

expenditures from our cash reserves. We anticipate that our operating expenditures may be partially offset by revenues from partners for license fees, milestone payments, and development and manufacturing services.

Table of Contents

Cash Provided by Investing Activities

Net cash provided by investing activities was $336.51 million and $~~156~~170.73 million for the ~~three~~six month periods ended ~~March~~June 3130, 2009 and 2008, respectively. The decrease in cash provided by investing activities was $~~153~~134.2 million and was primarily the result of the following factors:

· Proceeds from the sale of Genmab stock were $0 and $151.8 million for the ~~three~~six month periods ended ~~March~~June 3130, 2009 and 2008, respectively.

· Purchases of marketable securities totaled $0 and $3560.92 million for the ~~three~~six month periods ended ~~March~~June 3130, 2009 and 2008, respectively. The 2008 purchase was made with a portion of the ~~proceeds~~ proceeds received from the sale of our Genmab stock.

· Sales and maturities of marketable securities were $323.81 million and $4277.03 million for the ~~three~~ six month periods ended ~~March~~June 3130, 2009 and 2008, respectively. Proceeds from sales and maturities of marketable securities in 2009 and 2008 were primarily used to fund operations and capital expenditures.

Cash Provided by ~~(Used~~ ~~In)~~ Financing Activities

Cash provided by ~~(used in)~~ financing activities was $~~(6) thousand~~ 1.1 million and $13.02 million for the ~~three~~ six month periods ended ~~March~~June 3130, 2009 and 2008, respectively. Cash provided by financing activities for the six ~~three~~ month ~~period~~periods ended ~~March~~June 3130, 2009 and 2008 primarily represents cash received from the exercise of stock options.

Other Liquidity Matters

Merck License Agreement

On April 20, 2009 Merck & Co., Inc. (“Merck”), Medarex and Massachusetts Biologic Laboratories (“MBL”) announced that they had signed an exclusive worldwide license agreement for MDX-066/MDX-1388, an investigational fully human monoclonal antibody combination developed to target and neutralize Clostridium difficile toxins A and B, for use with respect to C. difficile infection. MDX-066 and MDX-1388 were co-developed by us and MBL.

Under the terms of the agreement, Merck gains worldwide rights to develop and commercialize MDX-066 and MDX-1388. We and MBL ~~will~~ each ~~receive~~received an upfront payment of $30.0 million and are ~~potentially~~ potentially eligible to each receive additional cash payments up to $82.5 million upon the achievement of certain events associated with the development and approval of a drug candidate covered by the license agreement. Upon commercialization, we and MBL will also be eligible to receive double digit royalties on product sales and milestone payments if certain sales targets are met. In accordance with the pre-existing collaboration agreement between us and MBL, all payments will be divided equally. ~~The closing of the transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvement Act, as well as other customary closing conditions.~~

BMS Collaboration

In January 2005, we entered into a collaboration and co-promotion agreement and a related securities purchase agreement with BMS. Under the terms of the collaboration, we and BMS each granted the other certain intellectual property licenses and product rights on a worldwide basis in order to enable us to collaborate in research and development of certain therapeutic antibody-based products for the treatment of cancer and other diseases, and, in the event that further development work is successful, to commercialize any resulting products. In particular, the collaboration includes a grant by us to BMS of a license to commercialize

3543

Table of Contents

ipilimumab, a fully human antibody product candidate developed using our UltiMAb® technology. Ipilimumab is currently under investigation for the treatment of a broad range of cancers and other diseases.

As part of the collaboration, BMS is responsible for 65% of all development costs related to clinical trials intended to support regulatory approval in both the U.S. and ~~Europe~~the European Union, with the remaining 35% to be paid by us. We and BMS will share equally the costs of any clinical trials of products intended solely for regulatory approval in the U.S., and BMS will be fully responsible for all development costs that relate solely to ~~regulatory~~ regulatory approval in ~~Europe~~the European Union and other parts of the world.

Under the terms of the collaboration, we have the option to co-promote any product in the U.S. If we exercise a co-promotion option with respect to a product for use in the first cancer indication for which an initial regulatory approval filing is accepted by the FDA, we will have the right and obligation to co-promote such product for use in all cancer indications, even if such indications are the subject of additional filings or approvals, and even if we opted-out of the development of any such indication. Even if we elect to co-promote a product for cancer indications, however, we would need to exercise a separate option to co-promote that product with respect to any indication other than cancer. If we do not exercise our co-promotion option with respect to a product for use in the first cancer indication for which an initial regulatory approval filing is accepted by the FDA, then we will not have the right or obligation to co-promote such product for any cancer indications, unless the filing for that first cancer indication is not approved by FDA.

Under the terms of the collaboration, we could receive up to $205.0 million from BMS if all regulatory milestones are met, plus up to an additional $275.0 million in sales-related milestones. In addition, if we exercise our co-promotion option with respect to ipilimumab for the metastatic melanoma indication, and regulatory approval is obtained, we would receive 45% of any profits and bear 45% of all losses from commercial sales of ~~such~~ such product in the U.S. In the event we choose not to exercise our co-promotion rights with respect to a product, BMS will have exclusive commercial rights in the U.S. and will pay us royalties on commercial sales. Regardless of whether or not we exercise our co-promotion option outside the U.S., BMS will have exclusive commercial rights for products and will pay us royalties on commercial sales.

As part of the collaboration, BMS made a cash payment to us on January 21, 2005 of $25.0 million and also purchased 2,879,223 shares of our common stock at a purchase price equal to $8.6829 per share for an aggregate purchase price of $25.0 million.

Convertible Senior Notes

In May 2004, we sold $150.0 million in aggregate principal amount of our 2.25% notes to qualified institutional investors. The 2.25% notes are initially convertible into shares of our common stock at the rate of 72.9129 shares per each $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $13.72 per share, subject to anti-dilution adjustments. Interest is payable on May 15 and November 15 of each year. The first interest payment was made on November 15, 2004.

The 2.25% notes mature on May 15, 2011 and are redeemable at our option on or after May 15, 2010. Holders of the 2.25% notes may require us to repurchase the notes if we undergo a “change in control” as defined in the indenture. (See Note 10 to the consolidated financial statements for a description of a pending tender offer which could result in a change of control). We received net proceeds from the offering of the 2.25% notes of approximately $145.2 million (after deducting the initial purchasers’ discounts and offering expenses). The costs of issuance of the 2.25% notes of approximately $4.8 million have been deferred and are being amortized over the term of the 2.25% notes. In May 2011, or earlier if we undergo a change in control, we may be required to use a significant portion of our cash to repay the remaining balance ($150.0 million) of the 2.25% ~~notes. If our cash is not sufficient to meet our obligations under the 2.25% notes, we would be required to seek additional financing.~~

3644

Table of Contents

notes. If our cash is not sufficient to meet our obligations under the 2.25% notes, we would be required to seek additional financing.

Financial Uncertainties Related to Potential Future Milestone Payments

In 2002, we entered into a collaboration and license agreement with Kirin, which cross-licenses certain of each other’s technologies for the development and commercialization of human antibody products. Under the collaboration and license agreement, we and Kirin developed the KM-Mouse®, a unique crossbred mouse that combines the traits of our HuMAb-Mouse® with Kirin’s TC Mouse™ and exchanged cross-licenses with respect to the KM-Mouse® and other antibody-generating mice. In addition, certain of the cross-licenses granted under the collaboration and license agreement are subject to license, milestone and royalty payments by one party to the other.

Through ~~March~~June 3130, 2009, we have not made any milestone payments to Kirin although approximately $3.0 million has been paid to Kirin through ~~March~~June 3130, 2009 primarily representing a payment due Kirin as a result of our collaboration with Pfizer. Based on products we are developing which use or, we believe may use, Kirin technology that (i) are currently in clinical trials or (ii) we anticipate may enter clinical trials by the end of 2010, we may be required to make milestone payments to Kirin aggregating up to approximately $4.25 million per product with respect to such products. Our future milestone payment obligations to Kirin may or may not be triggered, and may vary in size, depending on a number of variables, almost all of which are currently unknown, including the following:

· whether or not a decision is made to request a license from Kirin;

· the type of license requested (research or commercial);

· the success and timing of development efforts and clinical trials of product candidates covered by any such licenses;

· the type of product developed (payment obligations differ depending on whether a product is an ex vivo therapeutic, in vivo therapeutic, research reagent or diagnostic); and

We have also entered into a number of other agreements that contain licenses of third-party technology which may be used together with our own platform technologies for the generation, development and/or manufacture of our antibody products. In addition, we have entered into other third-party agreements that contain licenses associated with antibody products that target specific antigens. Many of these agreements contain milestone payments that are due with respect to products using/targeting the licensed technology/antigen only if and when certain specified pre-commercialization events occur. Not all of our products currently under development trigger such milestone payments. Through ~~March~~June 3130, 2009, we have made milestone payments of approximately $2.2 million under these agreements. In addition, under the agreements we currently have in place (other than with Kirin), based on a total of ten products we are developing for which milestones are potentially due and that (i) are now in clinical trials or (ii) which we anticipate may enter clinical trials before the end of 2010, we may be obligated to make future milestone payments aggregating up to approximately $57.5 million with respect to such products. In general, potential milestone payments for our antibody products may or may not be triggered under these licenses, and may vary in size, depending on a number of variables, almost all of which are currently uncertain. Typically, the events that trigger these payments per product include:

· submission of IND(s) or foreign equivalents;

Table of Contents

· commencement of Phase 1, Phase 2 and/or Phase 3 clinical trials or foreign equivalents;

· submission of BLA(s) or foreign equivalents; and

Table of Contents

· receipt of marketing approval(s) to sell products in a particular country or region.

In addition, the licenses above may trigger royalty payments in connection with the commercialization of certain of our products. To date, we have not made any royalty payments on sales of our products and believe we are at least a year away from selling any products that would require us to make any such royalty payments. Whether we will be obligated to make milestone or royalty payments in the future is subject to the success of our product development efforts and, accordingly, is inherently uncertain.

Future Liquidity Resources

Our current sources of liquidity are our cash, cash equivalents and marketable securities, interest and dividends earned on such cash, cash equivalents and marketable securities, contract and licensing revenue and sales of our products for research. We believe that such sources of liquidity, including the proceeds received from the sale of our 2.25% convertible senior notes, will be sufficient to meet our operating, debt service, and capital requirements for at least the next 24 months. To the extent our 2.25% notes are not converted into shares of our common stock on or before their maturity date, we will have to either refinance the principal amount due or repay the principal amount of the notes. In any event, we may require additional financing within this time frame and may raise funds through public or private financings, sales of stock of partners in which we have an equity ownership, line of credit arrangements, collaborative relationships and/or other methods. The use of cash on hand or other financial alternatives will depend on several factors including, but not limited to, the future success of our products in clinical development, the prevailing interest rate environment, and access to the capital markets. We cannot assure you that we will be able to raise such additional funds. We may be unable to raise sufficient funds to complete development of any of our product candidates or to continue operations. As a result, we may face delay, reduction or elimination of research and development programs or preclinical or clinical trials, in which case our business, financial condition or results of operations may be materially harmed.

Recently Adopted Accounting Pronouncements

In December 2007, the EITF reached a consensus on Issue No. 07-1, Accounting for Collaborative Arrangements (EITF 07-1). The EITF concluded on the definition of a collaborative arrangement and that revenues and costs incurred with third parties in connection with collaborative arrangements would be presented gross or net based on the criteria in EITF 99-19 and other accounting literature. Based on the nature of the arrangement, payments to or from collaborators would be evaluated and the terms, the nature of the entity’s business, and whether those payments are within the scope of other accounting literature would be presented. Companies are also required to disclose the nature and purpose of collaborative arrangements along with the accounting policies and the classification and amounts of significant financial statement amounts related to the arrangements. Activities in the arrangement conducted in a separate legal entity should be accounted for under other accounting literature; however required disclosure under EITF 07-1 applies to the entire collaborative agreement. EITF 07-1 is effective for financial statements issued for fiscal years beginning after December 15, 2008, and interim periods within those fiscal years, and is to be applied retrospectively to all periods presented for all collaborative arrangements existing as of the effective date. We adopted EITF 07-1 effective January 1, 2009 and its adoption did not have a significant impact on our consolidated financial statements.

In December 2007, the FASB issued SFAS No. 141 (R), Business Combinations (Statement No. 141 (R)), which replaces SFAS No. 141, ~~Business~~ Business Combinations, and requires an acquirer to recognize the assets acquired, the liabilities assumed and any non-controlling interest in the acquiree at the acquisition date, measured at their fair values as of that date, with limited exceptions. Statement No. 141 (R) also requires ~~the~~ ~~acquirer in a business combination achieved in stages to recognize~~ the ~~identifiable~~ ~~assets and liabilities, as well as the non-controlling interest in the acquiree, at the full amounts of their fair values. Statement No. 141 (R)~~

3846

Table of Contents

~~makes~~acquirer in a business combination achieved in stages to recognize the identifiable assets and liabilities, as well as the non-controlling interest in the acquiree, at the full amounts of their fair values. Statement No. 141 (R) makes various other amendments to authoritative literature intended to provide additional guidance or conform the guidance in that literature to that provided in Statement No. 141 (R). Statement No. 141 (R) applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. The adoption of Statement No. 141 (R) did not have a significant impact on our consolidated financial statements.

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements (Statement No. 160), which amends Accounting Research Bulletin No. 51, Consolidated Financial Statements, to improve the relevance, comparability and transparency of the financial information that a reporting entity provides in its consolidated financial statements. Statement No. 160 establishes accounting and reporting standards that require the ownership interests in subsidiaries not held by the parent to be clearly identified, labeled and presented in the consolidated statement of financial position within equity, but separate from the parent’s equity. Statement No. 160 also requires the amount of consolidated net income attributable to the parent and to the non-controlling interest to be clearly identified and presented on the face of the consolidated statement of operations. Changes in a parent’s ownership interest while the parent retains its controlling financial interest must be accounted for consistently, and when a subsidiary is deconsolidated, any retained non-controlling equity investment in the former subsidiary must be initially measured at fair value. The gain or loss on the deconsolidation of the subsidiary is measured using the fair value of any non-controlling equity investment. Statement No. 160 also requires entities to provide sufficient disclosures that clearly identify and distinguish between the interests of the parent and the interests of the non-controlling owners. Statement No. 160 applies prospectively to all entities that prepare consolidated financial statements and applies prospectively for all fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008. We adopted Statement No. 160 effective January 1, 2009 and its adoption did not have a significant impact on our consolidated financial statements.

In November 2008, the FASB ratified the consensus reached in EITF Issue No. 08-6, Equity Method Investment Accounting Considerations (EITF 08-6). The equity method of accounting is required for investments when the investor does not control an investee but has the ability to exercise significant influence over its operating and ~~financial~~ financial policies in accordance with APB Opinion No. 18, The Equity Method of Accounting for Investments in ~~common~~Common Stock. The EITF concluded that an equity method investor shall recognize gains and losses in earnings for the issuance of shares by the equity method investee, provided that the issuance of shares qualifies as a sale of shares (and not a financing, as would be the case if the shares were sold subject to a forward contract to repurchase the shares).

Prior to the adoption of EITF 08-6, equity method investors followed the guidance of Staff Accounting Bulletin No. 51, Accounting for Sales of Stock by a Subsidiary (SAB No. 51), in accounting for the issuance of shares by the equity method investee. SAB No. 51 precludes gain recognition in certain situations (e.g. share issuance as part of a broader corporate reorganization, situations where an entity’s ability to exist is in question, etc.) and otherwise permits a registrant to elect an accounting policy of recognizing gains in the statement of operations or in equity. EITF 08-6 eliminated the SAB No. 51 exceptions to gain recognition and the accounting policy choice.

We previously accounted for sales of stock by a subsidiary in accordance with SAB No. 51 and accordingly, accounted for any gains as a component of equity as opposed to including such gains in the statement of operations. With the adoption of EITF 08-6, any gains arising out of sales of stock by a subsidiary will be included in our statement of operations.

~~In May 2008, the FASB issued FASB Staff Position APB 14-1, Accounting for Convertible Debt Instruments That May Be Settled in Cash Upon Conversion (FSP APB 14-1). FSP APB 14-1 requires the issuer~~47

Table of Contents

In May 2008, the FASB issued FASB Staff Position APB 14-1, Accounting for Convertible Debt Instruments That May Be Settled in Cash Upon Conversion (FSP APB 14-1). FSP APB 14-1 requires the issuer of certain debt instruments that may be settled in cash (or other assets) on conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer’s nonconvertible debt borrowing rate. FSP APB 14-1 is effective for financial statements issued for fiscal years beginning after December 15, 2008 and requires retroactive application to all periods presented and does not grandfather existing instruments. We adopted FSP APB 14-1 effective January 1, 2009 and its adoption had no impact on our consolidated financial statements.

Recently Issued and Adopted Accounting Pronouncements

At its April 2009 Board meeting, the FASB issued the following:

· Staff Position No. 115-2, FAS 124-2 and EITF 99-20-2, Recognition and Presentation of Other-Than-Temporary Impairments (FSP 115-2). FSP 115-2 provides new guidance on the recognition of an Other Than Temporary Impairment and provides new disclosure requirements. The recognition and presentation provisions apply only to debt securities classified as available for sale and held to maturity.

~~Each~~· SFAS ofNo. 165, ~~the~~Subsequent Events ~~accounting~~(“Statement ~~pronouncements~~No. 165”) provides authoritative ~~listed~~literature ~~above~~for isa ~~effective~~topic ~~for interim~~that ~~and~~was ~~annual~~previously ~~periods~~addressed ~~ending~~only ~~after~~in ~~June~~the accounting literature, AICPA AU Section 15560, ~~2009~~Subsequent Events. WeStatement ~~are~~No. 165 resulted in three modifications to the ~~process~~guidance ofunder ~~reviewing~~AU Section 560: (i) the ~~impact~~ names of ~~each~~the two types of subsequent ~~the~~events ~~accounting~~have ~~pronouncements~~been ~~listed~~changed ~~above~~to ~~but~~recognized wesubsequent events do(currently ~~not~~referred ~~expect~~to as Type I) and nonrecognized subsequent events (currently referred to as Type II), (ii) the ~~adoption~~definition of ~~these~~subsequent ~~accounting~~events ~~pronouncements~~has been modified to ~~have~~refer ato ~~material~~events ~~impact~~or transactions onthat ~~our~~occur after the balance sheet date, but before the issuance ~~financial~~of ~~consolidated~~the financial statements; and (iii) establishing a requirement for all entities to disclose the date through which the entity has evaluated subsequent events.

We adopted the above standards during the quarter ended June 30, 2009. The adoption of these accounting pronouncements did not have a material impact on our consolidated financial statements.

Table of Contents

In June 2009, the FASB issued SFAS No. 168, The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles (Statement No. 168). Statement No. 168 will become the source of authoritative U.S. generally accepted accounting principles (GAAP) recognized by the FASB to be applied by nongovernmental entities. Rules and interpretive releases of the SEC under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants. On the effective date of Statement No. 168, the Codification will supersede all then-existing non-SEC accounting and reporting standards. All other non-grandfathered non-SEC accounting literature not included in the Codification will become non-authoritative. Statement No. 168 is effective for financial statements issued for interim and annual periods ending after September 15, 2009. We do not expect the adoption of Statement No. 168 to have an impact on our results of operations, financial condition or cash flows.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Consistent with our investment policy, we do not use derivative financial instruments in our investment portfolio. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. To minimize risk, we maintain our portfolio of cash, cash equivalents and short-term investments in interest-bearing instruments, which may include United States government and agency securities, high-grade United States corporate bonds, commercial paper and money market funds. We do not have exposure to market risks associated with changes in interest rates as we have no variable interest rate debt outstanding. We do not believe we have any material exposure to market risks associated with interest rates, however, we may experience reinvestment risk as fixed income securities mature and are reinvested in securities bearing lower interest rates.

Table of Contents

market risks associated with interest rates, however, we may experience reinvestment risk as fixed income securities mature and are reinvested in securities bearing lower interest rates.

The recent and precipitous decline in the market value of certain securities backed by residential mortgage loans has led to a large liquidity crisis affecting the broader U.S housing market, the financial services industry and global financial markets. Investors holding many of these and related securities have experienced substantial decreases in asset valuations and uncertain secondary market liquidity. Overall liquidity for many debt issues has declined, meaning that we may realize losses if we are required to liquidate securities upon short notice. Additionally, the credit quality of certain issues and issuers has declined, causing ratings downgrades and in some cases uncertainty regarding the ability of issuers to repay principal amounts. Credit rating authorities have, in many cases, been slow to respond to the rapid changes in the underlying value of certain securities and pervasive market illiquidity regarding these securities. Also, with respect to mortgage and asset backed securities, overall economic conditions have generated concerns about the value of the underlying assets held as collateral and highlighted risks associated with insurance policies used to enhance the credit of the related debt issues. To date, we have not experienced defaults on any of our investment securities.

As a result, this “credit crisis” may have a potential impact on the determination of the fair value of financial instruments or possibly require impairments in the future should the value of certain investments suffer a decline in value which is determined to be other than temporary. We currently do not believe that any change in the market value of fixed income investments in our portfolio is material, or warrants a determination that there was an other than temporary impairment, and we continue to monitor our investments closely.

We may be exposed to exchange conversion differences in translating the value of our investment in Genmab to U.S. dollars. Depending upon the relative strengthening or weakening of the U.S. dollar, the conversion difference could be significant.

Table of Contents

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures: Our principal executive officer and principal financial officer reviewed and evaluated our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our principal executive officer and principal financial officer have concluded that as of ~~March~~June 3130, 2009 our disclosure controls and procedures were effective in ensuring that all material information required to be included in this Quarterly Report on Form 10-Q was made known to them in a timely fashion.

Changes in Internal Control Over Financial Reporting: Such evaluation did not identify any significant changes in our internal control over financial reporting that occurred during the quarter ended ~~March~~June 3130, 2009 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Limitations on the effectiveness of controls: A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected.

Table of Contents

Part II — Other Information

Item 1. Legal Proceedings

The SEC is conducting an informal inquiry into our historical stock option granting practices and related accounting and disclosures. In addition, we have received subpoenas from the U.S. Attorney’s Office, District of New Jersey, relating to the same matters. At the conclusion of this inquiry and investigation, we could be subject to criminal or civil charges and significant fines or penalties.

InOn July ~~addition~~22, to2009, the ~~inquiry~~Company and ~~investigation~~Bristol-Myers Squibb Company (“BMS”) announced ~~described~~the ~~above~~signing of a merger agreement providing for the acquisition of the Company by BMS, through a tender offer, for $16.00 per share in cash. Following that announcement, certain Company shareholders filed similar lawsuits relating to this transaction against the Company, ~~ordinary~~the ~~course~~members of ~~our~~the ~~business~~Company’s board of directors, weand ~~are~~BMS. Those atlawsuits ~~times~~include: Blevins v. Medarex, Inc. ~~subject~~et toal., ~~various~~U.S. ~~legal~~District ~~proceedings~~Court, District of New Jersey, Case No. 3:09-cv-03778-AET-DEA We(filed doJuly ~~not~~30, ~~believe~~2009); ~~that~~Blumberg ~~any~~v. Pien et al., U.S. District Court, District of ~~our~~New ~~current~~Jersey, Case No. ~~ordinary~~3:09-cv-03615-AET-DEA ~~course~~(filed ~~legal~~July ~~proceedings~~23, ~~individually~~2009); orDessoye inv. Pien ~~the~~et ~~aggregate~~al., ~~will~~Superior ~~have~~Court of New Jersey, Law Division, Mercer aCounty, ~~material~~(filed ~~adverse~~July ~~effect~~29, on2009); ~~our~~Gordon ~~operations~~v. orMedarex, ~~financial~~Inc. ~~condition~~et al., Superior Court of New Jersey, Chancery Division, Mercer County, Docket No. C-73-09 (filed July 24, 2009); Halegoua v. Medarex, Inc. et al., Superior Court of New Jersey, Chancery Division, Mercer County, Docket No. C-72-09 (filed July 23, 2009); Halegoua v. Medarex, Inc. et al., U.S. District Court of New Jersey, Case No. 3:09-cv-03824-FLW-DEA (filed July 31, 2009); Hersh v. Pien et al., Superior Court of New Jersey, Chancery Division, Mercer County, Docket No. C-71-09 (filed July 23, 2009); Jerjian v. Pien et al., Superior Court of New Jersey, Chancery Division, Mercer County (filed July 23, 2009); Roelofsz v. Pien et al., Superior Court of New Jersey, Chancery Division, Mercer County; Sargent v. Pien et al., Superior Court of New Jersey, Law Division, Middlesex County, Docket No. L-6438-09 (filed July 28, 2009); and Roth v. Rubin et al., Superior Court of New Jersey, Chancery Division, Mercer County, Docket No. C-75-09 (filed July 24, 2009).

Table of Contents

The Company is unable to reasonably estimate any possible range of loss or liability associated with the stock option inquiry and/or lawsuits due to their uncertain resolution.

In addition to the inquiry and investigation and litigation described above, in the ordinary course of our business, we are at times subject to various legal proceedings. We do not believe that any of our current ordinary course legal proceedings, individually or in the aggregate, will have a material adverse effect on our operations or financial condition.

Item 1A. Risk Factors

We have marked with an asterisk (*) those risk factors that reflect substantive changes from the risk factors included in our Form 10-KQ filed on ~~February~~May 275, 2009 with the SEC for the ~~year~~three month period ended ~~December~~March 31, ~~2008~~2009.

Additional factors that might affect future results include the following:

Risks Related to Our Business and Industry

Successful development of our product candidates is uncertain.

Our development of current and future product candidates is subject to the risks of failure and delay inherent in the development of new pharmaceutical products and products based on new technologies. These risks include, but are not limited to:

· delays in product development, clinical testing or manufacturing;

· slower than expected patient enrollment;

· unplanned expenditures in product development, clinical testing or manufacturing;

· failure in clinical trials;

· failure to receive or delay in receipt of regulatory approvals;

· emergence of superior or equivalent products;

· inability to manufacture on our own, or through others, product candidates on a commercial scale;

· inability to market products due to third-party proprietary rights;

· election by our partners not to pursue product development;

· failure by our partners to develop products successfully;

· failure to receive adequate coverage and reimbursement for our products from health care payors;

· changes in legal and regulatory requirements; and

· failure to achieve market acceptance.

Because of these risks, our research and development efforts or those of our partners may not result in commercially viable products. If a significant portion of these development efforts are not successfully completed, required regulatory approvals are not obtained or are significantly delayed, or any approved products are not commercially successful, our business, financial condition and results of operations may be materially harmed.

Table of Contents

products are not commercially successful, our business, financial condition and results of operations may be materially harmed.

Our revenue and profit potential are unproven. No revenues have been generated from the commercial sale of our products and our products may not generate commercial revenues in the future.

Table of Contents

Because we have not begun commercial sales of our products, our revenue and profit potential are unproven, which makes it difficult for an investor to evaluate our business and prospects. No revenues have been generated from the commercial sale of our products, and our products may not generate revenues in the future. Our business and prospects should be considered in light of the heightened risks and unexpected expenses and problems we may face as a company in a rapidly evolving biopharmaceutical industry.

*We have incurred large operating losses, and we anticipate that these losses will continue.

We have incurred large operating losses, and we anticipate that these losses will continue for the foreseeable future. In particular, as of ~~March~~June 3130, 2009, we had an accumulated deficit of approximately $1.1 billion. Our net loss was $4877.69 million and $38.5 million for the ~~three~~ six month period ended ~~March~~June 3130, 2009 and the year ended December 31, 2008, respectively. Our net loss for the year ended December 31, 2008 included a realized gain of approximately $151.8 million from the sale of a portion of our Genmab stock. Excluding this realized gain, our net loss for the year ended December 31, 2008 would have been $190.3 million. Our losses have resulted principally from:

· research and development costs relating to the development of our technology and antibody product candidates;

· costs associated with the establishment of our laboratory and manufacturing facilities and manufacturing of products; and

· general and administrative costs relating to our operations.

We intend to continue to make significant investments in:

· research and development;

· preclinical testing and clinical trials;

· manufacturing clinical supplies of our antibody product candidates;

· establishing new collaborations; and

· new technologies.

In addition, we may be obligated to make milestone payments with respect to certain of our product candidates as they progress through the clinical trial process.

We do not know when or if we or our partners will complete any pending or future product development efforts, receive regulatory approval or successfully commercialize any approved products.

We may continue to incur substantial operating losses even if our revenues increase. As a result, we cannot predict the extent of future losses or the time required for us to achieve profitability, if at all.

Table of Contents

Our operating results may vary significantly from period-to-period, which may result in a decrease in the price of our securities.

Our future revenues and operating results are expected to vary significantly from period-to-period due to a number of factors. Many of these factors are outside of our control. These factors include:

· the timing of the commencement, completion or termination of partnership agreements;

· the introduction of new products and services by us, our partners or our competitors;

· delays in, or termination of, preclinical testing and clinical trials;

Table of Contents

· changes in regulatory requirements for clinical trials;

· delays in manufacturing;

· costs and expenses associated with preclinical testing and clinical trials;

· the timing of regulatory approvals, if any;

· sales and marketing expenses; and

· the amount and timing of operating costs and capital expenditures relating to the expansion of our business operations and facilities.

Period-to-period comparisons of our results of operations may not be relied upon as an indication of future performance.

It is possible that in some future periods, our operating results may be below expectations of analysts and investors. If this happens, the price of our securities may decrease.

We may modify our business strategy in light of developments in our business and other factors.

We continually evaluate our business strategy and, as a result, may modify our strategy in the future. We may, from time to time, focus our product development efforts on different products or may delay or cease development of various products. In addition, as a result of changes in our business strategy, we may also change or refocus our existing research and development activities. This could require changes in our facilities and personnel and the restructuring of various financial arrangements. We cannot be certain that changes that we implement will be successful.

We are subject to an informal inquiry by the SEC and a grand jury investigation by the United States Attorney’s Office for the District of New Jersey, relating to our stock option granting practices, and such governmental inquiry and investigation may result in charges filed against us and in fines or penalties.

The SEC is conducting an informal inquiry into our historical stock option granting practices and related accounting and disclosures. In addition, the United States Attorney’s Office for the District of New Jersey is conducting a grand jury investigation relating to the same matters. We understand that the governmental inquiry and investigation relate to the same subject matter underlying the investigation (the “Investigation”) conducted by a special investigation committee of our independent directors relating to our stock option grant practices from 1996 through June 30, 2006. Based upon the information obtained in the Investigation, through July 2002, we had a practice, in many instances, of selecting dates for our stock option grants and restricted stock grants as of the date when the stock price was the lowest during the month of grant, without disclosing this practice in our public filings and without properly measuring the compensation expense on a date that the terms of the equity awards were finalized. Subsequent to July 2002, while this practice of selecting dates ceased by us in response to new legal ~~and~~ and regulatory reporting requirements, there were two annual equity grants for ~~rank~~ rank and file employees for which the measurement dates differed from the grant dates recorded in our books and records, which the Investigation revealed were primarily a result of administrative delays, with no apparent intent to achieve favorable exercise prices. Based on the results of the Investigation, we restated our financial statements for the quarter ended March 31, 2006 and the years ended December 31, 2005, 2004 and 2003, respectively.

44Criminal or civil charges could be filed against us and we could be required to pay significant fines or penalties in connection with either or both of the governmental inquiry and investigation or other governmental investigations. We have incurred, and continue to incur, substantial costs related to the governmental inquiry

Table of Contents

~~our~~and investigation ~~books~~ and ~~records,~~they ~~which~~continue ~~the Investigation~~to ~~revealed~~cause ~~were primarily~~ a ~~result~~diversion of ~~administrative~~our ~~delays,~~management’s ~~with~~time noand ~~apparent~~attention ~~intent~~which tocould ~~achieve~~have ~~favorable~~a ~~exercise~~material ~~prices. Based~~adverse effect on ~~the~~our financial condition and results of operations. Any criminal or civil charges by the ~~Investigation,~~SEC weor the U.S. Attorney’s Office or any fines ~~restated~~or ~~our~~penalties ~~financial~~imposed ~~statements~~by ~~for~~either the ~~quarter~~SEC ~~ended~~or ~~March 31,~~the ~~2006~~U.S. ~~and~~Attorney’s Office or other ~~the~~governmental ~~years~~agency ~~ended~~could ~~December 31~~materially harm our business, ~~2005~~results of operations, financial ~~2004~~position and ~~2003,~~cash ~~respectively~~flows.

Criminal or civil charges could be filed against us and we could be required to pay significant fines or penalties in connection with either or both of the governmental inquiry and investigation or other governmental investigations. We have incurred, and continue to incur, substantial costs related to the governmental inquiry and investigation and they continue to cause a diversion of our management’s time and attention which could have a material adverse effect on our financial condition and results of operations. Any criminal or civil charges by the SEC or the U.S. Attorney’s Office or any fines or penalties imposed by either the SEC or the U.S. Attorney’s Office or other governmental agency could materially harm our business, results of operations, financial position and cash flows.

We are subject to the risks of lawsuits and regulatory actions in connection with our historical stock option granting practices, the resulting restatements, and the remedial measures we have taken.

In addition to the possibilities that there may be additional governmental actions or shareholder lawsuits against us, we may be sued or taken to arbitration by current or former officers or employees in connection with their stock options or other matters. These governmental actions, lawsuits and arbitrations may be time consuming and expensive, and cause further distraction from the operation of our business. The adverse resolution of any specific action could have a material adverse effect on our business, financial condition and results of operations.

We are at risk for additional tax liabilities.

In connection with the investigation of our historical stock option grant practices, we evaluated the related tax issues to determine if we may be subject to additional tax liabilities. Due to revision of measurement dates for certain stock option grants, certain stock options that were previously treated as incentive stock options may not actually qualify for such treatment and may be treated as non-statutory stock options. As a result, we may be subject to fines or penalties relating to the tax treatment of such stock options. It is possible that additional tax liabilities exist arising out of our past stock option granting practices, and the amount of such additional tax liabilities could be material.

We are at risk of securities class action litigation.

In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. The risk is relevant for us because our market price has experienced a decline due, in part, to announcements regarding top-line results and the subsequent delay of the Biologics License Application, or BLA, for ipilimumab in December 2007 and April 2008, respectively. If we faced such litigation, while we would vigorously contest, it could result in substantial costs and a diversion of management’s attention and resources, which could materially harm our business.

45*In connection with BMS’ tender offer to purchase all of our outstanding shares, lawsuits have been filed against us and our board of directors.

Following our announcement on July 22, 2009 that we and BMS signed a merger agreement providing for the acquisition of the Company by BMS through a tender offer, certain Company shareholders filed similar lawsuits relating to this transaction against us, the members of our board of directors and BMS. The plaintiffs in these cases generally assert that our directors breached fiduciary duties owed to shareholders, the price offered by BMS in the tender offer is inadequate, and that our directors did not take sufficient steps to maximize shareholder value in connection with the decision to enter into an agreement with BMS. The plaintiffs also allege that we and BMS aided and abetted the purported breaches of fiduciary duties by the directors. These complaints seek to enjoin the proposed tender offer, in addition to seeking other relief. We believe the plaintiffs’ claims lack merit and we intend to defend these cases vigorously. However, this could result in

Table of Contents

substantial costs and a diversion of management’s attention and resources, which could materially harm our business.

*We cannot assure you that all conditions to the merger with BMS will be completed and the merger consummated.

The merger agreement with BMS contains representations, warranties and covenants of the parties customary for transactions of this type. We have also agreed not to solicit or initiate discussions with third parties regarding other acquisition proposals and to certain restrictions on our ability to respond to such proposals, subject to the fulfillment of certain fiduciary requirements of our board of directors. The merger agreement also contains customary termination provisions and provides that, in connection with the termination of the merger agreement under specified circumstances involving competing transactions or a change in our board of directors’ recommendation, we may be required to pay BMS a termination fee of $70.80 million, representing 2.95% of the aggregate offer price. We cannot assure you that the conditions of the merger agreement will be satisfied or waived or that the merger will close in the expected time frame or at all.

We may need substantial additional funding. We may not be able to obtain sufficient funds to grow our business or continue our operations.

We will continue to expend substantial resources for research and development, including costs associated with developing our technology platforms and conducting preclinical testing and clinical trials. Our future capital requirements will depend on a number of factors, including, for example:

· the size and complexity of research and development programs;

· the scope and results of preclinical testing and clinical trials;

· the retention of existing and establishment of further partnerships, if any;

· continued scientific progress in our research and development programs;

· the time and expense involved in seeking regulatory approvals;

· competing technological and market developments;

· the time and expense of filing and prosecuting patent applications and enforcing patent claims; and

· the cost of establishing commercial scale manufacturing capabilities, conducting commercialization activities and arrangements and in-licensing products.

We believe our current sources of liquidity, including the proceeds received from the sale of our 2.25% convertible senior notes, will be sufficient to meet our operating, debt service and capital requirements for at least the next 24 months. To the extent our 2.25% convertible senior notes due in 2011 are not converted into shares of our common stock on or before their maturity date, we will have to either refinance the principal amount due or repay the principal amount of the notes. In any event, we may require additional financing within this time frame and may raise funds through public or private financings, line of credit arrangements, collaborative relationships, sale of assets, and/or other methods. The use of cash on hand or other financial alternatives will depend on several factors including, but not limited to, the future success of our products in clinical development, the prevailing interest rate environment and access to the capital markets. We may be unable to raise sufficient funds to complete development of any of our product candidates, to continue operations or to repay our debt obligations at maturity. As a result, we may face delay, reduction or elimination of research and development programs or preclinical or clinical trials, in which case our business, financial condition or results of operations may be materially harmed.

We have a significant amount of debt and may have insufficient cash to satisfy our debt service obligations. In addition, the amount of our debt could impede our operations and flexibility.

We have $150.0 million in aggregate principal amount of our 2.25% convertible senior notes outstanding, which, unless converted to shares of our common stock or redeemed, will mature in 2011. Generally, during the last five years, our operating cash flows were negative and insufficient to cover our fixed charges. Our ability to generate sufficient operating cash flow to service our indebtedness, including the notes, and fund our operating requirements will depend on our ability, alone or with others, to successfully develop, manufacture, and obtain required regulatory approvals and market our product candidates, as well as other factors, including general economic, financial, competitive, legislative and regulatory conditions, some of which are beyond our control. If we are unable to generate sufficient operating cash flow to service our indebtedness and fund our operating requirements, we may need to obtain additional debt or equity financing to do so, which may not be available to us on satisfactory terms or at all. In addition, if new indebtedness is incurred, the risks relating to our ability to service our indebtedness that we face could intensify.

4655

Table of Contents

If we are unable to generate sufficient operating cash flow to service our indebtedness and fund our operating requirements, we may need to obtain additional debt or equity financing to do so, which may not be available to us on satisfactory terms or at all. In addition, if new indebtedness is incurred, the risks relating to our ability to service our indebtedness that we face could intensify.

Even if we are able to meet our debt service obligations, the amount of debt we have could adversely affect us in a number of ways, including by:

· limiting our ability to obtain any necessary financing in the future for working capital, capital expenditures, debt service requirements or other purposes;

· limiting our flexibility in planning for, or reacting to, changes in our business;

· placing us at a competitive disadvantage relative to our competitors who have lower levels of debt;

· making us more vulnerable to a downturn in our business or the economy generally; and

· requiring us to use a substantial portion of our cash to pay principal and interest on our debt, instead of applying those funds to other purposes such as working capital and capital expenditures.

We have investments in financial instruments which could potentially decrease in value as a result of the “credit crisis.”

Due to recent market developments, including continued rating agency downgrades of sub-prime U.S. mortgage-related assets and insurers of long-term debt, the value of sub-prime-related investments and certain tax-exempt long-term debt has declined. This recent and precipitous decline in the market value of certain securities backed by residential mortgage loans and long-term debt insured by these bond insurers has led to a large liquidity crisis affecting the broader U.S. housing market, the financial services industry and global financial markets. As a result, investors in many industry sectors have experienced substantial decreases in asset valuations and uncertain market liquidity for their investments. Overall liquidity for many debt issues has declined, meaning that we may realize losses if we are required to liquidate securities upon short notice. To date, we have not experienced any defaults on any of our investment securities.

As a result, this “credit crisis” may have a potential impact on the determination of the fair value of certain of our investments, or possibly require impairments in the future, should the value of certain of our investments suffer a decline in value which is determined to be other than temporary. We currently do not believe that any change in the market value of fixed income investments in our portfolio is material, nor does it warrant a determination that there was an other than temporary impairment. We continue to monitor our investments closely and a future decline in value of such investments which is determined to be other than temporary may require us to record a material impairment of the fair value of those investments.

4756

Table of Contents

Clinical trials required for our product candidates are expensive and time-consuming, and their outcome is uncertain.

To obtain FDA approval to market a new drug product, we or our partners must demonstrate proof of safety and efficacy in humans. To meet these requirements, we or our partners will have to conduct extensive preclinical testing and “adequate and well-controlled” clinical trials. Conducting clinical trials is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity, novelty and intended use of the product candidate, and often can be several years or more per trial. Delays associated with product candidates for which we are directly conducting preclinical or clinical trials may cause us to incur additional operating expenses. Moreover, we will continue to be affected by delays associated with the preclinical testing and clinical trials of certain product candidates conducted by our partners over which we have no control. We rely on third parties, including our partners, academic institutions and clinical research organizations to conduct, supervise or monitor many of our clinical trials. We have less control over the timing and other aspects of these clinical trials than if we conducted them entirely on our own.

The commencement and rate of completion of clinical trials may be delayed by many factors, including, for example:

· the inability to manufacture sufficient quantities of qualified materials in accordance with current good manufacturing practices, or cGMPs, for use in clinical trials;

· the need or desire to modify our manufacturing processes;

· slower than expected rates of patient recruitment;

· modification of clinical trial protocols;

· the inability to adequately observe patients after treatment;

· changes in regulatory requirements for clinical trials;

· the lack of effectiveness during the clinical trials;

· unforeseen safety issues;

· delays, suspension or termination of clinical trials due to the institutional review board responsible for overseeing the study at a particular study site, or for some studies due to the data safety monitoring committee charged with overseeing the study as a whole; and

· government or regulatory delays or “clinical holds” requiring suspension or termination of the trials.

Even if we obtain positive results from preclinical testing or clinical trials, we may not achieve the same success in future trials. Clinical trials may not demonstrate statistically sufficient effectiveness and safety to obtain the requisite regulatory approvals for our product candidates. In a number of instances, we have terminated the development of certain product candidates in the early stages of human clinical testing due to a lack of or modest effectiveness.

Generally, our clinical trials, including our cancer trials for ipilimumab and other antibodies, are conducted in patients with serious or life-threatening diseases for whom conventional treatments have been unsuccessful or for whom no conventional treatment exists, and in some cases, our product candidate is used in combination with approved therapies that themselves have significant adverse event profiles. During the course of treatment, these patients could suffer adverse medical events or die for reasons that may or may not be related to our product candidates. In trials of ipilimumab, the most commonly reported drug-specific adverse events are primarily immune-related, ranging from mild in most cases to severe in a very few number of instances, and are consistent with the mechanism of action of CTLA-4 blockade. These events are organ-specific, principally involving the gastrointestinal tract (diarrhea or colitis), the skin (severe rash or pruritis), the endocrine glands (reduced pituitary function) and the liver (increased liver enzymes). Other than a very small number of fatalities not directly related to disease progression or complications of the disease being treated, representing

4857

Table of Contents

approximately 1% of over 4,000 patients treated in all previous trials of ipilimumab, which may or may not be attributable to our product candidates, the majority of adverse events resolved or improved with treatment and without further significant complications. From our collective experience in treating over 4,000 patients with ipilimumab, treatment guidelines have been established to ensure proper management and most of these adverse events are manageable and resolve following withdrawal of ipilimumab or appropriate medical therapy, such as corticosteroids. In addition, we and BMS are exploring potential biomarkers that may be predictive of clinical responses. We cannot assure you that additional safety issues will not arise with respect to our products in the future.

We have, at times, experienced slower than expected rates of patient recruitment in certain of our clinical trials. As a result, in certain instances, we may experience delays in our product development and clinical testing.

Clinical trials that we conduct or that third parties conduct on our behalf may not demonstrate sufficient safety and efficacy to obtain the requisite regulatory approvals for any of our product candidates. We expect to commence new clinical trials from time to time in the course of our business as our product development work continues. The failure of clinical trials to demonstrate safety and effectiveness for our desired indications could harm the development of that product candidate as well as other product candidates. Any change in, or termination of, our clinical trials could materially harm our business, financial condition and results of operations.

Success in early clinical trials may not be indicative of results obtained in later trials.

Results of our early clinical trials and those of our partners using our human antibody technology are based on a limited number of patients and may, upon review, be revised or negated by authorities or by later stage clinical results. Historically, the results from preclinical testing and early clinical trials have often not been predictive of results obtained in later clinical trials. A number of potential new drugs and biologics have shown promising results in initial clinical trials, but subsequently failed to establish sufficient safety and efficacy data to obtain necessary regulatory approvals. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval.

In addition, regulatory delays or rejections may be encountered as a result of many factors, including changes in regulatory policy during the period of product development.

Products employing our antibody technology may fail to gain market acceptance.

Even if clinical trials demonstrate the safety and efficacy of product candidates developed by us or our partners using our technology and all regulatory approvals have been obtained, products employing our antibody technology may not gain market acceptance among physicians, patients, third-party payors and the medical community. For example, the current delivery systems for antibody-based therapeutic products are intravenous and subcutaneous injection, which are generally less well received by patients than tablet or capsule delivery. The degree of market acceptance of any products employing our technology will depend on a number of factors, including, for example:

· establishment and demonstration of clinical efficacy and safety, especially as compared to conventional treatments;

· cost-effectiveness;

· alternative treatment methods;

· reimbursement policies of government and third-party payors; and

4958

Table of Contents

· marketing and distribution support for our product candidates.

In addition, many of our activities involve genetic engineering in animals and animal testing, controversial subjects which have generally received adverse publicity from animal rights activists and various other interest groups. Such adverse publicity could decrease market acceptance of products employing our technology.

If products employing our technology do not achieve significant market acceptance, our business, financial condition and results of operations will be materially harmed.

The successful commercialization of our antibody products will depend on obtaining coverage and reimbursement for use of these products from third-party payors.

Sales of pharmaceutical products largely depend on the reimbursement of patients’ medical expenses by government health care programs and private health insurers. Without the financial support of the government or third-party payors, the market for products employing our human antibody technology will be limited. These third-party payors are increasingly challenging the price and examining the cost effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. We may need to conduct post-marketing studies to demonstrate the cost-effectiveness of our products. Such studies may require us to dedicate a significant amount of resources. Our product candidates may not be considered cost-effective. Third-party payors may not reimburse sales of products employing our human antibody technology, or enable us or our partners to sell them at profitable prices.

The continuing efforts of governmental and third-party payors to contain or reduce the costs of healthcare may impair our future revenues and profitability.

The pricing of our future products may be influenced in part by government controls and restrictions from private payors. For example, in certain foreign markets, pricing or profitability of prescription pharmaceuticals is subject to government control. In the United States, measures have been put in place to attempt to reduce expenditures under the Medicare and Medicaid programs. In addition, there have been, and we expect that there will continue to be, a number of federal and state proposals to implement more rigorous provisions relating to government payment levels. Private managed care organizations in the United States also seek to restrict the pharmaceutical products that doctors in those organizations can prescribe through the use of formularies, the lists of drugs which physicians are permitted to prescribe to patients in a managed care organization.

While we cannot predict whether the government will adopt any new legislative or regulatory proposals with respect to the pricing or reimbursement of medicines, the announcement or adoption of these proposals could have a material adverse effect on our business, results of operations, financial condition and cash flow. Managed care and other private payor exclusion of our pharmaceutical products from their formularies or demands for price concessions necessary to be included on formularies could also have a material adverse effect on our business, results of operations, financial condition and cash flow.

Our manufacturing facilities may not continue to meet regulatory requirements and may have limited capacity.

Before approving a new drug or biologic product, the FDA requires that the facilities at which the product will be manufactured are in compliance with cGMP requirements. To be successful, our therapeutic products must be manufactured for development and, following approval, in commercial quantities, in compliance with regulatory requirements and at acceptable costs. While we believe our current facilities are adequate for the

5059

Table of Contents

limited production of product candidates for clinical trials, our facilities are not adequate to produce sufficient quantities of any products for commercial sale.

If we are unable to establish and maintain a manufacturing facility or secure third-party manufacturing capacity within our planned time and cost parameters, the development and commercialization of our products and our financial performance may be materially harmed.

We may also encounter problems with the following:

· production yields;

· quality control and assurance;

· shortages of qualified personnel;

· compliance with FDA regulations, including the demonstration of purity and potency;

· changes in FDA requirements;

· production costs; and/or

· development of advanced manufacturing techniques and process controls.

We are aware of only a limited number of companies on a worldwide basis that operate manufacturing facilities in which our product candidates can be manufactured under cGMP regulations, a requirement for all pharmaceutical products. We are currently pursuing late-stage clinical and commercial supply agreements with cGMP-compliant third-party manufacturers with available capacity to meet our internal production timetables. We have entered into a clinical supply agreement with Lonza with respect to ipilimumab. As part of our collaboration with BMS, we assigned to BMS the clinical supply agreement with respect to ipilimumab. Our partner BMS is responsible for securing commercial supply agreements for ipilimumab. BMS may not be able to successfully consummate such arrangements. We do not currently have the capability to manufacture our product candidates under development in large commercial quantities and have no experience in commercial-scale manufacturing. It would take a substantial period of time for a contract facility that has not been producing antibodies to begin producing antibodies under cGMP regulations.

We cannot make assurances that we will be able to contract with such companies for clinical and/or commercial supply on acceptable terms or in a timely manner, if at all. Moreover, even if we are able to enter into clinical and/or commercial supply manufacturing arrangements with cGMP-compliant third-party manufacturers, we cannot assure you that such manufacturers will be able to produce products that are substantially equivalent to the product candidates that we have produced in our own facilities and used in our clinical trials. Such manufacturers may encounter difficulties in production scale-up, including problems involving production yields, quality control and quality assurance and shortage of qualified personnel. Moreover, they may not perform as agreed or may not continue to manufacture our products for the time required by us to successfully market our products. These third parties may fail to deliver the required quantities of our products or product candidates on a timely basis and at commercially reasonable prices. If such companies are not able to produce products that are substantially equivalent to our product candidates, the progress of our clinical trials and/or commercialization of our products may be delayed and our business, financial condition and results of operations may be materially harmed.

In addition, we and any third-party manufacturer will be required to register manufacturing facilities with the FDA and other regulatory authorities, and provide periodic product listing information on the products manufactured at each registered facility. The facilities will be subject to inspections confirming compliance with cGMP or other regulations. If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other regulatory authorities can impose regulatory sanctions including, among other

5160

Table of Contents

things, imposition of a shut down of manufacturing operations, refusal to approve a pending application for a new drug product or biologic product, or revocation of a pre-existing approval.

The development and commercialization of our lead product candidate, ipilimumab, is, in large part, dependent on the actions of BMS, which are outside of our control.

We depend, in part, on our partners to support our business, including the development of product candidates generated through the use of our antibody technology. In particular, under the terms of our collaboration and co-promotion agreement with BMS, we have granted a license to commercialize our lead product candidate, ipilimumab, to BMS for the treatment of all diseases. The successful development and commercialization of ipilimumab is dependent, in large part, on the actions of BMS, which are outside of our control. The failure of BMS to act in accordance with its obligations under the collaboration and co-promotion agreement or to prioritize or devote sufficient resources to ipilimumab development and commercialization, or a change of control of BMS, may cause us to incur substantial additional costs in order to develop and commercialize ipilimumab, which could materially harm our business.

We are, in part, dependent on our partners’ willingness and ability to devote resources to the development and commercialization of product candidates or otherwise support our business as contemplated in our partnership agreements.

We currently, or in the future may, rely on our partners to:

· access proprietary antigens for the development of product candidates;

· access skills and information that we do not possess;

· fund our research and development activities;

· manufacture products;

· fund and conduct preclinical testing and clinical trials;

· seek and obtain regulatory approvals for product candidates; and/or

· commercialize and market future products.

Our dependence on our partners subjects us to a number of risks, including:

· our partners have significant discretion whether to pursue planned activities;

· we cannot control the quantity and nature of the resources our partners may devote to product candidates;

· our partners may not develop product candidates generated using our antibody technology as expected; and

· business combinations or significant changes in a partner’s business strategy may adversely affect that partner’s willingness or ability to continue to pursue these product candidates.

If we do not realize the contemplated benefits from our partners, our business, financial condition and results of operations may be materially harmed.

Our existing partnerships may be terminated, and we may not be able to establish additional partnerships.

Our licensing partners generally have the right to terminate our partnerships at any time. Our ability to continue our current partnerships and to enter into additional partnerships is dependent in large part on our ability to successfully demonstrate that our UltiMAb® technology is an attractive method of developing fully

5261

Table of Contents

human antibody therapeutic products. Existing or potential partners may pursue alternative technologies, including those of our competitors, or enter into other transactions that could make a collaboration with us less attractive to them. For example, if an existing partner purchases or is purchased by a company that is one of our competitors, that company could be less willing to continue its collaboration with us and may, instead, become one of our competitors. In April 2006, Abgenix and Amgen completed a merger that resulted in Amgen’s ownership of Abgenix’s XenoMouse® technology. As a result, Amgen may be less willing to continue its collaboration with us and may, through the use of the XenoMouse® technology, engage in direct competition with us in the area of generating fully human monoclonal antibodies for antibody-based therapeutics. In addition, a company that has a strategy of purchasing companies rather than entering into partnership arrangements might have less incentive to enter into a collaboration agreement with us. Moreover, disputes may arise with respect to the ownership of rights to any technology or products developed with any current or future partner. Lengthy negotiations with potential new partners or disagreements between us and our partners may lead to delays or termination in the research, development or commercialization of product candidates. If we are not able to establish additional partnerships on terms that are favorable to us or if a significant number of our existing partnerships are terminated and we cannot replace them, we may be required to increase our internal product development and commercialization efforts. This would likely:

· limit the number of product candidates that we will be able to develop and commercialize;

· significantly increase our need for capital; and/or

· place additional strain on management’s time.

Any of the above may materially harm our business, financial condition and results of operations.

*DueOur tostrategic ~~the~~equity ~~size~~investments ofin our partners expose us to equity ~~interest~~price inrisk ~~Celldex~~and, ~~Therapeutics~~in addition, ~~we must~~investments ~~include~~in aour ~~portion~~partners may ofbe ~~its~~deemed ~~income~~impaired, ~~and~~which ~~losses~~would inaffect our ~~financial~~results ~~statements~~of operations.

Due to the size of our equity interest in Celldex Therapeutics, Inc., we are currently required to account for our interest in Celldex Therapeutics under the equity method of accounting, which provides that we must include a portion of Celldex Therapeutics’s income and losses equal to our percentage equity interest in Celldex Therapeutics in our consolidated financial statements. For the three month period ended March 31, 2009, our share of the net loss of Celldex Therapeutics was approximately $2.4 million.

*Our strategic equity investments in our partners expose us to equity price risk and, in addition, investments in our partners may be deemed impaired, which would affect our results of operations.

We have a number of strategic investments that expose us to equity price risk. These investments may become impaired, which would adversely affect our results of operations.

We are exposed to equity price risk on our strategic investments in our publicly-traded partners, and as part of our business strategy, we may choose to make additional similar investments in public companies in the future. Under SFAS No. 115, Accounting for Certain Investments in Debt and Equity Securities, these investments are designated as available-for-sale and are reported at fair value on our consolidated balance sheet. Unrealized holding gains and losses on available-for-sale securities are generally excluded from earnings and reported within other comprehensive income which is a separate component of shareholders’ equity. Under our accounting policy, marketable equity securities are generally considered to be impaired if their fair value is less than our cost basis in such securities for more than six months, or some other period in light of the particular facts and circumstances surrounding the investment. If a decline in the fair value of available-for-sale securities is considered to be other than temporary, the cost basis of the security is written down to fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. For the years ended December 31, 2008, 2007 and 2006, we recorded impairment charges of $48 thousand, $0 and $5.2 million, respectively, on investments in partners whose securities are publicly traded. If we deem these investments to be further impaired at the end of any future reporting period, we may incur additional impairment charges on these investments.

53In addition, we have investments in several of our partners whose securities are not publicly traded. The value of our investments in these companies is inherently more difficult to estimate than our investments in publicly traded companies. We estimate the value of these investments by using information acquired from industry trends, management of these companies, financial statements and other external sources. Specifically,

Table of Contents

~~ended~~our determination of any potential impairment of the value of privately held securities includes an analysis of the following for each company on a periodic basis: review of interim and year-end financial statements, cash position and overall rate of cash used to support operations, the progress and development of technology and product platform, the per share value of subsequent financing and potential strategic alternatives. Based on the information acquired through these sources, we record an investment impairment charge when we believe an investment has experienced a decline in value that is considered to be other than temporary. For the years ended December 31, 2008, 2007 and 2006, we recorded impairment charges of ~~$48 thousand,~~approximately $05.3 ~~and~~million, $5.2.1 million, and $0, respectively, on our investments in ~~partners~~privately-held ~~whose securities are publicly traded~~companies. IfFuture ~~we deem~~adverse ~~these~~changes ~~investments~~in tomarket beconditions or ~~further~~adverse ~~impaired~~changes atin ~~the~~operating ~~end~~results of ~~any~~these ~~future reporting~~companies ~~period, we~~ may ~~incur~~also ~~additional~~require an impairment ~~charges~~charge onin ~~these~~the ~~investments~~future.

In addition, we have investments in several of our partners whose securities are not publicly traded. The value of our investments in these companies is inherently more difficult to estimate than our investments in publicly traded companies. We estimate the value of these investments by using information acquired from industry trends, management of these companies, financial statements and other external sources. Specifically, our determination of any potential impairment of the value of privately held securities includes an analysis of the following for each company on a periodic basis: review of interim and year-end financial statements, cash position and overall rate of cash used to support operations, the progress and development of technology and product platform, the per share value of subsequent financing and potential strategic alternatives. Based on the information acquired through these sources, we record an investment impairment charge when we believe an investment has experienced a decline in value that is considered to be other than temporary. For the years ended December 31, 2008, 2007 and 2006, we recorded impairment charges of approximately $5.3 million, $2.1 million, and $0, respectively, on our investments in privately-held companies. Future adverse changes in market conditions or adverse changes in operating results of these companies may also require an impairment charge in the future.

Because competition for qualified personnel is intense, we may not be able to retain or recruit such qualified personnel, which could impact the research, development and commercialization of our products.

For us to pursue product development and commercialization plans, we will need to hire additional qualified scientific personnel to perform research and development. We will also need to hire personnel with expertise in clinical testing, government regulation, manufacturing, sales and marketing, relevant law and finance. We may not be able to attract and retain personnel on acceptable terms, given the competition for such personnel among biotechnology, pharmaceutical and healthcare companies, universities and non-profit research institutions. If we are not able to attract and retain qualified personnel, our business, financial condition and results of operations may be materially harmed.

We have had and may continue to face product liability claims related to the use or misuse of products developed by us or our partners.

The administration of drugs to humans, in clinical trials or after approval and during commercialization, may expose us to product liability claims. Consumers, healthcare producers or persons selling products based on our technology may be able to bring claims against us based on the use of our product candidates in clinical trials and the sale of products based on our technology. Product liability claims may be expensive to defend and may result in large judgments against us. We have obtained limited product liability coverage for our clinical trials, under which coverage limits are $20.0 million per occurrence and $20.0 million in the aggregate. Although we believe these coverage limits are adequate, we cannot be certain that the insurance policies will be sufficient to cover all claims that may be made against us. We intend to increase our coverage limits as we progress into additional late-stage clinical trials and to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for product candidates in development. Product liability insurance is expensive, difficult to obtain and may not be available in the future on acceptable terms.

Table of Contents

We face intense competition and rapid technological change.

The development of biotechnology and pharmaceutical products is a highly competitive business subject to significant and rapid technological change. We face competition in several different forms. First, our human antibody generation and antibody-drug conjugate activities currently face competition from competitors with similar technology to ours as well as distinctly different technologies. Second, product candidates being developed by us or by our partners also face actual or potential competition. Developments by our competitors may render our human antibody technology, our antibody-drug conjugate technology or our products obsolete or non-competitive.

Table of Contents

We are aware of several pharmaceutical and biotechnology companies that are actively engaged in research and development in areas related to antibody therapeutics. Some of these companies have commenced clinical trials of antibody product candidates or have successfully commercialized antibody products. Many of these companies are addressing the same disease indications as are we and our partners. Also, we compete with companies that offer antibody generation services to other companies that have disease related target antigens. These competitors have specific expertise or technology related to monoclonal antibody development. In the past, we competed directly with Abgenix, which merged with Amgen in April 2006, with respect to the generation of fully human antibodies from transgenic mice. Abgenix had offered potential partners the use of its XenoMouse® technology to generate fully human monoclonal antibodies. Regeneron has licensed its VelocImmune® monoclonal antibody generation technology to AstraZeneca, Astellas Pharma Inc. and sanofi-aventis, potentially enabling such licensees to compete with us in the generation of therapeutic antibodies. Regeneron may also compete with us directly in the generation of therapeutic antibodies or may enter into additional licenses with other companies. AstraZeneca also has access to antibody generation technologies through its ownership of Cambridge Antibody Technology. In addition, we have entered into agreements with each of Kirin and Genmab, respectively, that grant these companies licenses to our proprietary transgenic mouse technology platform, enabling them to compete with us in offering antibody generation and development services in certain markets.

Avanir and XTL have developed technologies that, according to Avanir and XTL, will allow them to generate fully human monoclonal antibodies in functionally modified mice. Numerous additional companies are developing therapeutic product candidates comprising human antibody components. Furthermore, several companies are developing, or have developed, technologies that do not involve immunization of animals for creating antibodies comprising human antibody sequences. XOMA and PDL BioPharma both offer technologies to convert mouse antibodies into antibodies closely resembling human antibodies. In addition, phage display technology is being used by companies, such as CAT, Dyax and MorphoSys to generate potentially therapeutic products comprising human antibody sequences. Companies such as Johnson & Johnson, MedImmune (a subsidiary of AstraZeneca), Amgen, Biogen Idec, Novartis, Genentech, PDL BioPharma, Wyeth, BMS, Abbott Laboratories, Alexion Pharmaceuticals, Inc. and GlaxoSmithKline have generated therapeutic products that are currently in development or on the market and that are derived from recombinant DNA that comprise human antibody components.

We have entered into license agreements with Pfizer, designed to give each party freedom to operate with respect to the development and commercialization of antibodies to CTLA-4. Among other things, these license agreements allow Pfizer to compete with us in such development and commercialization efforts, but Pfizer is obligated to make certain milestone and royalty payments to us based upon future sales of any Pfizer anti-CTLA-4 antibody product. Pfizer is developing tremelimumab, a fully human antibody generated by using transgenic mouse technology substantially ~~similar~~ similar to our HuMAb-Mouse® technology that targets the T-cell receptor CTLA-4. Although Pfizer announced the discontinuation of a Phase 3 clinical trial of tremelimumab for metastatic melanoma in April 2008, it continues to conduct clinical trials of this product candidate in several types of cancer.

55Other technologies can also be applied to the treatment of the diseases that we or our partners are pursuing. For example, ADCs are being developed by others, as well as by us. Companies such as Genentech, Seattle Genetics (and its partners, including Progenics Parmaceuticals, Inc. and Curagen Corporation), Immunogen (and its partners, including Bayer HealthCare and sanofi-aventis), and Wyeth have generated ADCs that are currently in development or on the market that utilize ADC technologies other than Medarex’s ADC technology, and these ADC product candidates may compete with ADC product candidates developed using Medarex’s ADC platform technology. Other companies are developing antibodies linked to radioactive isotopes. Companies are also developing technologies for the creation of antibody alternatives or mimetics,

Table of Contents

~~for~~alternative ~~metastatic~~products ~~melanoma~~with inproperties ~~April 2008~~similar to antibodies. In addition, itthe ~~continues~~application of recombinant DNA technology to ~~conduct~~develop ~~clinical~~potential ~~trials~~ products consisting of ~~this~~proteins (such ~~product~~as ~~candidate~~growth factors, hormones, enzymes, cytokines receptor fragments and fusion proteins) that do not occur normally in ~~several~~the ~~types~~body, or occur only in small amounts, has been under way for some time. Included in this group are interleukins such as IL-2 and IL-11, interferons, colony stimulating factors such as G-CSF and GM-CSF, clotting factors, growth hormones, erythropoeitin, DNAse, tPA, glucocerebrosidase, PDGF and a number of ~~cancer~~other similar biological agents. Continuing development of new chemical entities and other drugs by pharmaceutical and other biotechnology companies carries with it the potential discovery of agents for treating disease indications also targeted by drugs that we or our partners are developing.

Other technologies can also be applied to the treatment of the diseases that we or our partners are pursuing. For example, ADCs are being developed by others, as well as by us. Companies such as Genentech, Seattle Genetics (and its partners, including Progenics Parmaceuticals, Inc. and Curagen Corporation), Immunogen (and its partners, including Bayer HealthCare and sanofi-aventis), and Wyeth have generated ADCs that are currently in development or on the market that utilize ADC technologies other than Medarex’s ADC technology, and these ADC product candidates may compete with ADC product candidates developed using Medarex’s ADC platform technology. Other companies are developing antibodies linked to radioactive isotopes. Companies are also developing technologies for the creation of antibody alternatives or mimetics, alternative products with properties similar to antibodies. In addition, the application of recombinant DNA technology to develop potential products consisting of proteins (such as growth factors, hormones, enzymes, cytokines receptor fragments and fusion proteins) that do not occur normally in the body, or occur only in small amounts, has been under way for some time. Included in this group are interleukins such as IL-2 and IL-11, interferons, colony stimulating factors such as G-CSF and GM-CSF, clotting factors, growth hormones, erythropoeitin, DNAse, tPA, glucocerebrosidase, PDGF and a number of other similar biological agents. Continuing development of new chemical entities and other drugs by pharmaceutical and other biotechnology companies carries with it the potential discovery of agents for treating disease indications also targeted by drugs that we or our partners are developing.

Some of our competitors have received regulatory approval or are developing or testing product candidates that compete directly with product candidates employing our antibody technology. Many of these companies and institutions, either alone or together with their partners, have substantially greater financial resources and larger research and development staffs than we or some of our partners do. In addition, many of these competitors have significantly greater experience than we do in:

· developing products;

· undertaking preclinical testing and clinical trials;

· obtaining FDA and other regulatory approvals of products; and

· manufacturing and commercializing products.

Accordingly, our competitors may obtain patent or regulatory protection, receive FDA approval or commercialize products before we or our partners do. If we or our partners commence commercial product sales, we or our partners will be competing against companies with greater manufacturing, marketing and sales capabilities, areas in which we and certain of our partners have limited or no experience.

We also face intense competition from other pharmaceutical and biotechnology companies to establish partnerships, as well as relationships with academic and research institutions, and to in-license proprietary technology from these institutions. These competitors, either alone or with their partners, may succeed in developing or licensing technologies or products that are more effective than ours.

Seeking orphan drug designation for eligible products is an uncertain process, and we may not receive any effective or competitive results from this competitive strategy.

Our competitive strategy includes seeking orphan drug designation for eligible products (i.e., certain products for diseases with small patient populations). In the United States, the first drug with an orphan drug designation for a given disease to receive regulatory approval for such disease generally receives marketing exclusivity for the use of the drug for such disease for a period of seven years from approval. The orphan drug exclusivity bars others from obtaining approval for the same drug for the designated indication during the seven years, unless the subsequent applicant can demonstrate that its product is clinically superior to the drug with exclusivity or the prior applicant is unable to provide adequate supply to meet medical need. Orphan drug exclusivity is also available in markets outside the United States on similar terms.

56We have obtained orphan drug designation in the United States for ipilimumab and certain of our other product candidates in development, and therefore each is eligible for orphan drug exclusivity if approved first. The FDA’s approach with respect to orphan drug status for antibody products is uncertain, particularly with respect to whether two antibody products against the same disease target would be considered to be the same for orphan drug purposes under current law and regulations. Furthermore, we are not aware of established FDA policies or precedent for how orphan drug exclusivity applies in circumstances where two or more compounds

Table of Contents

with orphan drug designations are approved for combination therapy. The FDA may not grant us exclusivity ~~bars~~for ipilimumab, or may permit others ~~from~~to ~~obtaining approval~~receive approval for ~~the~~differing ~~same~~combinations of similar compounds despite any orphan drug exclusivity we receive for ~~the~~different ~~designated~~uses ~~indication~~or ~~during~~for ~~the~~treating ~~seven years~~metastatic melanoma, depending ~~unless~~on the ~~subsequent~~FDA’s ~~applicant~~assessment ~~can~~of ~~demonstrate~~the ~~that~~similarity ~~its~~of ~~product~~the ~~is clinically~~other ~~superior~~drugs to ~~the~~our products. Orphan drug ~~with~~ exclusivity oralso does not prevent the ~~prior~~FDA ~~applicant~~from ~~is unable~~permitting others to ~~provide~~market ~~adequate~~the ~~supply~~same tocompound ~~meet~~for different ~~medical~~uses ~~need~~than the orphan use. ~~Orphan~~ ~~drug~~We ~~exclusivity~~therefore ismay ~~also~~not ~~available~~receive inany meaningful ~~markets~~protection ~~outside~~for ~~the~~ipilimumab ~~United~~or ~~States~~our other product candidates based on ~~similar~~orphan ~~terms~~drug exclusivity.

We have obtained orphan drug designation in the United States for ipilimumab and certain of our other product candidates in development, and therefore each is eligible for orphan drug exclusivity if approved first. The FDA’s approach with respect to orphan drug status for antibody products is uncertain, particularly with respect to whether two antibody products against the same disease target would be considered to be the same for orphan drug purposes under current law and regulations. Furthermore, we are not aware of established FDA policies or precedent for how orphan drug exclusivity applies in circumstances where two or more compounds with orphan drug designations are approved for combination therapy. The FDA may not grant us exclusivity for ipilimumab, or may permit others to receive approval for differing combinations of similar compounds despite any orphan drug exclusivity we receive for different uses or for treating metastatic melanoma, depending on the FDA’s assessment of the similarity of the other drugs to our products. Orphan drug exclusivity also does not prevent the FDA from permitting others to market the same compound for different uses than the orphan use. We therefore may not receive any meaningful protection for ipilimumab or our other product candidates based on orphan drug exclusivity.

We are subject to extensive and costly government regulation.

Product candidates employing our human antibody technology are subject to extensive and rigorous domestic government regulation including regulation by the FDA, the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services, the U.S. Department of Justice, state and local governments and their respective foreign equivalents. The FDA regulates the research, development, preclinical and clinical testing, manufacture, safety, effectiveness, record-keeping, reporting, labeling, storage, approval, advertising, promotion, sale, distribution, import, and export of biopharmaceutical products. The FDA regulates human antibodies as biologics, subject to a BLA, under the Public Health Service Act, as amended, and the Federal Food, Drug, and Cosmetic Act, as amended. If products employing our human antibody technology are marketed abroad, they will also be subject to extensive regulation by foreign governments, whether or not we have obtained FDA approval for a given product and its uses. Such foreign regulation may be equally or more demanding than corresponding U.S. regulation.

Government regulation substantially increases the cost and risk of researching, developing, manufacturing, and selling our products. The regulatory review and approval process, which includes preclinical testing and clinical trials of each product candidate, is lengthy, expensive and uncertain. We or our partners must obtain and maintain regulatory authorization to conduct clinical trials, and register our clinical trials in accordance with new legal requirements to register clinical trials on publicly available databases. We or our partners must obtain regulatory approval for each product candidate we intend to market, and the manufacturing facilities used for the products must be inspected and meet legal requirements. Securing regulatory approval requires the submission of extensive preclinical and clinical data and other supporting information for each proposed therapeutic indication in order to establish the product’s safety, efficacy, potency and purity for each intended use. The development and approval process takes many years, requires substantial resources, and may never lead to the approval of a product. Failure to obtain regulatory approvals, or delays in obtaining regulatory approvals may:

· adversely affect the successful commercialization of any drugs that we or our partners develop;

· impose additional costs on us or our partners;

· diminish any competitive advantages that we or our partners may attain; and

Table of Contents

· adversely affect our receipt of revenues or royalties.

Even if we are able to obtain regulatory approval for a particular product, the approval may limit the indicated medical uses for the product, may otherwise limit our ability to promote, sell, and distribute the product, may require that we conduct costly post-marketing surveillance, and/or may require that we conduct ongoing post-marketing studies. Material changes to an approved product, such as, for example, manufacturing changes or revised labeling, may require further regulatory review and approval. Once obtained, any approvals may be withdrawn, restrictions may be placed on our ability to market or distribute the product, or post-approval study or other requirements might be imposed, including, for example, if there is a later discovery of previously unknown problems with the product, such as a previously unknown safety issue. If we, our partners ~~or our contract manufacturers fail to comply with applicable regulatory requirements at any stage during the regulatory process, such noncompliance could result in, among other things:~~

Table of Contents

or our contract manufacturers fail to comply with applicable regulatory requirements at any stage during the regulatory process, such noncompliance could result in, among other things:

· delays in the approval of applications or supplements to approved applications;

· refusal of a regulatory authority, including the FDA, to review pending market approval applications or supplements to approved applications;

· warning letters;

· fines;

· import and/or export restrictions;

· product recalls or seizures;

· injunctions;

· total or partial suspension of production;

· civil penalties;

· withdrawals of previously approved marketing applications or licenses;

· limitations on previously approved marketing applications or licenses, or new post-approval requirements;

· recommendations by the FDA or other regulatory authorities against governmental contracts; and

· criminal prosecutions.

In certain cases, we expect to rely on our partners to file Investigational New Drug Applications (INDs) with the FDA and to direct the regulatory approval process for product candidates employing our human antibody technology. Our partners may not be able to conduct clinical testing or obtain necessary approvals from the FDA or other regulatory authorities for their product candidates employing our human antibody technology. If they fail to obtain required governmental approvals, our partners will be delayed or precluded from marketing these products. As a result, commercial use of products employing our technology will not occur and our business, financial condition and results of operations may be materially harmed.

We do not have, and may never obtain, the regulatory approvals we need to market our product candidates.

To date, we have not applied for or received the regulatory approvals required for the commercial sale of any of our product candidates in the U.S. or in any foreign jurisdiction. We have only limited experience in filing and pursuing applications necessary to obtain regulatory approval. It is possible that none of our product candidates, including ipilimumab, will be approved for marketing. In April 2008, Medarex and one of its partners, Bristol-Myers Squibb Company, announced that, following a meeting with the FDA to discuss the regulatory pathway forward for ipilimumab, at the request of the FDA, no BLA filing would be submitted for market approval of ipilimumab in melanoma without additional overall survival data from an ongoing Phase 3 trial of ipilimumab in combination with chemotherapy in previously untreated melanoma (study 024). Clinical trial results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory approvals. Once submitted, the FDA may decide not to accept the BLA for filing and the FDA may never give its approval. We cannot guarantee that we will ever be able to produce commercially successful products.

Table of Contents

trial results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory approvals. Once submitted, the FDA may decide not to accept the BLA for filing and the FDA may never give its approval. We cannot guarantee that we will ever be able to produce commercially successful products.

Even if approved, our products will be subject to extensive post-approval regulation.

Once a product is approved, numerous post-approval requirements apply. Among other things, the holder of an approved BLA or New Drug Application, or NDA, is subject to periodic and other FDA monitoring and reporting obligations, including obligations to monitor and report adverse events and instances of the failure of a product to meet the specifications in the BLA or NDA. Application holders must submit new or ~~supplemental~~ ~~applications~~supplemental and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Application holders must also submit advertising and other promotional material to the FDA and report on ongoing clinical trials. New legal requirements have also been enacted to require disclosure of clinical trial results on publicly available databases.

Table of Contents

applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Application holders must also submit advertising and other promotional material to the FDA and report on ongoing clinical trials. New legal requirements have also been enacted to require disclosure of clinical trial results on publicly available databases.

Advertising and promotional materials must comply with FDA rules in addition to other potentially applicable federal and state laws. The distribution of product samples to physicians must comply with the requirements of the Prescription Drug Marketing Act. Manufacturing facilities remain subject to FDA inspection and must continue to adhere to FDA’s cGMP requirements. Sales, marketing, and scientific/educational grant programs must comply with the anti-fraud and abuse provisions of the Social Security Act, the False Claims Act and similar state laws, each as amended. Pricing and rebate programs must comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990 and the Veteran’s Health Care Act of 1992, each as amended. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. All of these activities are also potentially subject to federal and state consumer protection and unfair competition laws.

In recent years, several states in the United States, including California, Massachusetts, Maine, Minnesota, Nevada, New Hampshire, New Mexico, Texas, Vermont and West Virginia, as well as the District of Columbia, also have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical companies for use in sales and marketing. Similar legislation is being considered in other states and at the federal level in the United States. Many states also have laws requiring that drug and biotechnology manufacturers obtain annual registrations in order to ship products into the state, and some states have enacted requirements that shipments be accompanied by pedigree statements identifying the source and prior shipments of the product.

Depending on the circumstances, failure to meet these post-approval requirements can result in criminal prosecution, fines or other penalties, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, or refusal to allow us to enter into supply contracts, including government contracts. Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. In addition, even if we comply with FDA and other requirements, new information regarding the safety or effectiveness of a product could lead the FDA to modify or withdraw a product approval.

Table of Contents

New legal and regulatory requirements could make it more difficult for us to obtain approvals for our product candidates, and could limit or make more burdensome our ability to commercialize any approved products.

Federal legislation known as the FDA Amendments Act of 2007 grants FDA extensive authority to impose post-approval clinical study and clinical trial requirements, require safety-related changes to product labeling, review advertising aimed at consumers, and require the adoption of risk management plans, referred to in the legislation as risk evaluation and mitigation strategies, or REMS. The REMS may include requirements for special labeling or medication guides for patients, special communication plans to healthcare professionals, and restrictions on distribution and use. For example, if the FDA makes the requisite findings, it might require that a new product be ~~used~~ used only by physicians with certain specialized training, only in certain designated healthcare settings, or only in conjunction with special patient testing and monitoring. The legislation also includes requirements for providing the public information on ongoing clinical trials through a clinical trial registry and for disclosing clinical trial results to the public through a clinical trial database; renewed requirements for conducting trials to generate information on the use of products in pediatric patients; new requirements to pay the FDA a fee to obtain advisory review of certain consumer television advertisements; and new penalties, for example for false or misleading consumer advertisements. Other proposals have been made to impose additional requirements on drug approvals, further expand post-approval requirements, and restrict sales and promotional activities. The FDA Amendments Act, and the additional proposals if enacted, may make it more difficult or burdensome for us to obtain approval of our product candidates, any approvals we receive may be more restrictive or be subject to onerous post-approval requirements, our or our partners’ ability to commercialize approved products successfully may be hindered, and our business may be harmed as a result.

Table of Contents

conducting trials to generate information on the use of products in pediatric patients; new requirements to pay the FDA a fee to obtain advisory review of certain consumer television advertisements; and new penalties, for example for false or misleading consumer advertisements. Other proposals have been made to impose additional requirements on drug approvals, further expand post-approval requirements, and restrict sales and promotional activities. The FDA Amendments Act, and the additional proposals if enacted, may make it more difficult or burdensome for us to obtain approval of our product candidates, any approvals we receive may be more restrictive or be subject to onerous post-approval requirements, our or our partners’ ability to commercialize approved products successfully may be hindered, and our business may be harmed as a result.

If we are able to obtain approvals for our products, we could face competition from “generic” or “follow-on” versions of our products.

Under current U.S. law and FDA policy, generic versions of conventional chemical drug compounds, sometimes referred to as small molecule compounds, may be approved through an abbreviated approval process. In general terms, the generic applicant references an approved innovator product for which full clinical data demonstrating safety and effectiveness exist for the approved conditions of use. The generic applicant in turn need only demonstrate that its product has the same active ingredient(s), dosage form, strength, route of administration, and conditions of use (labeling) as the referenced innovator drug, and that the generic product is absorbed in the body at the same rate and to the same extent as the referenced innovator drug (this is known as bioequivalence). In addition, the generic application must contain information regarding the manufacturing processes and facilities that will be used to ensure product quality, and must contain certifications to patents listed with the FDA for the referenced innovator drug.

There is no such abbreviated approval process under current law for biological products approved under the Public Health Service Act through a BLA, such as monoclonal antibodies, cytokines, growth factors, enzymes, interferons and certain other proteins. However, various proposals have been made to establish an abbreviated approval process to permit approval of generic or follow-on versions of certain types of biological products. The proposals include proposals for legislation, and proposals for the FDA to extend its existing authority to this area.

If the law is changed or if the FDA somehow extends its existing authority in new ways, and third parties are permitted to obtain approvals of versions of our antibody products through an abbreviated approval mechanism, and without conducting full clinical studies of their own, it could materially harm our business. Such products would be significantly less costly than ours to bring to market, and could lead to the existence of multiple lower priced competitive products. This would substantially limit our ability to obtain a return on the investments we have made in those products.

Table of Contents

multiple lower priced competitive products. This would substantially limit our ability to obtain a return on the investments we have made in those products.

We are subject to federal, state, local and foreign laws and regulations, and complying with these may cause us to incur significant costs.

We are subject to laws and regulations enforced by certain federal, state, local and foreign health and environmental authorities and other regulatory statutes including:

· the Occupational Safety and Health Act;

· the Environmental Protection Act;

· the Toxic Substances Control Act;

· the Federal Food, Drug and Cosmetic Act;

· the Resource Conservation and Recovery Act; and

· other current and potential federal, state, local or foreign laws and regulations.

Table of Contents

In particular, with respect to environmental laws, our product development activities involve the use of hazardous materials, and we may incur significant costs as a result of the need to comply with these laws. Our research, development and manufacturing activities involve the controlled use of hazardous materials, chemicals, viruses and radioactive compounds. We are subject to federal, foreign, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these materials and waste products. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards prescribed by applicable laws and regulations, we cannot completely eliminate the risk of contamination or injury, by accident or as the result of intentional acts of terrorism, from these materials. In the event of an accident, we could be held liable for any damages that result, and any resulting liability could exceed our resources. We may also be required to incur significant costs to comply with environmental laws and regulations in the future.

Risks Related to Intellectual Property

We depend on patents and proprietary rights.

Our success depends in part on our ability to:

· apply for, obtain, protect and enforce patents;

· protect trade secrets;

· operate without infringing upon the proprietary rights of others; and

· in-license or acquire certain technologies.

We rely on patent protection against use of our proprietary products and technologies by competitors. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary rights are covered by valid and enforceable patents or are effectively maintained as trade secrets. We protect our proprietary position by filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements that are important to the development of our business. Our pending patent applications, those we may file in the future, or those we may license from third parties, may not result in patents being issued or, if issued, may not be held enforceable. The products and product candidates currently being developed or considered for development are in the area of biotechnology, an area in which there are extensive patent filings. The patent position of biotechnology intellectual property generally is highly uncertain and involves complex legal and factual questions; to date, no consistent policy has emerged regarding the breadth of claims allowed in biotechnology patents. Therefore, we cannot predict with certainty the breadth of claims that we may be allowed for our proprietary technology or products, or their enforceability.

Table of Contents

breadth of claims allowed in biotechnology patents. Therefore, we cannot predict with certainty the breadth of claims that we may be allowed for our proprietary technology or products, or their enforceability.

Granted patents may be invalidated, circumvented, or may expire before or soon after commercialization. Because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that before we commercialize any of our products, any related patent may expire, or its term may exist for only a short period once commercialization begins, thus reducing any advantage of the patent. Also, patent rights may not provide us with proprietary protection or competitive advantages against competitors having similar technology that falls outside the scope of our claims. Furthermore, others may independently develop similar technologies or duplicate any technology that we have developed which is not covered by an issued patent in a particular country. The laws of foreign countries may not protect our intellectual property rights to the same extent as do the laws of the U.S. Thus, any patents that we own or license from third parties may not provide sufficient protection against competitors. In addition to patents, we rely on trade secrets and proprietary know-how. We protect these secrets and know-how, in part, through confidentiality and proprietary information agreements.

Table of Contents

We generally require our staff members, material consultants, scientific advisors and parties to collaboration or licensing agreement to execute confidentiality agreements upon the commencement of employment, the consulting relationship or the collaboration or licensing arrangement with us. These agreements may not provide protection or adequate remedies in the event of unauthorized use or disclosure of confidential and proprietary information or breach of these agreements. Furthermore, our trade secrets may otherwise become known to, or be independently developed by, our competitors.

We do not have exclusive access to certain patents and therefore we may face increased competition from those entities that share access to these patents.

Even though we own issued patents and pending applications and have received licenses pertaining to the HuMAb-Mouse® and the KM-Mouse® technologies, this does not mean that we and our licensees of these technologies will have exclusive rights to all antibodies against the targets bound by these antibodies, or that we or our licensees will have the right to make, develop, use and sell the antibodies we make.

Our patents and applications covering the HuMAb-Mouse® and the KM-Mouse® technologies also cover particular human antibodies, but they do not cover all human antibodies. Additionally, our patents may not protect against the importation of products, such as antibodies, made using the HuMAb-Mouse® or KM-Mouse® technologies.

We do not have exclusive access to the patents underlying the HuMAb-Mouse® technology. In March 1997, prior to our acquisition of GenPharm, GenPharm entered into a cross-license and settlement agreement with Abgenix, Cell Genesys, Inc., Xenotech, L.P. and Japan Tobacco, Inc., pursuant to which Abgenix and these entities paid GenPharm a total of approximately $38.6 million in exchange for a non-exclusive license to certain intellectual property, including patents, patent applications, third-party licenses and inventions pertaining to the development and use of certain transgenic rodents, including mice, that produce fully human antibodies that are integral to our product candidates and business. This intellectual property and the related third-party licenses form the basis of our HuMAb-Mouse® technology. Amgen may have access to such intellectual property and licenses as a result of its acquisition of Abgenix in 2006. Our business may suffer from the competition of these entities and their licensees and sublicensees.

We are not the exclusive owner of the technology underlying the KM-Mouse®. Our collaboration and license agreement with Kirin contains certain cross-licenses for certain of each other’s technologies for the development and commercialization of human antibody products made using the HuMAb-Mouse®, the KM-Mouse® and certain other antibody-generating mice. Kirin has certain rights to distribute and use such mice throughout the world. Our business may be materially harmed as a consequence of competition from Kirin and its licensees and sublicensees or if the collaboration and license agreement were breached or terminated.

Table of Contents

development and commercialization of human antibody products made using the HuMAb-Mouse®, the KM-Mouse® and certain other antibody-generating mice. Kirin has certain rights to distribute and use such mice throughout the world. Our business may be materially harmed as a consequence of competition from Kirin and its licensees and sublicensees or if the collaboration and license agreement were breached or terminated.

Moreover, other parties could have blocking patent rights to products made using the HuMAb-Mouse® and KM-Mouse® technologies, such as antibodies, and their production and uses, based on proprietary rights covering the antibody or the antibody’s target or the method of manufacturing or use of the antibody. For example, we are aware of certain U.S. and foreign patents owned by third parties relating to antibody product candidates that we are developing alone or with our collaborators, including to specific targets for making monoclonal antibodies, to human monoclonal antibodies, and to the method of manufacture and use of such products.

Table of Contents

Third parties may allege our products or technologies infringe their patents or may challenge the validity of our patents and our other intellectual property rights, resulting in litigation or other time-consuming and expensive proceedings which could deprive us of valuable products and/or rights.

Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. If we become involved in any intellectual property litigation, interference or other judicial or administrative proceedings, we may incur substantial expenses and the efforts of our technical and management personnel may be diverted. If any of our products or technologies are found to infringe a third party’s patent or violate their proprietary rights, such an adverse determination may subject us to significant liabilities, including payment of significant monetary damages and royalties, or require us to seek licenses from third parties that may not be available on commercially favorable terms, if at all. Therefore, we and our partners may be restricted or prevented from further product development or commercializing and selling products that are covered by third party intellectual property. This could materially harm our business, financial condition and results of operations.

With respect to third party patent rights, we are aware of a U.S. patent owned by Genentech, relating to the production of recombinant antibodies in host cells. This patent is currently in a reexamination proceeding before the U.S. Patent and Trademark Office, or USPTO. The USPTO has issued a Notice of Intent to Issue a Reexamination Certificate confirming the patentability of the reexamined claims. It is anticipated that a reexamination certificate will issue later in 2009.

We currently produce our product candidates and our partners’ product candidates using recombinant antibodies from host cells and may choose to produce additional product candidates in this manner. If any of our antibody product candidates are produced in a manner subject to claims in the Genentech patent that survive the appeal processes, if any, then we may need to obtain a license from Genentech, should one be available. We have a license to this patent from Genentech for our anti-CTLA-4 product candidate (ipilimumab) but currently do not have licenses for any of our other antibody product candidates. If we desire a license for any of our other antibody product candidates and are unable to obtain a license on commercially reasonable terms or at all, we may be restricted in our ability to make recombinant antibodies from host cells, as claimed by Genentech, or to import them into the United States.

We are also aware of certain U.S. patents held by third parties relating to antibody expression in particular types of host cells, including Chinese hamster ovary, or CHO, cells, including certain media preparations and their use for culturing CHO cells, and particular antibody formulations, any of which may be relevant to our current or future manufacturing techniques. If we determine that we need a license to these or other patents relating to methods of making antibodies and are unable to obtain licenses on commercially reasonable terms or at all, we may be restricted in our ability to use these methods to make antibodies or to import the antibodies into the United States.

Table of Contents

at all, we may be restricted in our ability to use these methods to make antibodies or to import the antibodies into the United States.

We cannot provide assurances that our product candidates and/or actions in developing or selling human antibody product candidates will not infringe the aforementioned patents. We intend to seek licenses to such patents when, in our judgment, such licenses are needed. If any licenses are required, there can be no assurance that we will be able to obtain any such license on commercially favorable terms, if at all. If these licenses are required and are not obtained, we might be prevented from using certain of our technologies for generating recombinant human antibody product candidates. Our failure to obtain a license to any technology that we may require may materially harm our business, financial condition and results of operations.

Table of Contents

Risks Related to Our Common Stock

*Our stock price may be volatile.

Historically, there has been significant volatility in the market prices of biotechnology companies’ securities. During the two-year period ended ~~March~~June 3130, 2009, the sale prices of our common stock ranged between $3.40 and $18.23. Various factors and events may have a significant impact on the market price of our common stock. These factors include, by way of example:

· interim or final results of, or speculation about, clinical trials of and the regulatory filing schedule for our lead product candidate, ipilimumab;

· progress with clinical trials;

· fluctuations in our operating results;

· announcements of technological innovations or new commercial therapeutic products by us or our competitors;

· published reports by securities analysts;

· governmental regulation;

· developments in patent or other proprietary rights;

· developments in our relationship with collaborative partners;

· public concern as to the safety and effectiveness of our product candidates or products;

· changes in our management;

· matters relating to the investigation of our past stock option grant practices; and

· general market conditions.

The trading price of our common stock has been, and could continue to be, subject to wide fluctuations in response to these or other factors, including the sale or attempted sale of a large amount of our common stock into the market. Broad market fluctuations may also adversely affect the market price of our common stock.

*We have obligations to issue shares of our common stock in the future, which may have a dilutive effect on the shares of our common stock currently outstanding.

As of ~~April~~July 3031, 2009, we had 21,~~942~~302,~~255~~527 shares of common stock reserved for issuance pursuant to options and other stock based awards which had been granted under our equity incentive plans having a weighted average exercise price of $98.1471 per share and we had reserved 8,~~719~~970,~~121~~797 shares of common stock for issuance pursuant to future grants of options under our equity incentive plans. We have filed registration statements on Form S-8 under the Securities Act of 1933, as amended, covering all of these shares. Shares issued pursuant to these plans, other than shares issued to affiliates, will be freely tradable in the open market. Shares held by affiliates may be sold pursuant to the requirements of Rule 144.

64As of July 31, 2009, we had reserved 501,013 shares of common stock for issuance pursuant to our 2002 Employee Stock Purchase Plan. We have filed a registration statement on Form S-8 under the Securities Act covering all of those shares. All shares issued under this plan, other than shares issued to affiliates, will be freely tradable on the open market. Shares held by affiliates may be sold pursuant to the requirements of Rule 144.

Table of Contents

~~these~~and ~~plans,~~sale ~~other~~of ~~than~~the shares ~~issued~~of toour ~~affiliates,~~common ~~will~~stock beupon ~~freely tradable in~~ the ~~open~~ ~~market.~~exercise ~~Shares~~thereof ~~held by affiliates~~ may behave ~~sold~~an adverse ~~pursuant~~effect toon the ~~requirements~~ price of ~~Rule 144~~our common stock.

As of ~~April~~July 3031, 2009, we had ~~reserved 171~~10,~~053~~ 936,935 shares of common stock reserved for issuance pursuant to ~~our~~the ~~2002~~conversion ~~Employee~~of ~~Stock~~the $150.0 ~~Purchase~~million ~~Plan.~~aggregate Weprincipal ~~have~~amount ~~filed~~of aour outstanding 2.25% Convertible ~~registration~~Senior ~~statement~~Notes ondue ~~Form~~May ~~S-8~~15, ~~under~~2011. ~~the~~Holders ~~Securities~~of ~~Act~~these ~~covering~~notes ~~all~~may convert their ofnotes ~~those~~into shares. ~~All~~of ~~shares~~common ~~issued~~stock ~~under~~at ~~this~~any ~~plan,~~time ~~other~~prior ~~than~~to ~~shares~~maturity ~~issued~~or toredemption ~~affiliates,~~by ~~will~~us beat ~~freely~~a ~~tradable~~conversion onrate ~~the~~of ~~open market~~72.9129 ~~Shares~~shares ~~held~~per ~~by affiliates~~each ~~may~~$1,000 beprincipal ~~sold~~amount of ~~pursuant~~the tonotes ~~the~~($13.72 ~~requirements~~per ofshare), ~~Rule 144~~subject to adjustment.

The exercise of all or a portion of the outstanding options may result in a significant increase in the number of shares of our common stock that will be subject to trading on the NASDAQ Global Market and the issuance and sale of the shares of our common stock upon the exercise thereof may have an adverse effect on the price of our common stock.

As of April 30, 2009, we had 10,936,935 shares of common stock reserved for issuance pursuant to the conversion of the $150.0 million aggregate principal amount of our outstanding 2.25% Convertible Senior Notes due May 15, 2011. Holders of these notes may convert their notes into shares of common stock at any time prior to maturity or redemption by us at a conversion rate of 72.9129 shares per each $1,000 principal amount of the notes ($13.72 per share), subject to adjustment.

Upon the occurrence of certain change of control events of our Company, we are required to offer to repurchase all of our debt, which may adversely affect our business and the price of our common stock.

Upon the occurrence of certain change of control events of our company, we are required to offer to repurchase all of our outstanding 2.25% Convertible Senior Notes due May 15, 2011. BMS commenced a tender offer on July 28, 2009 (see Note 10 to the consolidated financial statements for further information) which could result in a change of control. As of ~~April~~July 3031, 2009, $150.0 million aggregate principal amount of these notes was outstanding. In each instance, we may pay the repurchase price in cash or, at our option, in common stock. These change of control events include, without limitation, (i) the acquisition by any third party of at least 50% of our common stock; or (ii) our merger or consolidation with or into any other person, any merger or consolidation of another person into us or our sale or other disposal of all or substantially all of our assets, except in certain limited circumstances provided in the indentures relating to the notes. Such repurchase rights may be triggered at a time at which we do not have sufficient funds available to pay the repurchase price in cash or determine that payment in cash is otherwise inadvisable. In such event, the issuance of a significant number of additional shares of common stock in payment of the repurchase price may lower the market price of our common stock.

Table of Contents

Our restated certificate of incorporation, amended and restated by-laws, shareholder rights plan and New Jersey law contain provisions that could delay or prevent an acquisition of our Company even if the acquisition would be beneficial to our shareholders, and as a result, our management may become entrenched and hard to replace.

In May 2001, our board of directors adopted a shareholder rights plan. The shareholder rights plan provides for a dividend of one preferred share purchase right on each outstanding share of our common stock. Each right entitles shareholders to buy 1/1000th of a share of our Series A junior participating preferred stock at an exercise price of $150.00. Each right will become exercisable following the tenth day after a person or group announces an acquisition of 20% or more of our common stock. We will be entitled to redeem the rights at $0.001 per right at any time on or before the close of business on the tenth day following acquisition by a person or group of 20% or more of our common stock.

The shareholder rights plan and certain provisions of our restated certificate of incorporation and amended and restated by-laws and New Jersey law may have the effect of making it more difficult for a third party to acquire, or of discouraging a third party from attempting to acquire control of us. This could limit the price that certain investors might be willing to pay in the future for our common stock. The provisions of our restated certificate of incorporation and amended and restated by-laws include:

· a classified board of directors;

· a requirement that special meetings of shareholders be called only by our board of directors, chairman of the board, lead independent director, chief executive officer or president;

· advance notice requirements for shareholder proposals and nominations;

Table of Contents

· limitations on the ability of shareholders to amend, alter or repeal our by-laws; and

· the authority of the board of directors to issue, without shareholder approval, preferred stock with such terms as the board of directors may determine.

We are also afforded the protections of the New Jersey Shareholders Protection Act. This New Jersey statute contains provisions that impose restrictions on shareholder action to acquire control of our company. The effect of the provisions of our shareholder rights plan, restated certificate of incorporation and amended and restated by-laws and New Jersey law may discourage third parties from acquiring control of our company. In addition, these measures may result in the entrenchment of our management and may prevent or frustrate any attempt by shareholders to replace or remove our current management.

We do not intend to pay cash dividends on our common stock in the foreseeable future.

We intend to retain any future earnings to finance the growth and development of our business, and we do not plan to pay cash dividends on our common stock in the foreseeable future.

66Item 4. Submission of Matters to a Vote of Security Holders

~~Table~~At our annual meeting of shareholders held on May 21, 2009, our shareholders elected: (i) three Class I Directors each to serve for a term to expire in 2012. Our shareholders also voted to ratify the appointment of ~~Contents~~Ernst & Young LLP as our independent registered public accounting firm for 2009. Out of the 128,532,698 eligible votes, the following votes were cast at the meeting either by proxies solicited in accordance with Section 14 of the Securities Exchange Act of 1934, as amended, and the regulations set forth thereunder, or by securities holders voting in person. With respect to the election of directors, abstentions are treated as votes withheld and are included in the table:

Proposal 1

Nominees for Directors

Directors—Class I	Votes For	Votes Withheld
Marc Rubin, M.D.	103,258,540	5,588,642
Ronald J. Saldarini, Ph.D.	97,891,832	10,955,350
Charles R. Schaller	102,008,161	6,839,021

The following persons are incumbent directors whose terms of office continued after the 2009 annual meeting of shareholders:

Class III Terms Expiring in 2010		Class II Terms Expiring in 2011
Abhijeet J. Lele		Patricia M. Danzon, Ph.D.
Julius A. Vida, Ph.D.		Robert C. Dinerstein
		Howard H. Pien

Table of Contents

Proposal 2

Ratification of the appointment by the Board of Directors of Ernst & Young LLP as independent registered public accounting firm, to audit the financial statements of Medarex for 2009:

FOR		AGAINST		ABSTAIN
105,065,366		2,825,953		955,863

Table of Contents

Item 6. Exhibits

Exhibits:

10.1		License, Development and Commercialization Agreement, dated as of April 20, 2009, by and among Merck Sharpe & Dohme Research Ltd., University of Massachusetts, Massachusetts Biologic Laboratories, Worcester City Campus Corporation and the Registrant (incorporated by reference to Exhibit 10.1 to Registrant’s Current Report on Form 8-K/A filed on July 29, 2009)(1).
31.1*		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

* Filed herewith.

67(1) Portions of this exhibit have been omitted pursuant to a request for confidential treatment.

Table of Contents

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			~~MEDAREX, INC.~~	MEDAREX, INC.
			~~(Registrant)~~	(Registrant)
Date: May 4, 2009		By:	/s/ HOWARD H. PIEN
Date:	July 31, 2009		By:	/s/ HOWARD H. PIEN
			~~Howard H. Pien~~	Howard H. Pien
			~~President and Chief~~	President and Chief
			~~Executive Officer~~	Executive Officer
			~~(Principal Executive Officer)~~	(Principal Executive Officer)
Date: May 4, 2009		By:	/s/ CHRISTIAN S. SCHADE
Date:	July 31, 2009		By:	/s/ CHRISTIAN S. SCHADE
			~~Christian S. Schade~~	Christian S. Schade
			~~Senior Vice President~~	Senior Vice President
			~~Finance & Administration,~~	Finance & Administration,
			~~Chief Financial Officer~~	Chief Financial Officer
			~~(Principal Financial and~~	(Principal Financial and
			~~Accounting Officer)~~	Accounting Officer)

6878

Filing Compare · MEDAREX INC